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Summary 
Epstein-Barr virus (EBV) is a human herpes virus that, upon primary infection, 
establishes life-long persistence in B cells (latency). One viral protein, the 
immediate early lytic protein Zta (also known as BZLF1, ZEBRA, EB1, and Z) 
plays a significant role in disturbing this latency and inducing a viral productive 
(lytic) cycle. Expression of Zta, a basic leucine zipper transcription factor, 
induces a cascade of viral lytic cycle gene expression. The activation of many 
lytic genes requires the direct binding of Zta to its response elements (ZREs) 
within proximal promoters of these genes.  Much research in recent years has 
focused on investigating Zta reactivation of latency and its role in lytic viral DNA 
replication. This has revealed a wealth of knowledge about Zta as a 
multifunctional transcription factor. However, a complete understanding of Zta 
transcriptional activation is still missing. Here, utilising ChIP-qPCR, we showed 
conserved binding patterns for Zta across several EBV lytic gene promoters in 
two different EBV systems including a non-B cell EBV-infected cell line. Also, 
using luciferase reporter assays, we show the first functional evidence for a 
possible role of Zta in controlling transcription regulation at distal regulatory 
elements (enhancers). Importantly, we identified BNLF2a, an essential viral 
immune evasion gene, as a direct target for Zta. We identified five ZREs and 
mapped functional ones within the BNLF2a promoter using mutational analysis 
and luciferase reporter assays. We also expressed and purified a recombinant 
GFP-bZIP Zta protein to address Zta binding to BNLF2a ZREs in vitro. 
Interestingly, using in silico approach, we also identified a conserved sequence 
in the ZRE flanking region of all five ZREs within BNLF2a promoter and 
uncovered a role for a possible repressor at ZRE2 flanking region.  Our work 
not only adds to our understanding of Zta transcription regulation but 
characterises for the first time the regulation of a novel Zta target that has a role 
in evading the host immune system during EBV pre-latency and lytic cycle.  
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Chapter 1 Introduction 
1.1 Viruses and cancer 
Viruses were initially described as filterable agents and were known to be 
associated with diseases as early as 1898.  In this year, a Dutch scientist, 
Martinus Beijerinck not only replicated previous work showing that a filterable 
agent (which he called a “contagium vivum fluidum”) was capable of inducing 
disease in tobacco plant but more importantly demonstrated the fact that this 
agent gained potency after replicating in plant cells (Fields et al., 2013). 
Beijerinck’s findings clearly indicated that this filterable pathogen which was 
smaller than bacteria reproduced itself in living cells in contrast to an earlier 
hypothesis by the Russian scientist Dimitri Ivanofsky, who suggested that this 
filterable material could be a toxin  (Fields et al., 2013).    
 
Around the same time, two German scientists, Friedrich Loeffler and Paul 
Frosch, presented the first evidence that pathogens smaller than bacteria are 
capable of causing diseases in animals. In their experiments, they were able to 
show the transmission of the foot and mouth infection from infected animals to 
healthy livestock by using only germ-free filtered vesicle lymph. What’s more, 
they illustrated that animals injected with infectious vesicle lymph that had been 
heated, developed immunity to the disease. This led to their conclusion that an 
ultra-filterable and ultra-visible particle is the cause of the foot and mouth 
disease in animals (Rott and Siddell, 1998).  
 
These pioneering findings were soon followed by other major discoveries of 
viruses that cause devastating diseases in humans such as the yellow fever 
virus described by Walter Reed in 1901 (Reed et al., 1901) and poliovirus 
described by Karl Landsteiner and Erwin Popper in 1909  (De Jesus, 2007)). 
 
However, the link between cancer and viruses was not established until the 
early 20th century. In 1908, two Danish scientists, Ellerman and Bang 
demonstrated that a filterable agent could transmit leukaemia in chickens  
(Cardiff and Kenney, 2007). Three years later, Peyton Rous was also able to 
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show the transmission of chicken sarcoma tumour by injecting healthy chickens 
with cell-free tumour filtrate. Rous reported his conclusion that this tumour is 
transferable through a small filterable agent, “The first tendency will be to regard 
the self-perpetuating agent active in this sarcoma of the fowl as a minute 
parasitic organism” (Rous, 1911).   
 
Despite this early evidence that viruses cause cancer in animals, the origin of 
these tumors remained highly debatable, and many pioneer scientists were 
sceptical about the emerging theories that viruses could cause cancer in 
humans. 
 
It took nearly another 50 years before the first evidence of a human tumour 
virus was reported. A fruitful collaboration between two British doctors Denis 
Burkitt and Anthony Epstein led to the identification of the first human tumour 
virus, a new herpesvirus (known today as Epstein-Barr virus (EBV) or human 
herpesvirus 4).  
 
In 1958, Denis Burkitt, who was working in Uganda at that time, encountered 
many cases of a very unusual lymphoma that was seen in young children with a 
high incidence rate (Burkitt, 1958). Burkitt mapped the geographical region 
where high rates of this lymphoma were often reported. The geographic 
distribution of the tumour was mostly in sub-Saharan areas where temperature 
and rainfall are usually high (Burkitt, 1962a, b; Burkitt and Wright, 1963; Burkitt, 
1961). Interestingly, this geographic distribution correlated with the distribution 
of the malaria parasite, Plasmodium falciparum (Dalldorf et al., 1964; Guerra et 
al., 2008). Indeed, malaria was later shown to play a role in the development of 
Burkitt’s lymphoma as will be discussed in Section 1.3.6.2.  
 
While visiting London to present his findings at the Middlesex Hospital Medical 
School, Burkitt met Anthony Epstein, who was at the time working as a 
researcher at this hospital. On viewing data presented by Burkitt, Epstein was 
immediately convinced that a pathogen might be causing this lymphoma. He 
further speculated that this pathogen could be a tumour virus transmitted by an 
arthropod (Crawford, 2014).  
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Epstein had gained significant experience in electron microscopy and tumour 
viruses from his previous work on Rous fowl sarcoma virus (Epstein and Holt, 
1958) and he knew that to prove his hypothesis, he needed to show the 
presence of a virus in these lymphoma cells. Luckily, it took Epstein only a few 
years to prove his theory. In 1964, Anthony Epstein and his colleagues 
Yvonne Barr and Bert Achong were able to show herpes virus-like particles in 
cell lines derived from Burkitt’s lymphoma using electron microscopy (Epstein et 
al., 1964). However, this did not prove that the newly identified virus was the 
cause of this lymphoma. Epstein therefore published his work without 
concluding any link between the virus and Burkitt’s lymphoma (Epstein et al., 
1964).  
 
Fortunately for the scientific community, this was not the end of the story. 
Indeed, further links between EBV and cancer were revealed a few years later 
through another successful collaboration between Epstein and the Werner 
Henle group in Philadelphia, USA (Epstein et al., 1965). The Henle group were 
able to show immunofluorescent staining in the lymphoma cell lines, using 
various sera from Burkitt’s lymphoma patients that were thought to be specific 
to an EBV antigen in these cells  (Henle and Henle, 1966). 
 
The Henle group were also able to establish the first concrete evidence of EBV 
lymphoproliferative effects by co-culturing healthy B cells with lethally irradiated 
EBV-positive Burkitt’s lymphoma cells, which induced the healthy B cells to 
grow in culture for a few weeks (Henle et al., 1967). Soon after, they were able 
to establish continuously proliferating lymphoblastoid cell lines (LCLs) from EBV 
umbilical cord lymphocytes co-cultured with EBV Burkitt’s cell lines (Nilsson et 
al., 1971). The scientific and personal events that led to the discovery of EBV 
have been the subject of several reviews (Crawford, 2014; Epstein, 2015; 
Epstein, 2001; Young and Murray, 2003).  
 
Currently, cancers associated with virus infections are estimated to account for 
nearly 15% of all cancer cases worldwide (Moore and Chang, 2010). There are 
seven viruses classified as definitely carcinogenic to human. These are Epstein-
Barr virus (human herpesvirus 4), Kaposi's sarcoma herpesvirus (human 
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herpesvirus 8), hepatitis B and C viruses, human papillomavirus (HPV), human 
T-cell lymphotropic virus, and Merkel cell polyomavirus (Table 1.1) (Oh and 
Weiderpass, 2014).  
 
Despite the fact that this percentage of cancer cases is considered relatively 
low the high prevalence of these viruses in some cancers cannot be ignored. 
For instance, in endemic Burkitt’s lymphoma and nasopharyngeal carcinoma, 
EBV is found in nearly 100% of the cases in high incidence regions. Similarly,  
high HPV prevalence is seen in most cervix carcinomas (de Martel et al., 2012).   
 
Table 1.1 Cancers caused by viruses. 
 
It is worth noting that viruses are not only seen as a cause of cancer but, 
possibly, a way to prevent and cure cancer. For example, vaccine development 
for tumour viruses will help to reduce cancer cases. This is clearly seen in the 
development of human papillomavirus  (HPV) vaccine, which has been used in 
preventing cervical cancer in women (Crosignani et al., 2013). 
 
Furthermore, oncolytic viruses are currently leading the way in viral cancer 
therapy.  Such viruses are being engineered to infect and replicate within 
specific tumour cells; this replication leads to tumour cell death. Furthermore, 
these viruses provoke a host immune system response against the tumour cells 
which will further help in destroying these cells (Kaufman et al., 2015).  Indeed, 
a recently FDA approved modified herpes simplex virus-1 (HSV-1) has shown 
Virus Associated cancers 
Epstein-Barr virus 
Nasopharyngeal carcinoma, Burkitt’s lymphoma, 
non-/Hodgkin lymphoma and gastric carcinoma  
Hepatitis B and C virus Hepatocellular carcinoma 
Kaposi sarcoma herpes virus Kaposi sarcoma 
Human immunodeficiency virus 
type 1 
Kaposi sarcoma, non-/Hodgkin lymphoma, 
carcinoma of the cervix, anus and conjunctiva 
Human papillomavirus type 16 
Carcinoma of the cervix, vulva, vagina, penis, 
anus, oral cavity, and oropharynx and tonsil 
Human T-cell lymphotropic virus 
type 1 
Adult T-cell leukaemia and lymphoma 
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promising results in treating advanced melanoma (Andtbacka et al., 2015; 
Emens et al., 2016).  
 
These facts highlight the importance of studying tumour-virus biology to 
understand the development of many viral related cancers so that new 
prevention and treatment measures can be developed. 
 
1.2 Herpesviruses 
Herpesviruses are double-stranded DNA viruses which are one of the most 
significant pathogens associated with tumors and several diseases in human as 
well as other hosts. Clear examples of such diseases are genital herpes caused 
by herpes simplex viruses, infectious mononucleosis caused by EBV, and 
Kaposi's sarcoma caused by Kaposi's sarcoma-associated herpes virus  
(KSHV) (Arvin et al., 2007).  Many of these diseases were known to humans for 
centuries. Indeed, the word herpes, which means “to creep” in Greek, was used 
as a medical term to describe lesions in ancient Greece times 2500 years ago 
(Beswick, 1962).  
 
Viruses in the herpesviruses family (Herpesviridea) were initially classified 
based on their shared biological features such as the primary natural host, viral 
structure and genome (Roizman et al., 1981). However, more recently, the 
taxonomy of herpesviridae was revised by the International Committee on 
Taxonomy of Viruses (ICTV) to the new order Herpesvirales (Davison et al., 
2009). This new order is split into three families: Herpesviridae which retains the 
mammal, bird and reptile viruses, Alloherpesviridae which comprises the fish 
and frog viruses, and Malacoherpesviridae which consists of a bivalve virus. A 
new genus incorporating new species has also been added under the 
subfamilies of the Herpesviridae family (Davison, 2010; Davison et al., 2009).  
 
The Herpesviridae family, which includes the mammalian herpesviruses is 
divided into three subfamilies: alpha-, beta- and gamma- herpesvirnae. This 
classification was initially based on structural similarities (Roizman et al., 1981). 
However, more advanced phylogenetic tools have not resulted in any changes 
to this classification (McGeoch et al., 1995).  These subfamilies comprise nine 
1-19 
 
  
known human herpesviruses (listed in Table 1-2). The alphaherpesviruses 
include the herpes simplex viruses (HSVs) and the varicella-zoster virus (VZV). 
These viruses establish latency primarily in sensory ganglia but can infect a 
variety of cells. The betaherpesviruses include cytomegalovirus which can infect 
a variety of human lymphocytes but mostly cells of myeloid origins (Arvin et al., 
2007).  
 
The gammaherpesviruses, which infect lymphocytes and induce 
lymphoproliferation, is further split into two genera: the lymphocryptoviridae 
(LCV) and rhadinoviridae (RV). The lymphocryptoviridae herpesviruses contain 
Epstein-Barr virus (EBV) and other related viruses identified in various primates 
species while, the rhadinoviridae herpesviruses include  Kaposi’s sarcoma-
associated herpes virus (KSHV) (known as human herpesviruses 8 (HHV-8)) 
(Arvin et al., 2007).  
 
Name 
Other given 
names 
Genome 
size (kb) 
Herpesvirdae subfamily 
Human herpesvirus 1 
(HHV-1) 
Herpes simplex 
virus 1 (HSV-1) 
152 Alphaherpesvirinae 
Human herpesvirus 2 
(HHV-2) 
Herpes simplex 
virus 2 (HSV-2) 
155 Alphaherpesvirinae 
Human herpesvirus 3 
(HHV-3) 
Varicella-zoster 
virus (VZV) 
125 Alphaherpesvirinae 
Human herpesvirus 4 
(HHV-4) 
Epstein-Barr virus 
(EBV) 
172 
Gammaherpesvirinae: 
Lymphocryptovirus genera 
Human herpesvirus 5 
(HHV-5) 
Cytomegalovirus 
(CMV) 
236 Betaherpesvirinae 
Human herpesvirus 
6A (HHV-6A) 
HHV-6 variant A 159 Betaherpesvirinae 
Human herpesvirus HHV-6 variant B 162 Betaherpesvirinae 
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6B (HHV-6B) 
Human herpesvirus 7 
(HHV-7) 
 145 Betaherpesvirinae 
Human herpesvirus 8 
(HHV-8) 
Kaposi’s sarcoma-
associated 
herpesvirus 
(KSHV) 
170 
Gammaherpesvirinae: 
Rhadinoviridae genera 
Table 1.2: Human herpesviruses.  
 
In herpesviruses, it is believed that, apart from the fish herpesviruses 
(Alloherpesviridae), all mammalian and avian herpesviruses share a common 
origin (McGeoch et al., 1995). For the mammalian herpesviruses 
(Herpesviridae), the three subfamilies (alpha, beta, and gamma) appear to 
share a common root and may have appeared around 180 to 220 million years 
ago, while the major sublineages under these subfamilies may have appeared 
80 to 60 million years ago (McGeoch et al., 1995). 
  
1.3 Epstein- Barr virus (EBV) 
The gammaherpesvirus EBV is a DNA virus that infects over 90% of the 
population worldwide (Borer et al., 1999; de-The et al., 1975) EBV establishes a 
life-long persistence in B cells and can also infect epithelial cells.  
 
1.3.1 EBV structure  
In common with other herpesviruses, the EBV virion ranges in size between 
120-260 nm and has a DNA core containing a single molecule of linearised 
naked viral double-stranded DNA (Pellett and Roizman, 2013).  
 
As illustrated in Figure 1-1, this DNA is contained in a nucleocapsid which 
consists of 162 subunits called capsomeres. The nucleocapsid is composed of 
several proteins including major capsid and minor capsid proteins.  The capsid 
is separated from the outer envelope by tegument proteins. These various 
proteins are distributed asymmetrically and are believed to play a significant 
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role in mediating the early events of viral entry. Multiple late lytic genes encode 
for tegument proteins such as BPLF1, BOLF1, BGLF4, BRRF2, BKRF4 and 
BNRF1 (Longnecker et al., 2013; Pellett and Roizman, 2013).  
 
More recently, a study by (Jochum et al., 2012) showed the existence of various 
packed viral RNAs within the virion. These RNAs include viral lytic transcripts 
such as viral BZLF1 and BNLF2a transcripts, miRNAs, and other noncoding 
RNAs. The virion-packed viral RNAs role appears to be important in triggering a 
pre-latent EBV infection phase, inducing cellular cytokines, and host immune 
evasion, as is known for the BNLF2a transcript (Jochum et al., 2012).   
 
The outer envelope is composed of external glycoprotein spikes; there are at 
least nine different glycoproteins in EBV envelope including gp350, gp150, gH, 
gB and gL (Longnecker et al., 2013; Pellett and Roizman, 2013). 
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1.3.2 EBV genome 
The EBV genome is double-stranded DNA, about 172 kbp long, and has 60% of 
GC content. The viral DNA exists as either linear packed within the virion or 
circular in infected cells. The linearised genome becomes circular episome 
inside the host cell by the fusion of the two-terminal repeat ends of the linear 
DNA.  The EBV genome contains nearly 84 protein-coding open reading frames 
(ORF) (Longnecker et al., 2013). In addition to this, EBV encodes for various 
noncoding RNAs. The nonpolyadenylated EBV-encoded small RNAs EBER 
(1&2) (Lerner et al., 1981), BamHI-A rightward transcripts (BARTs),  and 
miRNAs transcribed from within BHRF1 ORF and BARTs locus (Pfeffer et al., 
2005; Pfeffer et al., 2004).  
 
As illustrated in Figure 1-2, the genome consists of a unique long sequence 
containing coding regions interspersed by four major internal repeats (IR1 to 
IR4). The separate coding regions resemble five unique segments referred to 
as U1-U5. The length of each internal repeat is different: IR1 is the longest 
(3072 bp), IR2 is 123 bp, IR3 is 708 bp, and IR4 is 103 bp. The two tandem 
repeat regions at each end of the linear genome (terminal repeats (TR)) are 
around 500 bp (Longnecker et al., 2013).  
 
IR1, the longest internal repeat, consists of similarly arranged repeats (3 kbp in 
length) known as BamHI W repeats. The repeat contains a promoter (Wp), and 
two exons referred to as W1 and W2 coding for the repeats in latent EBNA-LP 
protein, as will be discussed in subsequent sections. The number of the W 
repeats is variable between different EBV isolates (Allan and Rowe, 1989).  IR2 
and IR4 (also known as DL and DR, respectively) share highly similar sequence 
(Dambaugh and Kieff, 1982). IR3 is characterised by tandem repeats of a GGA 
motif and is part of BKRF1 gene, which encodes for the latent protein EBNA1 
(Heller et al., 1985; Heller et al., 1982).  
 
The first complete sequencing of the EBV isolate B95-8 was achieved by 
sequencing clones from EBV DNA BamHI-digested fragments (Baer et al., 
1984). In this B95-8 sequence, the first nucleotide was considered to be the 
base located before the leftmost EcoRI restriction site within the U1 coding 
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region. The nomenclature of the various ORFs was based on the relative 
location and transcription orientation of the ORF within the DNA fragments that 
resulted from BamHI restriction digest of the viral DNA. The BamHI fragments 
were given alphabetical letters (A-Z) where A is the largest fragment and Z is 
the smallest. For example, an ORF such as BZLF1 will be the first ORF within 
BamHI Z (BZ) fragment and has a leftward orientation (LF).  If the ORF is 
located over two BamHI fragments, the name is based on the 5’ fragment 
(Longnecker et al., 2013; Sample et al., 2009). In the published literature, most 
lytic cycle genes are referred to by their gene names. However, latent cycle 
genes are commonly known by their protein names.  
 
The EBV genome has a single origin of replication during latency (OriP).  This 
origin of EBV DNA replication is about 1.7 kbp in length and has two functional 
domains, the family of repeats (FR) and the Dyad symmetry (DS) element. 
Replication during latency is mediated through EBNA1, which binds to multiple 
sites on FR and DS, and subsequently recruits the cellular DNA replication 
machinery (Yates et al., 2000). 
 
Replication during the EBV lytic cycle is not dependent on latency DNA 
replication. Unlike in latency, the EBV genomic DNA is amplified up to several 
hundred-fold within 24 hours (Hammerschmidt and Sugden, 1988). During EBV 
lytic cycle, DNA replication is mediated through two identical copies of two 
regions across the viral genome separated by nearly 100 kbp. These two 
regions are known as the origins of replication during EBV lytic cycle; OriLyt Left 
(L) and OriLyt Right (R). These regions are also referred to as left and right 
duplicated sequences of the genome (DSL and DSR) (Hammerschmidt and 
Sugden, 1988; Schepers et al., 1993b). Each OriLyt consists of a 1055 bp 
sequence known as the OriLyt core element.  The core element is identical in 
both regions and consists of two essential replication components separated by 
approximately 530 bp. The essential components contain multiple binding sites 
for viral BZLF1 as well as cellular proteins such as the transcription factors SP1 
and ZBP-89. In OriLyt L, BHLF1 and its promoter is found at one end of the 
OriLyt core element, while BHRF1 along with its promoter is found at the other 
end. These flanking genes are known as auxiliary components and contribute to 
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enhancing OriLyt activity. The whole region of the OriLyt including the core 
promoters of BHLF1 and BHRF1 genes span around 7.7 kbp (Hammerschmidt 
and Sugden, 2013).  
 
It is worth noting that a deletion of one OriLyt does not affect the ability of EBV 
to replicate during lytic cycle. Naturally occurring EBV strains with such 
deletions exist. For example, the B95-8 (deletion of OriLyt R) and P3HR1 
(deletion of OriLyt L) strains have the ability to induce lytic cycle and produce 
new virions (Cho et al., 1984; Raab-Traub et al., 1980).  A diagram illustrating 
the main features of EBV genome is presented in Figure 1-2. 
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B
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Figure 1-2 EBV genome. The EBV genome is about 172 kbp double-stranded DNA.
The viral DNA exists as either linear within viral virions (A) or circular in infected cells
(B). There are four internal repeat regions (IR 1-4) separating the unique coding
regions (U1-5) and two terminal repeat regions (TR), which are fused together to
give the circular genome (A). OriP (green) is used to replicate the EBV genome
during latency. OriLyts R and L (orange) drive DNA replication during lytic cycle.
OriLyt R is deleted in EBV B95-8 strain. The immediate-early lytic proteins and the
early lytic BNLF2a ORFs are shown in (A) as red arrows. Image adapted from
(Longnecker et al., 2013; Price and Luftig, 2014).
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1.3.3 EBV strains and subtypes 
Worldwide EBV isolates are grouped into two types, known as type 1 (A) (e.g. 
B95-8 strain) and type 2 (B) (e.g. AG876 strain). This classification is based on 
differences in EBNA2 gene sequence. The identity between EBNA2 in the two 
strains is only 54% at the protein level. Type 1 EBV is the most prevalent type 
worldwide. However, the distribution of type 2 EBV is equal to type 1 EBV in 
certain geographical regions such as sub-Saharan Africa or even dominant over 
type 1 in other areas such as in Mexico (Farrell, 2015). An important feature of 
Type 1 EBV is that it is more efficient at immortalising B cells in vitro than type 
2, emphasising the role of EBNA2 in transforming B cells (Rickinson et al., 
1987).   
As described earlier, the prototypical type 1 EBV strain B95-8 strain was the 
first available complete sequence of the EBV genome (Baer et al., 1984). This 
strain, which was isolated from an infectious mononucleosis patient (Blacklow et 
al., 1971), has a deletion of about 13.6 kbp that spans IR4 and OriLyt R region 
affecting three open reading frames including LF1 and LF2, (Farrell, 2001; 
Farrell, 2015; Parker et al., 1990). The sequence of the deleted region has been 
determined based on EBV Raji strain (Parker et al., 1990).  
 
The available wildtype EBV type 1 sequence is based on B95-8 sequence 
integrated with the Raji sequence to complete the deleted region. The wildtype 
strain is the most annotated EBV genome sequence and available through 
NCBI accession number (NC_007605.1). In contrast to the B95-8 strain, EBV 
identified in Raji cells is incapable of complete lytic replication due to various 
deletions in the reading frames for its structural proteins (Hatfull et al., 1988). As 
mentioned earlier, another deletion (6.6-8.5-kbp) affecting OriLyt L, is also 
reported in various Burkitt’s lymphoma EBV isolates such as in Daudi and 
P3HR1 (Farrell, 2015). 
 
With the advancement of second generation sequencing technologies, many 
other strains from different parts of the world are being sequenced. 
Interestingly, particular EBV strains are more prevalent in certain tumors and 
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ethnic groups which may suggest a strong link between certain EBV strains and 
the tumor development. For example, the EBV type 2 strain (AG876) has been 
sequenced (NCBI accession number DQ279927) (Dolan et al., 2006). Also, 
complete DNA sequences are now available for many EBV isolates from 
different BL cells such as Raji, Akata, and Mutu. Furthermore, genome 
sequences of EBV strains such as GD1, GD2, HKNPC1, and M81, isolated 
from nasopharyngeal carcinoma Chinese patients, are available (Farrell, 2015; 
Kwok et al., 2012; Tsai et al., 2013). 
 
It is worth noting that sequence polymorphisms have been documented in 
various EBV latent genes such as in LMP1, LMP2A, EBNA1, and EBNA3B.  
EBV latency and latent genes will be discussed in the next sections. Apart from 
the known variations in latent EBNA2 between EBV type1 and type 2, there is 
either little evidence or more investigations are needed to establish any 
functional relevance of these variations (Farrell, 2015).  
 
Similarly, such sequence variations are seen in lytic cycle genes such as in 
BZLF1, BRLF1, BHRF1 and BNLF2a (Farrell, 2015). In particular, three BZLF1 
promoter (Zp) natural existing variants were shown to be associated with 
different types of lymphoma (Lorenzetti et al., 2014; Martini et al., 2007).   
 
 
1.3.4 EBV life cycle 
1.3.4.1 EBV biphasic life cycle 
In common with other herpesviruses, EBV shows a biphasic life: A dormant life 
phase known as latency and an acute productive phase (lytic cycle). Evidence 
for the EBV biphasic life cycle was observed initially in the differences between 
EBV producer and non-producer cell cultures.  EBV viral capsid antigen (VCA) 
and early antigen (EA), which are specific for EBV lytic cycle, are detected in 
the majority of EBV producer cell lines. On the contrary, these antigens were 
barely detected in non-producer cell lines. Also, EBNA1, a protein expressed 
during latency, was detected in over 90% of non-producer cells (Klein et al., 
1972; Reedman and Klein, 1973). 
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In latency, the virus establishes a life-long persistence in B cells as an episomal 
DNA, and only expresses a limited set of genes. On the contrary, during lytic 
cycle, the virus initiates a cascade of gene expression that facilitates the 
replication and packaging of EBV DNA into newly produced virus particles 
(virions).  
The EBV latency phase can be seen in healthy memory B cells, lymphomas 
and cancers from epithelial origins; while the lytic phase is typically seen in 
permissive epithelial cells and primary infected B cells (pre-latency). Latency is 
essential for EBV genome persistence and maintenance while in lytic, where 
most of EBV genes are expressed, the viral DNA is being replicated and packed 
in virions to produce new viral particles. EBV latency can be divided into four 
phases (latency 0, I, II and III) based on the set of genes expressed at each 
stage.  
In contrast, EBV lytic induction initiates a rapid cascade of genes expression to 
facilitate the production of new viruses. Latency and lytic cycles will be 
discussed in more details in the following sections.  
 
1.3.4.2 EBV primary infection 
EBV can be detected in the saliva of healthy infected carriers and is typically 
transmitted through the saliva from one person to another. However, whether 
EBV infects first B cells or epithelial cells in the oropharynx in vivo is still 
unclear. It is widely documented that EBV exists as a cell-free virus as well as a 
cell-associated virus in the oropharynx (Haque and Crawford, 1997). Also, the 
presence of virus-producing epithelial cells in vivo is well-documented (Lemon 
et al., 1977, 1978; Sixbey et al., 1984). EBV particles found in the saliva have 
similar characteristics to viruses shed from epithelial cells which has higher viral 
envelope glycoproteins gp42 (Jiang et al., 2006). However, recent studies 
showed that cell-free EBV is less efficient at infecting epithelial cells and 
requires resting B cells to mediate this infection (Shannon-Lowe and Rowe, 
2011; Shannon-Lowe et al., 2006). This adds ambiguity to the cells targeted in 
primary EBV infection.  
1-30 
 
  
The current model of EBV primary infection suggests that upon entry through 
saliva, infectious virus particles cross epithelial barriers to directly infect 
surrounding non-dividing naive B cells. This activates EBV-infected B cells into 
proliferating latent cells expressing all EBV latent genes. The expression of all 
EBV latent genes is known as type III latency program; latency will be 
discussed in the next sections.  
 
EBV newly infected B cells move into the germinal centre (GC) where they 
differentiate into memory B cells and EBV latent expression shifts to a more 
restricted latency expression profile. These cells join the memory B cell pool 
and establish EBV life-long persistence within the host (reviewed in 
(Chesnokova et al., 2015; Thorley-Lawson, 2015; Thorley-Lawson et al., 2013; 
Young and Rickinson, 2004)).   
 
Upon antigen-activation of memory B cell infected cells, they become terminally 
differentiated B cells (plasma cells) capable of producing new virions that are 
either shed into saliva by B cells surrounding the epithelial oropharynx or 
transferred to polarized basal surface epithelia (Shannon-Lowe and Rowe, 
2011; Shannon-Lowe et al., 2006).  Moreover, it is suggested that EBV released 
from productive B cells within the oral lymphoid tissue infects other nearby cells 
such as monocytes which subsequently migrate into the oral epithelia and 
transfer the virus to the epithelial cells (Tugizov et al., 2007).  Once the virus is 
transferred into the oral epithelium, viral replication and shedding into saliva 
begins in terminally-differentiated epithelial cells (Allday and Crawford, 1988).  
 
The fact that epithelial cell terminal differentiation supports EBV replication 
comes from studies in oral hairy leukoplakia (OHL) (Greenspan et al., 1985). In 
OHL EBV DNA, lytic proteins, as well as latent proteins, were detected in the 
mid-upper layer of OHL lesions but not the basal levels (Löning et al., 1987; 
Niedobitek et al., 1991; Sandvej et al., 1992; Zhang et al., 1988). For example, 
BZLF1 protein, which is essential for lytic cycle induction,  was only detected in 
the upper layers of OHL lesions but not the basal layers (Young et al., 1991b).  
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Despite the initial failure to detect EBV DNA using in situ hybridization in OHL 
basal layers (Niedobitek et al., 1991), it is believed that EBV infects and 
establishes latency in undifferentiated epithelia. Therefore, virus shedding only 
occurs at the mucosal surface layer (Allday and Crawford, 1988; Nawandar et 
al., 2015; Wille et al., 2013).  In Figure 1-3, a model of EBV primary infection 
and biphasic life cycle is illustrated, showing the virus major events that lead to 
viral latency.  
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Figure 1-3 EBV life cycle. The main route of EBV transmission is through
saliva. EBV infection in naïve B cells leads to their activation. The activated B
cells migrate into the germinal centre (GC). Changes to EBV expression profile
take place at this stage, and a few EBV-infected cells join the memory B cell pool.
In memory B cells, EBV expression becomes restricted to allow for lifelong
persistence (latency 0/I). Activation of EBV-infected memory B cells triggers their
differentiation into plasma cells. Cellular factors associated with this differentiation
activate BZLF1 (Zta) which leads to the productive EBV (lytic) cycle. Newly
produced virions in the plasma cells infect oral epithelial cells. Differentiated oral
epithelia allow EBV lytic activation thus acting as further amplifiers of EBV. New
EBV virions are shed from oral epithelia into saliva.
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1.3.4.1 EBV epigenetic regulation 
 
Like other herpesviruses, EBV DNA enters the nucleus as a naked linear DNA 
lacking any chromatin-associated proteins or DNA CpG methylation. This linear 
DNA becomes a covalently closed circular episome approximately 20 hours 
post-transfection. The rapid circularisation process helps to protect the 
linearised DNA ends from degradation and also reduces any DNA damage 
response in the host cell (Hurley and Thorley-Lawson, 1988). A delayed DNA 
damage response (DDR) up to seven days post-transfection is observed in 
EBV-infected cells.  It is thought that this DDR is not related to EBV linear DNA 
but as a consequence of induced stress by cellular proliferation (Nikitin and 
Luftig, 2012; Nikitin et al., 2010).  
 
The naked structure of DNA in the early infection stage (also known as pre-
latent phase) is thought to allow transcription at viral promoters. Thus, soon 
after the entry of EBV DNA into the nucleus, several EBV proteins are 
expressed such as the latent proteins EBNA1, EBNA2, and EBNA-LP 
(Hammerschmidt, 2015). EBNA2 mRNA expression, one of the earliest 
expressed protein in EBV infection, is driven from the Wp promoter. EBNA-LP is 
co-expressed with EBNA2 from the same promoter. Transcription from this 
promoter is mainly regulated by the B cell factor PAX5. EBNA2 causes the 
switch from the Wp promoter to an alternate promoter (Cp) which leads to the 
expression of a longer transcript that includes EBNA1 and EBNA3 genes 
(EBNA 3A, 3B &3C). EBNA1 can be expressed independently from a separate 
promoter (Qp) in the absence of other EBNAs. EBNA2 activates transcription of 
the viral latent membrane proteins  LMP1 and LMP2 (reviewed in (Lieberman, 
2015). The genomic locations of EBV latent promoters and transcripts are 
indicated in Figure 1-2. At this pre-latency stage, viral genes expression at this 
stage is not restricted to these latent proteins. Many lytic cycle genes are also 
transcribed. These include BZLF1 and BRLF1 (Kalla et al., 2010) as well as the 
early lytic genes such as BHRF1, BALF1, BMRF1, BCRF1, and BNLF2a 
(Hammerschmidt, 2015). The unmethylated state of EBV DNA at this stage 
inhibits the induction of EBV lytic cycle and DNA replication despite the 
expression of the BZLF1 (Kalla et al., 2012; Kalla et al., 2010). Many of the 
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expressed proteins at this stage facilitate B cell proliferation and apoptosis 
escape (Woellmer and Hammerschmidt, 2013). For instance, BZLF1 and 
BNLF2a help to avoid apoptosis and host immune response, respectively 
(Hislop et al., 2007; Inman et al., 2001). As described earlier, some of these 
proteins, e.g. BZLF1 and BNLF2a, are found in the virion as packed RNA, 
further illustrating their importance at this stage (Jochum et al., 2012). The pre-
latency phase takes around 10-14 days post-EBV infection (Hammerschmidt, 
2015). 
 
Epigenetic regulation of EBV DNA plays an essential role in EBV life cycle 
control bringing the EBV pre-latent phase to an end (reviewed in 
(Hammerschmidt, 2015; Lieberman, 2015).  The viral infection phase switches 
from pre-latent stage to latent stage. The EBV DNA becomes chromatinised 
and acquires DNA methylation. EBV DNA is chromatinised in a very similar way 
to the host genome; resembling a highly complex, and heterogeneous 
chromatin structure (Dyson and Farrell, 1985). Moreover, DNA CpG methylation 
is detected widely across the EBV episome (Diala and Hoffman, 1983; Dyson 
and Farrell, 1985). These changes in the EBV genome are also synchronised 
with changes within the EBV-infected cell itself. For instance, as shown in 
Figure 1-3, once EBV infects naïve B cells they rapidly become activated and 
enlarged, to begin proliferation.  
 
Nucleosome occupancy of viral DNA starts very early during the pre-latency 
stage around four days post-transfection. CTCF binding sites across the EBV 
genome are believed to be key players in organising EBV chromatin structure 
(Arvey et al., 2012; Lieberman, 2015)  On the contrary, DNA methylation of viral 
DNA is a slow process in infected primary B lymphocytes. CpG methylation 
becomes first detectable after two weeks and continues to increase for three 
months after EBV infection (Hammerschmidt, 2015; Kalla et al., 2010). 
 
DNA methylation and histone remodelers are critical in controlling EBV life 
cycle. DNA methylation is involved in silencing most latent EBV promoters with 
the exception for a few active sites such as Q promoter (Hammerschmidt, 
2015). Nucleosomes are dense on repressed lytic promoters during latency 
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ChIP analysis for histone 3 at various lytic promoters indicated a loss in 
nucleosomes occupancy at these promoters during lytic cycle activation 
(Woellmer et al., 2012). Furthermore, repressed lytic cycle promoters carry 
repressive chromatin marks such as H3K9me3 and H3K27me3. The latter, 
which is a polycomb repressor complex-associated mark, is reported to 
decrease significantly upon lytic cycle induction. ChIP analysis for EZH2, the 
H3K27me3 methyltransferase, validated the changes seen in H3K27me3 during 
EBV lytic cycle. In agreement with this, the chromatin activation marks such as 
histone acetylation and H3K4me3 are reported to increase at lytic promoters 
during lytic cycle induction (Murata et al., 2012; Woellmer et al., 2012). Histone 
repressive marks are also present on BZLF1 promoter (Zp) such as H3K27me3, 
H3K9me2/3 and H4K20me3 in Raji cells (Murata et al., 2012) and H3K27me3 
and H3K9me3 in Akata cells (Ramasubramanyan et al., 2012b).   
 
In conclusion, EBV DNA chromatin structure governs the viral life cycle. In the 
early events of EBV infection, the key lytic cycle inducer BZLF1 is expressed. 
However, this does not lead to a viral productive life cycle because of the lack of 
viral DNA CpG methylation which is required for BZLF1 induced lytic cycle.The 
viral genome then becomes heavily associated with nucleosomes, CpG 
methylation, and chromatin repressive marks to facilitate a latent phase and 
establish persistence.  During the productive phase, these marks have to be 
reversed to allow the transcription of EBV lytic genes that contributes to the 
production of new virus particles. This phase is regulated by BZLF1 which can 
bind CpG methylated motifs and recruit histone modifiers such as CBP 
(discussed further in Section 1.4).  
 
 
1.3.4.2 EBV latency and transformation 
As discussed in earlier sections, latency is divided into different stages (Latency 
0, I, II and III) based on the set of expressed genes. The full latency profile 
(latency III) includes the expression of a set of six polycistronic nuclear proteins 
known as EBV nuclear antigens (EBNA1, 2, 3A, 3B, 3C, and EBNA-LP), three 
proteins found in the cell membrane (LMP1, 2A, and 2B) and several small 
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RNAs, specifically, the non-polyadenylated EBV-encoded small RNAs (EBERs), 
the noncoding RNA transcripts of the BamHI rightward transcripts (BARTs) and 
multiple miRNAs (reviewed in (Longnecker et al., 2013; Young and Rickinson, 
2004)) (see Table 1.3 for different EBV latency stages).   
 
Latency stage Genes expressed Associated cells and diseases 
Latency 0 
EBERs and miRNA/BART 
transcripts 
Peripheral memory B cells and 
non-dividing Burkitt’s lymphoma 
cells 
Latency I 
EBERs, miRNA/BART 
transcripts, and EBNA1 
Dividing memory B cells and 
Burkitt’s lymphoma 
Latency II 
EBERs, miRNA/BART 
transcripts EBNA1, LMP1 
and LMP2A/B 
Germinal centre B cells, Hodgkin 
lymphoma, nasopharyngeal 
carcinoma (NPC) and gastric 
carcinoma 
Latency III 
EBERs, BHRF1 miRNAs, 
miRNA/BART transcripts, 
EBNA1, EBNA-LP, EBNA2, 
EBNA3s, LMP1 and 
LMP2A/B 
EBV-infected naïve B cells, post-
transplant lymphroliferative 
diseases (PTLD) and 
Lymphoblastoid cell lines (LCLs) 
(in vitro) 
Table 1.3 Latency program.  
Data collected from (Longnecker et al., 2013; Price and Luftig, 2014).  
 
 
The importance of latency is not only seen in the ability of the virus to hide and 
establish life-long persistence but in its ability to readily hijack various cellular 
pathways and immortalise infected cells.  Thus, much of EBV research is 
focused on understanding the role of different latency proteins as these 
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contribute to our understanding of how EBV-associated cancers develop. The 
viral latency proteins have evolved to be specialised in mimicking cellular 
pathways, driving cell growth, transformation, chromatin remodelling, and 
immune evasion.   
 
The role of EBV latent proteins 
The role of EBV latency proteins in B cells transformation is evident from the 
ability of EBV to transform and establish latency III in B cells in vitro generating 
lymphoblastoid cell lines (LCLs) (Henle et al., 1967; Nilsson et al., 1971). 
Latency III EBV-infected B cells in vivo are associated with the development of 
lymphomas in immunocompromised patients. These cells, which are highly 
immunogenic, are readily cleared by the host immune system in healthy 
individuals. B cells expressing various latency programs in vivo have been 
detected in different disorders.  Latency II has a more restricted expression 
profile limited to EBNA1, LMP1, LMP2 and the noncoding RNAs. This latency 
program is seen in NPC and HL (discussed in Section 1.3.6).  In latency I, 
which is associated with BL, only EBNA1 and the noncoding RNAs are detected 
while the latter are detected exclusively in Latency 0. Latency program 0 and I 
do not lead to any immune response (Longnecker et al., 2013; Young and 
Rickinson, 2004). The role of each latent protein/RNA will be discussed briefly 
in the following paragraphs.  
 
EBNA1 
The 641 amino acids EBNA1 protein, expressed in all latency programs, has a 
primary role in mediating  EBV genome replication and persistence in dividing 
cells (Yates et al., 1984). EBNA1 is transcribed from the Q promoter (Qp) in the 
restricted latency programs where the other EBNAs are not expressed. EBNA1 
binds OriP and tether the EBV genome to cell chromosomes to mediate the 
replication of the EBV genome once per cell cycle. EBNA1 also acts as a 
transcription activator inducing the expression of latent genes from the viral C 
promoter (Cp). The Cp  is also adjacent to OriP which contains multiple binding 
sites for EBNA1 (Frappier, 2015). EBNA1 plays a role in cancer pathogenesis 
as it disrupts promyelocytic leukaemia nuclear bodies (PML), decreases p53 
activation, inhibits the NF-kB pathway, and enhances AP1 activity in NPC. 
1-38 
 
  
Unlike other EBNA proteins, EBNA1 peptides are not presented on the major 
histocompatibility complex class I (MHC I) so that it does not trigger any 
immune response by CD8 T cells. This is mainly attributed to the Gly-Ala 
repeats within EBNA1, which also explains the survival of cells displaying 
latency I in vivo (Frappier, 2015; Kang and Kieff, 2015).   
 
EBNA-LP 
EBNA-LP is expressed from the W repeats (W1 and W2 exons) within IR1 as 
mentioned earlier. Expression of EBNA-LP can be driven from either the Wp 
(upon infection) or the C promoter in later EBV infection phases in LCLs. The 
switch in promoters is attributed to EBNA2 expression which regulates C 
promoter. EBNA-LP and EBNA2 are transcribed as bicistronic RNA. The EBNA-
LP protein varies in size based on the number of W repeats (Allan and Rowe, 
1989). The primary function of EBNA-LP is to co-activate transcription with 
EBNA2 at various promoters (Kang and Kieff, 2015; Kempkes and Ling, 2015).   
 
EBNA2 
EBNA2 associates with cellular proteins such as RBPJ (also known as CBF1) 
and PU.1, to mediate transcriptional regulation through its two transactivation 
domains. EBNA2 stabilises RBPJ binding to DNA, recruits general transcription 
factors such as TFIIB, TAF40 as well as various coactivators and histone 
acetylases proteins such as CBP/P300 (Kempkes and Ling, 2015). The 
numerous targets of EBNA2 indicate the importance of EBNA2 in regulating 
viral and cellular genes. The Wp is the first active promoter upon EBV infection 
that leads to the expression of the EBNA proteins (Cheung and Kieff, 1982; 
Kempkes and Ling, 2015). EBNA2 is known to activate and mediate the switch 
to the C promoter. EBNA2 also activates the expression of LMP1 and LMP2 
proteins. Furthermore, at the cellular level, many EBNA2 identified targets are 
critical for cell transformation, viability and proliferation such as NF-κB complex 
as well as RUNX1, RUNX3, CXCR7 and c-Myc genes (Kempkes and Ling, 
2015). In recent years, the global association between EBNA2 and the cellular 
genome has been addressed using genome-wide ChIP-Seq analysis. These 
experiments identified thousands of EBNA2 binding sites within proximal 
promoters and distal enhancers across the genome; many of these sites were 
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also shown to be targeted by EBNA3s (McClellan et al., 2013; Portal et al., 
2013). More recently, EBNA2 was shown to associate with various super 
enhancer elements (Zhou et al., 2015) and regulate RUNX1 and RUNX3 
through distal super enhancer elements (Gunnell et al., 2016).  
The EBNA3 family comprises three proteins EBNA3A, EBNA3B and EBNA3C.  
These proteins bind to DNA and associate with RBPJ acting as a 
coactivator/repressor of EBNA2. Both EBNA3A and EBNA3C are essential for B 
cell transformation but EBNA3B is not. EBNA3A and EBNA3C promote cell 
proliferation by repressing the expression of pro-apoptotic proteins such as Bim 
(also known as BCL2L11) as well as tumour suppressors such as p16.  In 
contrast to EBNA2, EBNA3A and EBNA3C inhibit RBPJ recruitments to DNA, 
thus, interfere with EBNA2 activation which is mediated through RBPJ 
(reviewed in (Allday et al., 2015; Kang and Kieff, 2015). 
LMP1 and LMP2 
LMP1 and LMP2 are two latent essential proteins for cell immortalisation. Latent 
membrane protein 1 is a primary EBV oncogene and has six transmembrane 
domains. These domains ensure stable association with the membrane 
glycolipoproteins and mediate constitutive cell signalling. LMP1 mimic surface 
CD40 on B cells, which mediate the activation of CD4 T cells (T helper cells).  
LMP1 expression is reported in HL, LCLs, undifferentiated NPC and during EBV 
lytic cycle (Kang and Kieff, 2015). LMP1 contributes directly to cell 
transformation; fibroblasts and B cells transfected with LMP1 show uncontrolled 
growth and proliferation (Kilger et al., 1998; Yang et al., 2000). It is known to 
activate various pathways such as the NF-κB and MAPK pathways. It also 
affects epithelial cell differentiation and epithelial-mesenchymal transition (EMT) 
in NPC cells (Kang and Kieff, 2015; Kieser and Sterz, 2015).  
EBV encodes two additional similar latent membrane proteins, LMP2A and 
LMP2B. Both proteins have 12 transmembrane domains but LMP2B lacks a 
cytoplasmic signalling domain. These two proteins associate with the B cell Lyn 
and Syk protein tyrosine kinases. LMP2A blocks normal B cell receptor (BCR) 
signal transduction by mimicking antigen-independent activated BCR signalling. 
This induces B cell growth, transformation and promotes the survival of B cells 
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that are lacking BCR during germinal centre selection. In LCLs, LMP1 blocks 
the activation of tyrosine kinases, which inhibit EBV lytic cycle activation (Cen 
and Longnecker, 2015; Kang and Kieff, 2015). In epithelial cells, LMP2A and 
LMP2B together promote epithelial-mesenchymal transition through the 
activation of integrin and increase global tyrosine phosphorylation in these cells 
(Allen et al., 2005; Cen and Longnecker, 2015).   
EBV-encoded small RNAs 
In addition to the proteins above, EBV expresses two EBV-encoded small RNAs 
known as EBER1 and EBER2 (Lerner et al., 1981; Rymo, 1979).  These non-
polyadenylated non-coding RNAs are transcribed by host RNA polymerase III. 
EBERs are highly abundant and up to 5 million copies can be found per cell 
(Lerner et al., 1981). EBERs function remains obscure. However, they might 
play a critical role in B cell transformation. Viruses that harbour a deletion for 
EBERs lose 50% of their transforming capacity (Yajima et al., 2005). Also, 
expressing EBERs in EBV-negative Akata cells restores their tumorigenic ability 
in SCID mice (Komano et al., 1999). 
EBERs bind various cellular proteins including the pattern-recognition receptors, 
autoantigen La, retinoic acid-inducible gene I (RIG-I), and AU-rich element 
binding factor 1 (AUF1) (Kang and Kieff, 2015; Lerner et al., 1981; Samanta et 
al., 2006; Skalsky and Cullen, 2015). EBERs are recognised by RIG-I, a 
cytosolic protein which senses viral dsRNA. RIG-I is part of the innate immune 
response to protect against viral infection by activating protective cellular genes 
such as type I interferons (INFs) (Samanta et al., 2006). RIG-I detection of 
EBERs also induces anti-inflammatory cytokines such as IL-10 which promotes 
cell growth.  The viral-induced IFNs induce RNA-dependent protein kinase 
(PKR), which leads to the inhibition of the translation machinery. However, 
EBERs bind PKR and block its activation (Kang and Kieff, 2015). 
EBV miRNAs 
EBV expresses at least 25 pre-miRNAs that form approximately 40 mature 
miRNAs. EBV miRNAs are transcribed from within the BART locus introns (21 
miRNAs) and from BHRF1 ORF (3 miRNAs) (Cai et al., 2006; Pfeffer et al., 
2004; Skalsky and Cullen, 2015). The expression level of EBV miRNAs is 
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variable between different cells and latency stages. EBV BART miRNAs are 
expressed in all latency stages while BHRF1 miRNAs are more restricted to 
Latency III (Pratt et al., 2009; Yang et al., 2013). Most EBV miRNAs facilitate 
viral persistence and cell transformation in EBV-infected cells. It is worth noting 
that the majority of the BART region is deleted in EBV B95-8 isolate. However, 
this does not affect the transformation ability of this EBV strain. EBV miRNAs 
target many cellular mRNAs; for instance, the BART miRNAs were reported to 
target PUMA and Bim, two pro-apoptotic proteins. Furthermore, cells infected 
with EBV that harbour a deletion for BHRF1 miRNA grew slower compared to 
cells infected with wild-type EBV. This suggests a role for EBV miRNAs in cell 
transformation. BHRF1 miRNAs were reported to target cellular genes involved 
in triggering a host immune response such as CXCL-11, a T cell-attracting 
chemokine. The expression and function of EBV miRNAs have been 
extensively reviewed in (Kuzembayeva et al., 2014; Skalsky and Cullen, 2015).  
 
A few EBV miRNAs were reported to target viral latent and lytic mRNAs. For 
instance, miR-BART20-5p was shown to directly target the immediate early lytic 
BZLF1 and BRLF1 mRNAs (Jung et al., 2014). Moreover, miR-BART2-5p was 
reported to target BALF5,  the viral DNA polymerase (Barth et al., 2008; Pfeffer 
et al., 2004). EBV miRNAs targeting viral lytic genes aid in suppressing EBV 
lytic cycle and promoting latency.  
 
EBV BARTs 
EBV is known to have several BamHI A rightward transcripts (BARTs) (also 
known as complementary strand transcripts (CSTs)). These are highly spliced 
polyadenylated mRNAs that span at least 16 overlapping exons (over 20 kbp) 
and arise from the same promoter (de Jesus et al., 2003; Sadler and Raab-
Traub, 1995; Smith et al., 2000). These various mRNAs were first reported in 
NPC cells passaged in nude mice.  Several ORFs were identified known as 
BARF0, RK-BARF0, RPMS1 and A73; however, results regarding the detection 
of an encoded protein for these mRNAs were contradicted (Raab-Traub, 2009; 
Smith, 2000). BART mRNAs are widely expressed in EBV-positive epithelial 
and B cell lines. Also, they are detectable by PCR in the peripheral blood of 
healthy EBV carriers (Chen et al., 2005; Chen et al., 1999). 
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1.3.4.3 EBV lytic cycle 
Once EBV lytic cycle is activated, a cascade of about 80 viral genes are 
expressed in a temporally regulated manner (Kenney, 2007; Longnecker et al., 
2013; Yuan et al., 2006). The first viral genes to be transcribed are the viral 
immediate-early (IE) genes BZLF1 and BRLF1 (Miller et al., 2007); both 
proteins are essential to complete EBV lytic cycle (Feederle et al., 2000). 
BZLF1 and BRLF1 expression in most latently infected cells induces EBV lytic 
cycle (Chevallier-Greco et al., 1986; Countryman and Miller, 1985; Darr et al., 
2001; Ragoczy et al., 1998).  The immediate-early lytic genes are characterised 
by the direct expression upon viral infection without being dependent on de 
novo viral or cellular protein synthesis. This was confirmed for BZLF1 where 
transcription was reported to be as early as 1.5 hours post-EBV infection in EBV 
-negative BL cell lines and primary B cells in the presence of a protein synthesis 
inhibitor (Amon et al., 2004; Wen et al., 2007).  
 
The viral IE proteins, either individually or cooperatively, activate the expression 
of the viral early (E) genes (Chevallier-Greco et al., 1986). For example, 
BMRF1, the viral DNA polymerase processivity factor, is activated more 
efficiently in the presence of both BZLF1 (Zta) and BRLF1 (Rta) (Cox et al., 
1990; Holley-Guthrie et al., 1990). In general, most EBV early genes act 
collectively to ensure successful completion of viral lytic DNA replication 
(Longnecker et al., 2013). This is clearly seen in EBV DNA replication where 
several core replication proteins are assembled at OriLyt. These proteins 
include the immediate-early proteins (BZLF1 and BRLF1), EBV DNA 
polymerase (BALF5), DNA polymerase processivity factor (BMRF1), EBV 
single-stranded DNA binding protein (BALF2), helicase (BBLF4), primase 
(BSLF1), and primase-associated factor (BBLF2/3) (El-Guindy et al., 2013; 
Fixman et al., 1992, 1995; Liao et al., 2005). Also, viral early lytic genes encode 
proteins such as viral kinase (BGLF4) (Chen et al., 2000), anti-apoptotic host 
BCL2 homologue (BHRF1) (Henderson et al., 1993), transcription factor 
(BRRF1) (Hong et al., 2004) and immune evasion protein (BNLF2a) (Hislop et 
al., 2007). The early lytic genes are dependent on de novo protein synthesis. 
However, unlike EBV lytic latent genes, they are not dependent on viral DNA 
replication (Amon et al., 2004). 
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The late lytic viral genes are more associated with EBV virion structural 
proteins. Transcription of most late lytic genes is dependent on both de novo 
protein synthesis and viral DNA replication (Amon et al., 2004; Kenney, 2007). 
An exception to this is the transcription of BcLF1 and BFRF3 genes which are 
not dependent on viral DNA replication (Serio et al., 1997). There are 
approximately 36 late lytic genes including tegument proteins, glycoproteins and 
a viral IL-10 homologue (McKenzie and El-Guindy, 2015; Yuan et al., 2006). 
The late lytic promoters are characterised by the presence of non-canonical 
TATA box (TATT) and thought to be regulated differently from early lytic 
promoters (Serio et al., 1998). The expression of the late lytic genes requires 
the assembly of several viral early proteins including BcRF1 which is a viral 
TBP-like protein that binds the TATT motif (Aubry et al., 2014; Buisson et al., 
1989; Gruffat et al., 2012; Gruffat et al., 2016; Serio et al., 1998). 
 
Lytic cycle reactivation is associated with the differentiation of cells in vivo. In B 
cells, the activation of memory B cells into plasma cells through the B cell 
receptor induces downstream B cell factors that activate the expression of the 
viral immediate early proteins (Crawford and Ando, 1986; Laichalk and Thorley-
Lawson, 2005). The human proteins XBP-1 and BLIMP-1, which are expressed 
during plasma cell differentiation, are thought to play a significant role in 
activating BZLF1 and BRLF1 promoters (Zp and Rp, respectively) (Bhende et 
al., 2007; McDonald et al., 2010; Reusch et al., 2015; Shaffer et al., 2002). 
Similarly, in epithelial cells, induced lytic cycle is linked with terminal 
differentiation (Karimi et al., 1995; Young et al., 1991a).  In epithelial cells, the 
cellular factors BLIMP-1 and KLF4 synergise in inducing lytic cycle (Nawandar 
et al., 2015). The epithelial differentiation-dependent kruppel like factor 4 (KLF4) 
is capable of inducing lytic cycle by binding consensus motifs within both Zp 
and Rp promoters in epithelial as well as B cells (Murata et al., 2013; Nawandar 
et al., 2015). 
In vitro, the transient expression of BZLF1 and BRLF1 can disrupt latency and 
induce EBV lytic cycle. In addition, several agents can activate lytic cycle such 
as the histone deacetylase (HDAC) inhibitor sodium butyrate, DNA 
methyltransferase inhibitors, and phorbol ester (McKenzie and El-Guindy, 
2015). Also, in EBV-positive BL Akata cells, cross-linking BCR with anti-
1-44 
 
  
immunoglobulin activates EBV lytic cycle (Takada and Ono, 1989). On the 
contrary, some compounds that specifically interfere with the viral DNA 
polymerase can inhibit EBV lytic cycle such as acyclovir and ganciclovir (Datta 
et al., 1980; Meng et al., 2010).  
 
Understanding the lytic cycle of the virus is highly significant because this phase 
leads to the production of infectious virus particles, thereby, promoting the 
infection of new cells as well as the transmission of the virus to new hosts. Also, 
various lytic proteins have a diverse role in manipulating different cellular 
pathways. More importantly, high EBV load in peripheral blood and antibody 
titre of viral capsid antigen (VCA) are two features that are always associated 
with either the pre-onset or pathogenesis of EBV-associated diseases as will be 
seen in Section 1.3.6. Moreover, expression of the viral lytic cycle genes 
BZLF1, BALF2, and BCLF1 were detected in NPC and healthy control biopsies 
while BRLF1 was identified specifically in NPC patients (Feng et al., 2000).  
Similarly, BZLF1 was detected in a subset of BL tumours and high anti-BZLF1 
IgG was also associated with BL (Asito et al., 2010; Niedobitek et al., 1995). 
These findings suggest a possible role for these lytic cycle genes in the 
pathogenesis of these diseases.   
 
1.3.5 EBV cell tropism 
As mentioned earlier, EBV infects B cells as well as epithelial cells. However, 
there are many differences between the events that associate with EBV 
infection in both cells. EBV infection of B cells is better understood because B 
cells are easily collected from peripheral blood samples and EBV infects these 
cells very efficiently in vitro (Moore et al., 1989). In contrast, EBV is less efficient 
at infecting epithelial cells as they do not express the CD21 receptor (Cohen, 
2000; Feederle et al., 2007).  
 
The dynamic entry of EBV into B cells is facilitated through high-affinity 
interaction between the EBV virion glycoprotein gp350 and CD21 (also known 
as complement receptor type 2 (CR2) on B cell surface (Fingeroth et al., 1984; 
Nemerow et al., 1987).  Another EBV glycoprotein gp220, a splice variant of 
gp350 that also has a binding site to CD21, might aid in the attachment 
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process. CD21 also exists as a complex with surface receptors CD19 and CD81 
on primary B cells. As the virus attaches, the crosslinking of CD19 and CD21 is 
mediated through gp350. This can activate the NF-κB and protein kinase C 
pathways which affect downstream events within the infected cells (Sinclair and 
Farrell, 1995). Also, EBV gp350 is known to interact with CD35, a complement 
receptor type 1, which helps in initiating EBV infection (Chesnokova et al., 
2015).  
 
Once attached to the B cell surface via CD21, the virus is endocytosed to form 
a membrane vesicle from which it escapes by fusing its envelope with the cell 
membrane. This fusion is mediated through the interaction of four EBV 
glycoproteins (gH, gL, gp42 and gB) with the cellular protein, HLA class II 
(Chesnokova et al., 2015).  EBV gH and gL are two glycoproteins that dimerise 
together to give a correct folding of the final protein structure (Matsuura et al., 
2010). Thus, they are commonly referred to as gHgL. The cleaved form of 
glycoprotein gp42 on EBV virion associates with gHgL and interacts with HLA II, 
which is essential for successful fusion (reviewed in (Chesnokova et al., 2015).  
 
In contrast to B cells, epithelial cells lack or express low levels of CD21 
(Fingeroth et al., 1999), which mediates EBV attachment through viral gp350 in 
B cells as discussed above. The high affinity of CD21 to gp350 plays a critical 
role in EBV infection. Epithelial cell lines that were engineered to express CD21, 
showed improved EBV infection (Li et al., 1992). Furthermore, epithelial cells 
lack CD19 and CD35 which also play a role in EBV attachment in B cells.  
 
In epithelial cells, EBV is believed to use gHgL to bind to a subset of integrin 
proteins that comprise the integrin alpha-v and beta integrins. Additionally, EBV 
BMRF2 encodes a glycoprotein that was also shown to interact with certain 
integrin proteins (Chesnokova and Hutt-Fletcher, 2014; Chesnokova et al., 
2015).  
 
EBV infection of epithelial cells in vivo is believed to be mediated by virus 
particles attached to CD21 on B cells interacting with epithelial cells at the 
basolateral surface. In vitro analysis showed epithelial cells are infected more 
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efficiently through B cell transfer infection. This interaction took place through 
the binding of the heparan sulphate moieties of CD44v3 to the lymphocyte-
endothelial-epithelial cell adhesion molecule (LEEP-CAM) (Shannon-Lowe et 
al., 2009; Shannon-Lowe and Rowe, 2011). 
 
Unlike in B cells, internalisation of the virus in epithelial cells is less understood 
due to the lack of an appropriate epithelial system. EBV gB, gH, and gL are 
required for epithelial fusion but not gp42. HLA II is not expressed in epithelial 
cells. Thus, the fusion is promoted by the interaction of gHgL and integrin 
proteins (Chesnokova and Hutt-Fletcher, 2014; Chesnokova et al., 2015).   It is 
worth noting that EBV virions produced in epithelial cells are more enriched for 
gp42 making the virions more competent at infecting B cells but not epithelial 
cells. Similarly, virions produced in B cells are more efficient in infecting 
epithelial cells due to the reduced gp42 expression (Jiang et al., 2006).  
 
1.3.6 EBV-associated diseases  
EBV infects and establishes life-long persistence in over 90% of the world 
population (Borer et al., 1999; de-The et al., 1975). EBV has been associated 
not only with the development of many cancers but also with several benign 
conditions such as infectious mononucleosis (IM) and oral hairy leukoplakia 
(OHL). EBV is recognised as the highly causative agent of lymphomas in 
immunocompromised patients and individuals with predisposing factors. EBV 
has been strongly associated with a wide variety of diseases. These diseases 
include Burkitt’s lymphoma, Hodgkin’s lymphoma (HL), nasopharyngeal 
carcinoma, T-cell malignancies, post-transplant lymphoproliferative disorder, 
gastric carcinoma (GC), breast cancer and several autoimmune disorders 
(reviewed in (Carbone et al., 2008; Chen, 2011; Kutok and Wang, 2006; Young 
and Rickinson, 2004)). 
 
1.3.6.1 Infectious mononucleosis (IM) 
Infectious mononucleosis (IM), also known as glandular fever, mono and kissing 
disease, is an acute disease caused by primary EBV infection in young adults 
1-47 
 
  
between the age of 15 -25 years (Dunmire et al., 2015).  Most studies carried 
out in children at the onset of EBV infection have failed to report any major or 
similar symptoms to IM (Fleisher et al., 1979). A recent study, in which over 500 
undergraduate students were monitored for EBV infection, showed that around 
75% of the students that encountered EBV between the age of 18-22 have 
developed typical IM symptoms while about 15% developed atypical symptoms 
and 10% were asymptomatic (Balfour et al., 2013; Dunmire et al., 2015).  
Typical IM infection is associated with various symptoms including sore throat, 
general fatigue, fever, swollen lymph nodes and an acute increase in white 
blood cells count (Hickey and Strasburger, 1997). 
 
The term ‘Infectious mononucleosis’ was suggested by Sprunt and Evans to 
describe the symptoms above over a 100 year ago (Butka, 1926). However, it is 
the same disease with glandular fever described by Emil Pfeiffer in 1889 (Tidy, 
1950).  The first indication that IM was associated with EBV occurred when a 
member of the Henle group, who used to give her blood as a negative control 
for EBV, had become seropositive for EBV after developing IM symptoms 
(Crawford, 2014). Further studies testing for EBV heterophile antibodies on 
various age groups over a long period showed that high antibody titre was 
associated with the conversion of seronegative to seropositive in IM patients 
(Henle et al., 1968). Although IM is mainly caused by EBV, it can also be 
associated with cytomegalovirus (CMV) (Hickey and Strasburger, 1997).  
 
EBV primary infection, primarily transmitted through kissing in young adults 
(Balfour et al., 2013), is followed by an incubation period of about six weeks 
before the development of any symptoms. IM symptoms are caused by a 
remarkable expansion in EBV-specific CD8 T cells. IM is also characterised by 
a high EBV load in the oral cavity and peripheral blood accompanied by a sharp 
rise in IgM antibodies against EBV viral capsid antigen (VCA) (Balfour et al., 
2013). EBV-infected B cells detected in tonsils in IM patients vary vastly in 
morphology and EBV latency gene expression (latency I-III). These cells include 
small to medium lymphoblasts as well as Reed-Sternberg cells similar to 
Hodgkin lymphoma (Kurth et al., 2000). 
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In general, the condition is self-limiting. However, in very rare cases 
complications such as haemolytic anaemia and thrombocytopenia were 
reported (Dunmire et al., 2015). There is no specific treatment for IM but 
corticosteroids can be prescribed to ease the inflammatory symptoms that 
accompany IM (Luzuriaga and Sullivan, 2010) 
 
1.3.6.2 Burkitt’s lymphoma (BL) 
Burkitt’s lymphoma (BL) is categorised into three types: endemic BL, sporadic 
BL and immunodeficiency-related BL (Schmitz et al., 2014). As described in 
Section 1.1, endemic BL was first described by Denis Burkitt in a restricted 
geographical area overlapping the malaria region in Africa (Burkitt, 1958; Burkitt 
and Wright, 1963; Dalldorf et al., 1964). Endemic BL is strongly associated with 
EBV and commonly seen in children between 2-15 years of age. Typically, 
patients present with a large tumour growth of the jaw. However, tumours are 
also frequently detected in the abdominal area, in organs such as the liver and 
intestine (Burkitt, 1958; Burkitt and O'Conor, 1961). The association of EBV with 
endemic BL is over 98% in contrast to sporadic EBV-associated BL, which is 
only about 20% (Rochford and Moormann, 2015). Despite this strong 
association with EBV, BL aetiology is a debatable subject as the malaria 
incidence rate has also been strongly associated with this tumour (Dalldorf et 
al., 1964; Rainey et al., 2007). 
 
A chromosomal translocation t(8:14) is recognised as a unique and driving 
factor of all types of BL (Hummel et al., 2006). This translocation places the 
oncogenic c-Myc gene under the control of the immunoglobulin (IG) heavy-
chain locus (Dalla-Favera et al., 1982; Zech et al., 1976). This results in high 
constitutive expression of c-Myc through the IG enhancer elements. The role of 
c-Myc in BL pathogenesis was confirmed, using mouse models which showed 
that constitutive expression of c-Myc was capable of driving tumours in different 
B cell lineages (Adams et al., 1985; Sander et al., 2012). 
 
EBV and malaria are the major risk factors in BL with a strong correlation 
between malaria and EBV infections in infant cases of endemic BL (Piriou et al., 
2012), Nevertheless, the role of both infections in the development of BL 
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remains ambiguous. However, both diseases are common in causing B cell 
hyperplasia. Thus, as a consequence of increasing the pool of B cells, the 
chance of chromosomal translocations increases. This  could, to some extent, 
explain the possible mechanisms in BL pathogenesis, although, other factors 
may also play a role (Magrath, 2012).  
 
Multiple copies of EBV DNA were shown to be present in BL biopsies as well as 
cell lines derived from BLs (zur Hausen, 1972; zur Hausen et al., 1970). 
Additionally, BL is believed to be a result of an expansion of one single cell 
infected with EBV. This was observed upon the examination of EBV genome 
terminal ends patterns in more than 10 cases of endemic BL  (Neri et al., 1991). 
 
Also, it is well-established that EBV transforms B cells in vitro which results in 
immortalised LCLs (Henle et al., 1967). However, unlike BL, these LCLs 
express program latency III which includes nine EBV proteins as previously 
discussed. These proteins are responsible for B cell immortalisation (Bornkamm 
and Hammerschmidt, 2001). In endemic BL tumours, EBV remains latent in 
these cells expressing only the virus nuclear protein EBNA1 and several small 
untranslated RNAs such as EBERs and miRNAs from the BHRF1 and BART 
regions (latency I) (Bornkamm and Hammerschmidt, 2001). EBNA1 is mainly 
associated with EBV episome maintenance. However, it could also play a role 
in inducing lymphomas as demonstrated in a transgenic mouse model (Wilson 
et al., 1996). Additionally, EBNA1 might aid in B cell survival as it is widely 
undetectable by the host immune response. In contrast, EBERs were reported 
to play a role in increasing cells tumorigenesis and resistance to apoptosis 
(reviewed in (Brady et al., 2007; Magrath, 2012; Rochford and Moormann, 
2015). It is worth noting that an atypical latency profile was reported in some BL 
cases where the cells contained EBV genome with a deletion in the EBNA2 
gene. These cells express EBNA1, EBNA3 and the viral Bcl2 homologue which 
aid in preventing apoptosis (Kelly et al., 2005). 
 
Malaria has been linked with B cell hyperplasia as well as causing B cell 
activation through the parasite Plasmodium falciparum encoded protein 
CIDR1α. This protein is expressed on the surface of infected red blood cells 
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leading to B cell activation and differentiation, thereby activating the EBV lytic 
cycle. This might play a role in increasing the viral load of EBV in endemic BL 
cases. Additionally, malaria could play a role in increasing the chances of 
chromosomal translocations through the interaction with Toll-like receptors 
(Magrath, 2012). 
 
BL is treated with chemotherapy with a success rate of over 80% and very low 
mortality rate especially among young adults (Burkitt, 1965; Burkitt et al., 1965; 
Costa et al., 2013). 
 
1.3.6.3 Hodgkin lymphoma  
Hodgkin’s lymphoma (HL) is one of the most prevalent lymphomas in western 
countries with an annual rate of three cases per 100,000  (Murray and Bell, 
2015). HL was first described by Sir Thomas Hodgkin in 1832, a lecturer in 
morbid anatomy at Guy’s Hospital Medical School in London (Hodgkin, 1832; 
Stone, 2005). HL is classified into two types: classical (cHL), which accounts for 
around 95% of cases and nodular-lymphocyte predominant Hodgkin lymphoma 
(NLPHL) which forms only 5% of HL cases. The difference between the two 
types is based on the morphology of the tumor cells present in each type.  In 
cHL, tumor cells are described as multinuclear Reed/Sternberg cells (HRS). 
These cells originate from pre-apoptotic germinal centre B cells and are 
characterised by a disrupted structure of lymph nodes, where malignant cells 
are surrounded by infiltrating cells such as T and B lymphocytes (Kuppers, 
2012). cHL is subdivided into four morphological types: mixed cellularity, 
nodular sclerosis, lymphocyte rich and lymphocyte depletion (Murray and Bell, 
2015).   
EBV is mostly associated with cHL in which the virus DNA is detected in around 
20-60% of cHL cases worldwide. Only a minority of NLPHL are believed to be 
associated with EBV (Kapatai and Murray, 2007). The association between 
EBV and cHL is widely variable between countries, gender and various age 
groups. For example, the percentage of EBV-positive cHL is about 57% in 
China, while lower rates have been reported in North America and Europe 
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(Kapatai and Murray, 2007).  A distinctive mark of HRS cells in cHL is the lack 
of a functional B-cell receptor (BCR), which is a result of mutations affecting the 
immunoglobulin gene. Furthermore, these cells have defects in the expression 
of B cell-specific transcription factors such as PAX5, and might express markers 
of other cell types such as T cells. HRS cells are also characterised by high 
expression of NF-kB transcription factors, which prevents apoptosis and 
contribute to the tumorigenesis of these cells (Murray and Bell, 2015). These 
cells are also characterised by the consistent expression of various 
lymphocytes markers such as CD30, CD15, CD20, ID2 and Notch1 (Kuppers et 
al., 2012).    
Similar to BL, monoclonal EBV genomes are detected in HL, which strongly 
suggests that HL results from the expansion of one cell that has been infected 
with EBV prior to tumorigenesis (Gulley et al., 1994).  High EBV antibody titre 
and symptomatic IM are considered as risk factors in cHL development (Massini 
et al., 2009).  It is not clear what role EBV plays in the development of HL, 
although, EBV may play a major role in promoting the survival of HRS cells. 
These cells express LMP1, LMP2A and -2B, EBNA1 and the EBER and BART 
transcripts (Latency II program). Although the HRS cells deficient BCR should 
promote apoptosis, LMP 1 and 2 proteins mimic normal CD40 and BCR 
signalling, respectively, contributing to the high expression of NF-kB and 
enhanced survival of these cells due to the activation of different pathways 
including RAS-PI3k-AKT pathway. Furthermore, the activation of EBV lytic cycle 
is prevented due to the lack of functional BCR signalling which is the major 
pathway that activates EBV lytic cycle and is required for B cell activation and 
differentiation to plasma cells (Murray and Bell, 2015).   
HL cases are widely treated with either chemotherapy or radiation therapy with 
a good prognosis; 65%–90% of patients in the early stages of HL are expected 
to make a full recovery within five years of the treatment (Kuppers et al., 2012). 
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1.3.6.4 EBV lymphoproliferative diseases (LPD) in 
immunocompromised individuals 
Patients with congenital or acquired immunodeficiency as well as post-
transplant patients who are undertaking immunosuppressive treatments are at 
risk of developing EBV-related lymphomas. This is due to the uncontrolled 
outgrowth of EBV-infected B cells. In immuno-competent individuals, cells 
expressing EBV latency III program are immediately cleared by host immune 
response mediated by EBV-specific cytotoxic T cell, (Hopwood and Crawford, 
2000).  
A good example of such EBV lymphoproliferative disease is post-transplant 
lymphoproliferative disorder (PTLD) where patients are usually the recipient of 
an organ or stem cells transplant. PTLD is dependent on the type of transplant 
and the course of immunosuppression treatment. High incidence rates are 
common with heart, lung, small intestine or multiple organs transplant (Ok et al., 
2015).   
PTLD can range from either benign (IM-like) or non-Hodgkin malignant 
polyclonal lymphocytic proliferation. Morphologically, PTLD can be classified 
into early lesions, polymorphic PTLD, and monomorphic PTLD. Early lesions 
are further categorised into plasmacytic hyperplasia (increased plasma cell 
numbers) and IM-like lesions (similar to IM-B cell hyperplasia).  On the other 
hand, polymorphic PTLD is characterised by lesions that affect the lymph node 
architecture. This is the result of an expansion of a polymorphic population of 
different lymphocytes including plasma cells and different B cells at various 
maturation stages (Ok et al., 2015). Unlike the polymorphic PTLD, 
monomorphic PTLD includes Burkitt’s lymphoma, diffuse large B-cell 
lymphomas and classic Hodgkin lymphomas that developed in post-transplant 
patients (Carbone et al., 2008).  
The pathogenesis of PLTD is linked with both EBV and KSHV (HHV-8). 
However, EBV is believed to be the major risk factor in PTLD as it is present in 
60%-80% of PTLD. In common with other EBV lymphomas, in monomorphic 
PTLD, the EBV genome is monoclonal suggesting that EBV infection happens 
1-53 
 
  
before the expansion of the malignant cells (Carbone et al., 2008). High EBV 
viral load and reduced EBV-specific T cells are used as a predictive marker of 
PTLD (Smets et al., 2002). In PTLD, the EBV latency expression profile 
depends on the type of lymphoma, however, typically type III latency is 
detected. EBV infection contributes directly to the development of PTLD. This is 
due to the presence of cells that express the full set of EBV latent proteins 
EBNAs, LMPs and BARTs RNA which are responsible for cell transformation 
and immortalisation.     
Additionally, the EBV replicative cycle might play a role in PTLD as over 80% of 
tumours associated with immunosuppression treatment show evidence of EBV 
DNA replication (Montone et al., 1996; Tanner and Alfieri, 2001). 
Immunohistochemical staining of PTLD biopsies confirmed the presence of the 
immediate-early lytic protein BZLF1 (Zta) (present in 81% of specimens) and 
late lytic gp350 antigens, confirming a complete lytic cycle in PTLD (Montone et 
al., 1996).  
Various treatment approaches are used in PTLD therapy including 
chemotherapy, and EBV viral load control. EBV viral load play an essential role 
in monitoring the disease and determine the best treatment approach. The 
overall survival rate of PTLD is estimated to be from 40%-60% within five years 
(Dierickx et al., 2015).  
 
1.3.6.5 Nasopharyngeal carcinoma  
Nasopharyngeal carcinoma (NPC) is a head and neck tumour and the most 
common cancer originating from the nasopharynx. NPC is rare worldwide but is 
prevalent in certain regions and among certain ethnic groups such as in 
Southern China, and North Africa (Chang and Adami, 2006). According to 
estimates from 2010, the incidence and mortality rates in Southern China were 
19.5 and 7.7 per 100,000 persons, respectively (Yang et al., 2016). 
 
NPC is classified into three subtypes: keratinizing squamous cell carcinoma 
(type I), non-keratinizing squamous cell carcinoma (types II) and 
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undifferentiated non-keratinizing squamous cell carcinoma (type III) (Young and 
Dawson, 2014). 
 
The etiology of NPC is associated with many factors including EBV infection, 
host genetics, and environmental factors. Epidemiological studies tracing NPC 
cases among Chinese patients living in Hong Kong and Chinese immigrants in 
the USA suggest that diet is also a possible etiologic factor. In some areas in 
China, preserved food such as salted fish is commonly consumed.   This type of 
food contains carcinogenic substances such as nitrosamines (Yu et al., 1981). 
This is further supported by the fact that such preserved food is also consumed 
in areas with high NPC incidence rates such as North Africa and Greenland 
(Raab-Traub, 2015). However, the fact that NPC is still high in Chinese 
immigrants born in the USA suggests that genetic factors also play a role in 
NPC (Buell, 1974). Indeed, various human leukocyte antigen (HLA)-DRB1 
polymorphisms have been strongly linked with the etiology of NPC (Yang et al., 
2016). 
 
The association between EBV and NPC was first based on the specific high 
antibody titre for EBV seen in approximately 84% of NPC cases from Africa, 
China and USA (Henle et al., 1970; Old et al., 1966). A few years later, the EBV 
genome was detected in NPC cells (Wolf et al., 1975). EBV is present in all 
types of NPC but it is commonly associated with the differentiated form 
(Pathmanathan et al., 1995; Sixbey et al., 1984; Young and Dawson, 2014). 
Similar to BL and cHL, Southern blot analysis of EBV DNA terminal repeats in 
NPC cells confirmed the presence of monoclonal EBV genome. This indicates 
that EBV infection took place before the expansion of the first tumor cell (Raab-
Traub and Flynn, 1986). 
 
EBV remains latent (type II latency) in NPC cells expressing only EBNA1, BART 
RNAs, EBERs and the latent membrane proteins, LMP1 and LMP2 (Young and 
Dawson, 2014). NPC cells are characterised by the reduced expression of 
typical epithelial factors such as catenin and N-cadherin, which induces 
epithelial to mesenchymal transition (EMT) indicating the metastasis capacity of 
this cancer. EBV proteins and miRNAs aid in altering cell growth regulation. For 
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example, in NPC cells, EBNA1 might play a role in increasing genetic instability 
by disrupting promyelocytic nuclear bodies (PML), which aid in DNA damage 
repair.  LMP1 is known to block p53-induced apoptosis while LMP2 might play a 
role in inducing epithelial cells transformation and inhibiting differentiation. 
Additionally, LMP2 induces cell migration by interfering with integrin expression 
and localization while BART miRNAs target pro-apoptotic cellular genes such 
as Bim (Raab-Traub, 2015). 
 
EBV strain variations isolated from various NPC cases may also play a role in 
NPC pathogenesis. For instance, an EBV strain isolated in Chinese NPC 
biopsies had a variant LMP1 harbouring a 10 amino acid deletion (Young and 
Dawson, 2014).  
 
EBV is an important tool in NPC diagnoses and prognosis. NPC is 
characterised by the presence of high IgA antibodies against EBV viral capsid 
antigen (VCA), and early antigen (EA). Also, EBV plasma viral load has been 
suggested as a useful marker in assessing NPC tumor load and stage (Chen et 
al., 2015). More recently, antibodies against the viral glycoproteins gH, and gL, 
which are required for EBV-epithelial cell infection, showed promising sensitivity 
in diagnosing NPC (Li et al., 2016). A combination of chemotherapy and 
radiotherapy is the current standard method for treating NPC. The overall five-
year survival rate for early NPC stage patients is over 90%. However, this rate 
decreases with NPC late stages (Zhang et al., 2013). 
 
1.3.6.6 Oral hairy leukoplakia (OHL) 
Oral hairy leukoplakia (OHL), also referred to as hairy leukoplakia (HLP), is a 
benign condition associated with epithelial cells of the tongue and is mostly 
seen in HIV-infected immunocompromised patients. Interestingly, EBV is not 
detected in tongue tissue of immunocompetent individuals (Pagano, 2009). 
Patients present with white lesions on their tongue that result from the high EBV 
replication level in these lesions (Greenspan et al., 1985). Early studies on the 
role of EBV in OHL have helped to broadening our understanding of the EBV 
infection cycle in epithelial cells.  BZLF1 protein was detected in the upper layer 
in OHL biopsies but not in lower layers indicating a link between BZLF1 
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expression and the degree of epithelial cells differentiation (Young et al., 
1991c). These initial findings were further supported by the activation of BZLF1 
promoter (Zp) by inducing differentiation in squamous epithelial cells (SCC12F) 
(Karimi et al., 1995).   Moreover, many other EBV transcripts were found to be 
abundant in OHL biopsies including BCRF1, BKRF4, BMRF2 and gp350/220 
(Lagenaur and Palefsky, 1999; Lau et al., 1993). Further studies on BMRF2 
promoter showed high basal level expression of this promoter in epithelial cells 
which explains its high abundance in OHL  (Lagenaur and Palefsky, 1999). In 
addition to lytic genes expression, the latent membrane protein LMP1 is also 
detected in OHL. LMP1 could play a role in the development of this disease by 
activating many proteins such as NF-κB, epidermal growth factor receptor 
(EGFR) and c-Jun terminal kinase 1 (JNK1) through the TRAF signalling 
pathway (Webster-Cyriaque et al., 2000). 
 
OHL is resolved quickly within 1-2 weeks of treatment with any EBV viral 
replication inhibitors such as acyclovir. However, recurrence of the disease after 
successful treatment is commonly reported (Resnick et al., 1988; Walling et al., 
2003). 
 
1.3.6.7 Gastric carcinoma (GC) 
Evidence that EBV was associated with gastric carcinoma (GC) was first 
obtained by the examination of around one thousand GC biopsies. 7% of the 
examined GC biopsies showed the expression of EBER1, and the EBV genome 
was detected in each cancer cell but not in surrounding lymphoid or mucosa 
stromal cells (Imai, 1994). This strongly suggested a role for EBV in EBV-
positive GCs. In common with other EBV lymphomas, EBV genome terminal 
repeat analysis indicated a monoclonal origin for these cancers (Imai, 1994). 
The EBV genes expressed in gastric carcinoma are (EBNA1), EBER1 and 
EBER2, and the BARTs transcripts; a small amount of latent membrane protein 
2A (LMP2A) is also expressed in some cases (Takada, 2000). EBV-positive GC 
patients had high serum EBV-specific antibodies, but EBV-specific cytotoxic T-
cells were not detected. This strongly correlates with the latency expression 
profile in which EBNA1 is known to evade any host immune response (Imai, 
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1994). Unlike Burkitt’s lymphoma and NPC, EBV positive gastric carcinoma 
cases are seen worldwide with no definite endemic regions; the incidence rate 
varies among regions ranging from 16–18% in the USA to 4.3% in China 
(Takada, 2000). Interestingly, Helicobacter pylori infection and smoking are 
recognised as the main risk factors for gastric carcinoma. Unlike NPC, there are 
no genetic predisposing factors identified in gastric carcinoma (Takada, 2000). 
Recently, it has been suggested that EBV-associated gastric carcinoma 
(EBVaGC) should be recognised as a separate subtype of gastric carcinomas 
(GCs) based on the unique molecular presentation of these GCs. The molecular 
markers of EBVaGC include recurrent mutations in the kinase gene PIK3CA, 
and DNA hypermethylation (Cho et al., 2016). Morphologically, EBVaGC is 
characterised by marked dense lymphocytic infiltration in which the number of 
tumour-infiltrating lymphocytes is greater than that of tumour cells. EBVaGC is 
subdivided into three types according to the cellular immune responses: 
Lymphoepithelioma-like carcinoma (LELC), carcinoma with Crohn's disease-like 
lymphoid reaction (CLR), and conventional adenocarcinoma (CA)  (Cho et al., 
2016). 
Currently, there is no specific treatment for EBVaGC. However, the primary 
option is surgical removal of the tumour. The use of EBV lytic cycle activation to 
induce cell lysis has been proposed. DNA demethylation agents can be used to 
target the hypermethylated EBV genome in EBVaGC; thereby inducing EBV 
lytic cycle (Iizasa et al., 2012). 
 
1.3.6.8 Other EBV-related diseases  
EBV may also play a role in a broad spectrum of benign, malignant, and 
autoimmune diseases. Here, some of these disorders will be discussed briefly. 
Firstly, although EBV infects and establishes latency in B cells, EBV infection in 
other lymphocytes, such as T cells and natural killer (NK) cells, has been 
reported. In fact, EBV-associated T cell lymphoproliferative diseases have been 
known for over 25 years. Patients with such diseases were reported to have a 
substantial increase in EBV viral capsid antigen (VCA) antibody titre (Jones et 
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al., 1988). Unlike EBV-associated B cell lymphomas, T cell lymphomas that are 
associated with EBV are very rare and show site-dependent patterns. EBV is 
mostly prominent in virus-associated hemophagocytic syndrome (VAHS) T cell 
lymphoma and nasal T/NK lymphomas.  Similar to other EBV-associated 
lymphomas, VAHS T cell lymphoma are infected with monoclonal EBV and 
express the latency I/II set of genes. VAHS T cell lymphoma might result in the 
life-threating fatal complication of hemophagocytosis (Kutok and Wang, 2006), 
in which hyperinflammatory cytotoxic T cells and NK cells mediate the 
engulfment of various hematopoietic cells by activated macrophages (George, 
2014).  
Similarly, nasal NK/T cell lymphomas have clonal EBV genome in all cases. 
These aggressive lymphomas are very rare throughout the world but commonly 
seen in Southeast Asian and South American populations (Kutok and Wang, 
2006; Tse and Kwong, 2013). Cells in these lymphomas, in most cases, are 
characterised by the lack of surface CD3 and T cell receptor as well as the 
presence of the NK marker CD56 and the expression of perforin, granzyme B, 
and TIA-1 (Kutok and Wang, 2006; Tse and Kwong, 2013). This correlates 
mostly with a NK cell origin for these tumours. However, in a small number of 
cases, EBV-associated T/NK lymphoma cells expressing CD2, CD3, and lack 
CD56 have been reported (Kutok and Wang, 2006; Tse and Kwong, 2013). 
The role of EBV in T and NK cells oncogenesis is not fully understood and there 
is no in vitro model for EBV immortalisation of such cells. However, various EBV 
latent genes might play a role in transformation. For example, LMP1 interacts 
with TRAF pathway proteins to activate and upregulate several proteins 
including NF-kB and BCL2 which leads to cell survival. EBER and BART RNAs 
induce various growth cytokines and promote cell proliferations (Cai et al., 
2015).  It is worth noting that that plasma EBV DNA load is correlated with 
tumour load, and high EBV DNA correlates with poor prognosis. These tumours 
are treated with a combination of chemo- and radiotherapy (Tse and Kwong, 
2013).  
An association of EBV infection with breast cancer remains to be proven 
despite many reports showing the presence of EBV DNA or EBERs in breast 
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cancer tissues. Contradicting results are presented in the literature regarding 
the correlation of EBV with breast cancer. For example, a recent meta-analysis 
of published reports found that 29.32% of breast cancer samples were infected 
with the Epstein-Barr virus and that EBV was more prominent in Asia (35.25%) 
compared to USA samples (18.27%) (Huo et al., 2012). However, a more 
recent study analysed EBV DNA in peripheral blood and tumour biopsies of 85 
breast cancer patients over a period of 7 years of follow-up, and found no clear 
correlation between EBV and tumour characteristics (Marrão et al., 2014).  
In the last four decades, EBV has been strongly linked to many autoimmune 
diseases. For example, the autoimmune disease systemic lupus erythematosus 
(SLE) has been linked with raised EBV-specific antibody titre and EBV viral load 
(Evans et al., 1971; Moon et al., 2004). However, a direct role of EBV in the 
development of SLE has not been established. Similarities between antibodies 
against EBNA1 and autoantibodies seen in SLE might indicate EBV as a 
causative agent (Ascherio and Munger, 2015).  
Another example of an EBV-related autoimmune diseases is multiple sclerosis 
(MS), a chronic autoimmune disease that causes damage to the nerve cell 
sheaths, and affects nearly 6000 individuals every year across the UK 
(Mackenzie et al., 2014).  The risk of developing MS was shown to increase 
substantially with the level of EBV antibody titre prior to the onset of the disease 
(Lunemann et al., 2007). Also, MS risk is 2.3 fold higher in patients with a 
history of infectious mononucleosis (Ascherio and Munger, 2015). The role of 
EBV in MS is unclear despite the fact that MS mostly occur in EBV- positive 
individuals with only a few exceptions where cases were reported in EBV-
negative children. In addition, MS is associated with many risk factors such as 
the genetic alleles of HLA-DR15, vitamin D deficiency, and smoking (Ascherio 
and Munger, 2015).  
An association between EBV and  rheumatoid arthritis (RA) was proposed when 
sera from RA patients reacted specifically with EBV-positive B cell cultures 
(Alspaugh et al., 1978). RA is characterised by chronic inflammatory 
polyarthritis that causes damage to the synovial joints. The incidence rate of RA 
is around 1% worldwide and 2-4 times more prevalent in women compared to 
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men (Costenbader and Karlson, 2006). The sequence similarities between 
EBV-encoded proteins such as gp110 and the β-chain of human leukocyte 
antigen (HLA)-DR4 might play a critical role in RA development. In common 
with the other diseases, EBV plasma load is higher in RA patients than in 
healthy controls and EBV-specific cytotoxic CD8 T cells are commonly seen in 
affected joints tissue (Costenbader and Karlson, 2006). The development of 
erosive RA in humanised mice infected with EBV is also a strong indication of 
the role of EBV in RA (Kuwana et al., 2011).  
In general, EBV is a plausible causative agent in autoimmune diseases. 
However, it is difficult to associate any single autoimmune disease with EBV. 
Like any other infectious agent, EBV might trigger an inflammatory reaction that 
leads to such diseases. EBV primary infection leads to the increased 
expression of several inflammatory cytokines such as IL-1β, TNF-α, and IL-6. B 
cell transformation by EBV initiates CD4+ T cells immune response that results 
in the expansion of EBV-specific CD8+ cells (Costenbader and Karlson, 2006).  
These diseases may therefore be the result of interactions between genetic 
predisposition factors and environmental factors that lead to an inflammatory 
reaction against self-antigens. 
1.4 Zta (BZLF1) 
The EBV immediate-early transcription factor Zta (also called BZLF1, Zta, 
ZEBRA, Z, and EB1) triggers the switch from latent to lytic infection 
(Countryman and Miller, 1985; Takada et al., 1986). The term Zta will be used 
throughout to refer to Zta protein.   
 
Zta expression is encoded by three exons in the BZLF1 gene and derived from 
the BZLF1 promoter (Zp). BRLF1 (Rta) gene is located upstream of Zp and 
transcribed from the BRLF1 promoter (Rp) (Figure 1-5 (A)). A longer alternative 
splice variant of the BRLF1 mRNA produces a fusion transcript of 
BZLF1/BRLF1. The fused protein, known as RAZ, interferes with Zta 
transcriptional activation (Longnecker et al., 2013).    
As discussed in Section 1.3.4.3, Zta is essential for the reactivation of latency 
in EBV infected cells (Feederle et al., 2000). Moreover, Zta orchestrates the 
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regulation of lytic cycle by directly regulating target viral and cellular promoters, 
hijacking various cellular pathways and initiating viral DNA lytic replication.    
 
1.4.1 Zta structure and DNA binding 
Zta is a basic leucine zipper (bZIP) protein which belongs to the AP-1 protein 
family. This family includes the human cellular proteins c-Jun, c-Fos and ATFs 
as well as the yeast GCN4 (Farrell et al., 1989; Lieberman and Berk, 1990). Zta 
shares homology in its basic domain with the AP-1 members, in particular c-Fos 
(Farrell et al., 1989). However, Zta contains 4 atypical heptad repeats (unlike 
other bZIP proteins) (Chang et al., 1990; Flemington and Speck, 1990c; 
Kouzarides et al., 1991). Zta is 245 amino acids (aa) in length and has a 
molecular weight of 35 KDa (Marschall et al., 1989; Seibl et al., 1986). This 
protein is encoded by three exons; each exon encodes a separate functional 
domain (Flemington et al., 1992; Lin and Flemington, 2010). Zta forms a 
homodimer and cannot dimerise with other cellular bZIP proteins to form 
heterodimers (Chang et al., 1990). Amino acid residues between 168-202 show 
similarity with c-Fos bZIP domain (Taylor et al., 1991). 
 
As shown in Figure 1-4, Zta can be divided into three major domains:  amino-
terminal transactivation (TA) domain (residues 1-167), basic DNA binding 
domain (DBD) (residues 175-197) and leucine zipper dimerization domain (DIM) 
(residues 197-221) (Flemington et al., 1992; Lin and Flemington, 2010).  
 
The three-dimensional structure of the Zta fragment (residues 175–237) 
harbouring two single point mutations (S186A and C189S) and bound to DNA 
(AP-1 site) was solved at 2.25 Å resolution (Figure 1-4 (A)) (Petosa et al., 
2006). This has demonstrated the unexpected structure of Zta where the C-
terminal residues fold back to stabilise the coiled-coiled dimerisation domain 
(Petosa et al., 2006; Schelcher et al., 2007; Sinclair, 2006).   
 
Zta has been subjected to large-scale mutagenesis studies which have 
revealed some of the structural features as well as the critical amino acid 
residues for Zta function. The TA domain is essential for Zta transcriptional 
activation, specifically, the region between residues 27-78 (Deng et al., 2001; 
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Flemington et al., 1992). The TA domain is also important for viral DNA 
replication; specifically, to interact and recruit the viral helicase (BBLF4). Zta 
with four point mutations (residues 22,26,74 and 75) failed to induce viral lytic 
DNA replication (Liao et al., 2001). This same Zta residues are required for Zta 
interaction with TFIIA-TFIID and the CREB-binding protein (CBP), and 
subsequently the stimulation of CBP histone acetyltransferase activity (Deng et 
al., 2001; Lieberman et al., 1997). 
 
The smallest region required for specific DNA binding is between residues 172-
227. However, the region between residues 141-245 is needed to give the 
same binding affinity seen in full-length Zta (Taylor et al., 1991). The atomic 
structure of Zta indicated that amino acids residues 182,185, 186 and 190 were 
in direct contact with the AP-1 site (Petosa et al., 2006). Zta with mutations in 
residues 178 to 180 or 187 to 189 failed to bind DNA (Taylor et al., 1991). In 
addition, the following Zta mutants Y180A, Y180E, or K188A were reported to 
affect DNA lytic replication (Heston et al., 2006).  Deletion of the region between 
residues 153-167 was shown to affect Zta binding affinity in vitro (Flemington et 
al., 1992). Several proteins (e.g. NF-κB, P53, Ku80 and EBV BMRF1) interact 
with the C-terminal region (Chen et al., 2011; Dreyfus et al., 2011; Zhang et al., 
1996). The C-terminal tail folds back against the zipper region which makes it 
important for stable dimerisation (McDonald et al., 2009; Petosa et al., 2006; 
Sinclair, 2006). Mutational analysis also showed this region is critical for binding 
with 53BP1 as well as DNA replication (Bailey et al., 2009a; McDonald et al., 
2009).  
 
Zta is also highly phosphorylated, and many crucial phosphorylation sites have 
been identified. The serine at 186 is phosphorylated by protein kinase C. The 
serine residue at 186 is found in Zta but not in the AP-1 protein c-Fos and it is 
vital for Zta binding at methylated ZREs in the BRLF1 promoter (Rp) but not 
binding to consensus AP-1 site (Adamson and Kenney, 1998; Bhende et al., 
2005; El-Guindy and Miller, 2004). The Zta S186A mutant failed to reactivate 
lytic cycle (Francis et al., 1997). Similarly, the Zta C189S mutant failed to bind 
methylated ZREs in Rp (Karlsson et al., 2008a). Also, S167, S173 are 
phosphorylated by Casein Kinase 2 (CK2). This phosphorylation is important for 
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the ability of Zta to repress Rta activation of the viral BLRF2 gene (El-Guindy 
and Miller, 2004). The Serine at 209 is phosphorylated by the viral kinase 
BGLF4; this phosphorylation mediates the interaction between Zta and BGLF4. 
This interaction results in the repression of Zta autoregulation at Zp (Asai et al., 
2006; Asai et al., 2009).  
 
A mutation introduced at C171 affected Zta DNA binding ability and impaired its 
capacity to initiate lytic cycle replication and transcription activation at several 
promoters such as BMRF1 and BRLF1 (Rp) (Wang et al., 2006). Similarly, a 
mutation at C189 impaired the ability of Zta to induce or to mediate cell cycle 
arrest and is required for Zta transcription activation function (Schelcher et al., 
2005).  
 
Zta is also known to be sumoylated at K12 which inhibits its transcriptional 
activity. A mutation in this site was shown to affect EBV DNA replication but not 
Zta transcriptional function (Adamson and Kenney, 2001; Deng et al., 2001; 
Hagemeier et al., 2010). 
 
Zta binds to the AP-1 canonical site (TGAGTCA) as well as many other sites 
related to AP-1 site, which are known as Zta response elements (ZREs) 
(Hardwick et al., 1988; Lieberman et al., 1990). Zta preferentially binds to 
methylated ZREs which is critical for activating the heavily methylated (silenced) 
EBV genome during latency (Bhende et al., 2004).  
ZREs are classified into unmethylated and methylated ZREs (Bergbauer et al., 
2010; Karlsson et al., 2008b). The unmethylated ZREs lack a CpG motif (class I 
ZREs). The methylated ZREs contain a CpG motif and are further classified into 
ZREs where Zta binding is enhanced by methylation (class III ZRE) or ZREs 
where Zta only recognises the methylated site (class III ZRE) (Karlsson et al., 
2008b).  
 
 
 
AB
Transactivation domain bZIP domain
N-terminus C-terminus
1 167 175 197 221 245
Figure 1-4 Zta (BZLF1) structure. Zta is a basic leucine zipper (bZIP) protein
which belongs to the AP-1 protein family. (A) The three dimensional structure of
the Zta fragment (residues 175–237) harbouring two single point mutations
(S186A and C189S) bound to DNA (AP-1 site) (Petosa et al., 2006). (B) A
schematic illustration of Zta protein showing the transactivation domain (dark
blue), the bZIP domain which consists of the basic DNA binding domain (blue)
and the dimerisation domain (green). The unstructured C-terminal tail is shown in
light blue.
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1.4.2  Zta promoter (Zp) 
Zta regulation at the transcriptional level is mediated by several cellular factors 
that are involved in either negatively or positively regulating its promoter. The 
Zta promoter (Zp) is divided into several cis - regulatory regions numbered ZI to 
ZV (Figure 1-5 (B)) (reviewed in (El-Guindy et al., 2013; Kenney and Mertz, 
2014)). 
 
ZI has four regulatory elements (ZIA-ZID) that are regulated by SP1/KLF and 
MEF2 transcription factors. MEF2D acts as a Zp repressor during latency in B 
cells and binds ZIA, ZIB, and ZID elements.  MEF2D repression is mediated by 
attracting histone deacetylation complexes (HDACs) to the promoter (Gruffat et 
al., 2002). Upon BCR receptor activation, MEF2D, which also bind ZII, becomes 
dephosphorylated by the cyclosporin A-sensitive calcium-mediated signalling 
pathway. Dephosphorylated MEF2D associates with histone acetylases, 
therefore, activating Zp (Bryant and Farrell, 2002). The ZII domain contains 
binding site for AP-1 and CREB proteins, which are important for Zp activation 
through AP-1 proteins. Both ZI and ZII are important for Zp activation through 
BCR crosslinking as well as TPA induction (Kenney and Mertz, 2014).  
 
ZIII has two ZRE elements for Zta binding (ZIIIA and ZIIIB) that mediate Zta 
autoregulation of Zp (Flemington and Speck, 1990a). Zta activates the promoter 
through binding to ZII and ZIIIB by associating with C/EBPα (Wu et al., 2004). 
SMAD proteins also play a role in Zp activation through five SMAD-binding 
elements (SBEs), located throughout Zp (El-Guindy et al., 2013).   
 
ZIV sites are involved in Zp silencing and bound by Zinc finger protein YY1 
(Kenney and Mertz, 2014). The ZV and ZV′ elements, located around the Zp 
transcription start site, are bound by E-box binding proteins ZEB1 and ZEB2 
(also called SIP1). These two proteins synergistically mediate Zp silencing (Ellis 
et al., 2010; Kraus et al., 2003). Other elements (HI and ZIIR elements) are also 
associated with Zp repression. The HI elements are bound by E-box binding 
protein E2-2, while the ZIIR element is bound by a protein that remains to be 
identified (Kenney and Mertz, 2014). 
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1.4.3 Zta protein interactions and functional diversity 
Zta is widely involved in many cellular pathways either directly or by regulating 
other viral and cellular genes. Also, it interacts and co-associates with many 
viral and cellular proteins (reviewed in (Sinclair, 2003)). For example, Zta 
interacts with the tumour suppressor protein p53 and interferes with its 
transcriptional function, preventing cell apoptosis (Mauser et al., 2002; Ning et 
al., 2003; Zhang et al., 1994). The anti-apoptotic role of Zta is further mediated 
by activating BHRF1 which encodes a viral BCL2 homolog (Ragoczy and Miller, 
1999) as well as activating human IL-10 (Mahot et al., 2003b).  
 
Zta was also shown to induce IL-13 by direct binding to the IL-13 promoter. The 
induction of IL-13 is believed to be important in the early stage of EBV infection 
to promote proliferation and growth of EBV-immortalised lymphoblastoid cell 
lines (LCLs) (Tsai et al., 2009). Also, Zta is known to upregulate IL-8 directly 
through binding to two ZREs within IL-8 promoter (Hsu et al., 2008) and 
indirectly through EGR-1 activation (Heather et al., 2009; Hsu et al., 2008). IL-8 
mediates infiltration of lymphocytes which indicates a possible role for Zta in 
EBV-positive lymphoma development and maintenance (Hsu et al., 2008). Zta 
is also involved in the regulation of several cytokines including inducing cellular 
cytokines that are involved in cell growth and proliferation such as TGF-β, and 
VEGF (reviewed recently in (Murata and Tsurumi, 2014)). 
 
The cellular CREB-binding protein (CBP) protein was shown to interact with Zta 
(Adamson and Kenney, 1999; Chen et al., 2001; Deng, 2003; Zerby et al., 
1999). This interaction requires the Zta dimerization domain (Adamson and 
Kenney, 1999). Furthermore, Zta is known to activate the cellular stress 
mitogen-activated protein (MAP) kinases (p38 and JNK) which result in ATF2 
phosphorylation and activation.  ATF2 plays an important role in activating Zp 
through ZII region of the promoter (Adamson et al., 2000). 
 
Zta interacts and inhibits NFҡB subfamily protein p65 as well as interferon 
regulatory factor 7, which helps in viral immune evasion. The role of Zta in 
immune evasion and transcriptional regulation is discussed further in the next 
sections.  
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The mitochondrial single-stranded DNA-binding protein (mtSSB) was found to 
co-immunoprecipitate with endogenous Zta during lytic cycle reactivation in the 
EBV-positive BL Mutu I and in LCLs. mtSSB knockdown affected Zta-induced 
viral replication but not its transcription regulation ability. A single point mutation 
in the Zta DNA binding domain (C189S) prevented mtSSB association with Zta 
(Wiedmer et al., 2008).   
 
Additionally, 53BP1, a DNA damage repair protein, associates with Zta through 
a region containing two BRCT domains (Bailey et al., 2009a). The C-terminus of 
both proteins was shown to be important for this interaction. Reduced viral 
replication was observed when 53BP1 was knocked down indicating its 
importance for viral replication (Bailey et al., 2009a).  
 
Zta interaction with Oct-2 inhibits Zta binding to lytic gene promoters and hence 
prevents lytic genes reactivation. The interaction between Zta and Oct-2 is 
mediated by the POU domain of Oct-2 and the DNA-binding/dimerization 
domain of Zta (Robinson et al., 2012).  
 
Additionally, high expression of Zta is known to disturb promyelocytic leukaemia 
bodies (PML). These nuclear structures contain many proteins and thought to 
be involved in many cellular functions such as apoptosis, MHC I presentation 
and DNA damage repair (Adamson and Kenney, 2001; Bell et al., 2000; 
Kenney, 2007). 
 
Zta hijacks the cell cycle to promote favourable conditions for viral lytic cycle 
DNA replication. Zta appears to mediate G0/G1 growth arrest and blocks G1/S 
transition. Zta facilitates this arrest by inducing cyclin-dependent kinase 
inhibitors, p21 and p27 as well as tumor suppressor protein p53. Furthermore, 
Zta reduces the expression of cyclin A and c-Myc (Cayrol and Flemington, 
1996a; Cayrol and Flemington, 1996b; Kudoh et al., 2003; Rodriguez et al., 
2001; Wu et al., 2003; Zhou et al., 2005). Zta induction of p21 expression 
involves the direct interaction with CCAAT/Enhancer Binding Protein C/EBP-α 
protein. Zta alone did not activate p21 promoter, but activation was reported in 
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the presence of C/EBP-α through a C/EBP-α binding sites in p21 promoter (Wu 
et al., 2003). 
 
Zta is essential for viral DNA replication during lytic cycle. It binds several ZREs 
in OriLyt and recruits viral replication proteins to OriLyt as previously described 
in Section 1.3.4.3.  Zta interacts with most viral replication proteins except for 
BALF2 (El-Guindy et al., 2007; McKenzie and El-Guindy, 2015). 
 
1.4.4 Zta transcriptional regulation function 
Zta induces transcription of its target promoters mainly by direct binding to Zta 
response elements (ZREs) including AP-1 sites within regulatory elements 
(Lieberman and Berk, 1990; Lieberman et al., 1990) as described previously in 
Section 1.4.3.  Additionally, Zta, through its transactivation domain, recruits and 
stabilises the general transcription factors TFIID and TFIIA at the core promoter 
to facilitate transcription (Chi and Carey, 1993; Lieberman, 1994; Lieberman 
and Berk, 1991, 1994; Lieberman et al., 1989; Lieberman et al., 1997). Zta is 
known to interact with coactivators CREB-binding protein (CBP) and its related 
protein P300 to stimulate histone acetyltransferase activity, and facilitate 
chromatin acetylation (Adamson and Kenney, 1999; Chen et al., 2001; Deng, 
2003; Zerby et al., 1999). Zta is thought to be involved in either the direct or 
indirect regulation of several viral and cellular genes.  For example, Zta 
interacts synergistically with the cellular oncogene c-myb to activate BMRF1 
promoter which requires Zta binding at the promoter (Kenney et al., 1992). A 
primary target for Zta is the viral immediate-early gene BRLF1 (Sinclair et al., 
1991). Zta binds preferentially to methylated sites on BRLF1, a unique feature 
that is essential for the induction of lytic cycle by Zta (Bhende et al., 2004, 
2005).  
 
Zta is known to directly activate several lytic genes such BMRF1 (Holley-
Guthrie et al., 1990), BALF2 (Hung and Liu, 1999), BHLF1 (Lieberman et al., 
1989) and BNLF2a, as will be shown in Chapter 5. Furthermore, the viral lytic 
genes (BSLF1, BSLF2, BALF2, BALF5, BBLF2/3, and BBLF4) are shown to be 
direct targets to Zta (Bergbauer et al., 2010). 
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Zta is known to autoregulate its own promoter (Zp) through direct binding to two 
adjacent ZREs within ZIIIA and ZIIIB regions of the promoter (Flemington and 
Speck, 1990a). The immediate-early protein Rta (BRLF1) is also activated by 
Zta (Bhende et al., 2004; Sinclair et al., 1991). 
 
Zta synergises with Rta through cellular MCAF1 and RanBPM to activate 
several viral promoters such as BHLF1, BHRF1, and BRLF1 (Chang et al., 
2010; Liu and Speck, 2003; Ragoczy and Miller, 1999; Yang et al., 2015). 
 
Zta, through its c-terminal region interacts with Ku80, a member of the DNA-
dependent protein kinase (DNA–PK) complex, to enhance the activation of 
BHLF1 promoter. This activation is mediated through Zta binding to ZREs within 
the promoter (Chen et al., 2011). The Ku protein is a heterodimer consisting of 
Ku70 and Ku80 and it is a known binding partner of Zta (Bailey et al., 2009a; 
Wiedmer et al., 2008). 
 
A number of cellular genes have also been identified as direct targets for Zta 
regulation (reviewed in (Chen et al., 2009; Sinclair, 2003). Activation of the host 
gene EGR-1 is mediated by Zta indirectly and directly through binding to ZREs 
within the EGR-1 promoter (Chang et al., 2006; Heather et al., 2009). This 
activation was enhanced at least 10-fold when the Zta binding site was 
methylated (Heather et al., 2009). 
 
A different example of Zta regulation is seen in the host CIITA gene. This 
important gene is constitutively expressed and encodes a transcription factor 
which is important in inducing MHC II expression (Germain, 1994). Unlike the 
previous promoters, CIITA is known to be downregulated by Zta; this is mainly 
mediated through a Zta binding site identified in the PIII region of the CIITA 
promoter. Although two ZREs ~1000 bp apart were identified by sequence 
analysis, Zta binding and regulation was dependent on one site only (Li et al., 
2009). Moreover, the TA domain of Zta was shown to reduce the activity of this 
promoter indicating a possible DNA binding-independent mechanism involved in 
CIITA downregulation by Zta.  A shorter region of the promoter lacking Zta 
1-71 
 
  
binding sites also showed reduced activity upon Zta transfection (Balan et al., 
2016).  
 
Several other cellular proteins are either positively or negatively regulated by 
Zta at the transcriptional level including human IL-10, c-Fos, and c-Jun 
(Flemington and Speck, 1990b; Mahot et al., 2003a; Sato et al., 1992). 
 
1.5 EBV immune evasion 
The co-existence of EBV with its host requires the virus to stay invisible to the 
sophisticated host immune system. Immediately upon viral infection, the host 
innate immune response is triggered. This response is facilitated by the pattern 
recognition receptors (PRRs) that are expressed in several immune and none 
immune cells.  Their function is to survey for any pathogen ligands such as 
nucleic acids, carbohydrates and proteins (commonly referred to as pathogen-
associated molecular patterns (PAMPs)). The PRRs are either cell surface 
receptors or unbound intracellular receptors (cytoplasmic). There are five 
families of PRRs including the Toll-like receptors (TLR) and RIG-I-like 
receptors. Activation of the PRRs expressed in the immune cells such as 
dendritic and macrophages cells mediates the secretion of many antiviral 
cytokines including interferons type I (IFN I). The biology and function of each 
receptor are reviewed in (Brubaker et al., 2015).  
 
The adaptive immune system also plays a role in blocking any viral infection. 
CD8 T cells are thought to be the major player in controlling primary viral 
infections. These specialized cells recognise viral peptides presented by MHC I 
molecules on the surface of infected cells. CD8 T cells have a cytotoxic function 
by secreting of cytolytic proteins such as Granzyme B and perforin, as well as 
cytokines such as IFNγ and TNFα. CD4 T subtype cells help in secreting 
various inflammatory cytokines and promote B cell survival and proliferation 
(Reviewed in (Zuniga et al., 2015)).  
 
Viruses including EBV have evolved to have various immune evasion 
mechanisms to escape the host innate and adaptive immune responses. These 
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mechanisms are usually dependent on viral life cycle stage. For example, 
during the entry of the virus, the EBV envelope glycoprotein gp42, which 
facilitate the viral entry and fusion to the host cell, binds to MHC II. This is 
thought to block MHC II interaction with CD4 T cells (Ressing et al., 2003). 
Moreover, the blockage of MHC II is mediated by a cleaved soluble form of 
gp42 (Ressing et al., 2005b).  
 
During pre-latency as well as lytic cycle, the expression of EBV lytic genes such 
as BZLF1, BCRF1 and BNLF2a are critical for immune evasion. Zta (BZLF1) 
interferes with the production of INFa4 and INFb by negatively regulating the 
interferon regulatory factor 7 (IRF7) (Hahn et al., 2005). Zta interferes with p65 
transcription activation, a subunit of NF-ҡB complex. This inhibits NF-ҡB 
signalling pathway and affects the regulation of many immune response genes 
triggered by this pathway (Morrison and Kenney, 2004). Furthermore, Zta 
directly downregulates the transcription of MHC class II trans activator (CIITA), 
a gene that promotes expression of MHC-II molecules (Balan et al., 2016; Li et 
al., 2009). In addition, Zta downregulates surface CD74, a chaperone for MHC 
II antigen presentation (Zuo et al., 2011b) On the other hand, BNLF2a inhibits 
viral peptide presentation on MHC I by inhibiting peptide loading into the 
transporter associated with antigen presentation (TAP) as will be discussed in 
the next section.  
 
BGLF5 and BILF1 are two other lytic cycle proteins which are involved in 
interfering with MHC I (Ressing et al., 2008; Zuo et al., 2009). BGLF5 inhibits 
cellular protein synthesis during lytic cycle. In EBV, this global protein synthesis 
shutoff is mediated by the viral BGLF5 which has not only DNase activity (Lin et 
al., 1995; Stolzenberg and Ooka, 1990) but RNase activity that affects global 
cellular mRNA stability (van Gent et al., 2011). This is thought to affect the 
protein synthesis of many cellular proteins involved in immune response such 
as TLR9 (van Gent et al., 2011) as well as the synthesis of HLA class I and II 
molecules (Ressing et al., 2008; Rowe et al., 2007). In a more recent report, the 
role of BGLF5 in reducing MHC I was shown to be less important as the 
downregulation of BGLF5 had minimal effects on MHC I presentation (Quinn et 
al., 2014).  
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BILF1 encodes a constitutively active G-protein-coupled receptor (GPCR) 
(Paulsen et al., 2005). The downregulation of MHC I by BILF1 is not associated 
with its GPCR function but it is due to the interaction and interference with HLA I 
transport to the cell surface as well as increased degradation of these 
molecules (Zuo et al., 2011a; Zuo et al., 2008). Furthermore, BDLF3, a viral 
glycoprotein (Nolan and Morgan, 1995) promotes the ubiquitination of both 
MHC molecules to facilitate their proteasomal degradation (Quinn et al., 2016). 
It is worth noting that MHC I targeting by EBV proteins is believed to be phase 
dependent. For example, the role of BNLF2a in reducing peptide presentation 
on MHC I affects the presentation of immediate-early and early lytic genes. In 
contrast, BILF1 affects antigen recognition of early and late lytic genes (Quinn 
et al., 2014). 
 
Furthermore, BCRF1, the host IL-10 homologue affects T cell activation by 
inhibiting various immune response modulators such as MHC I and MHC II 
complexes, as well as the ICAM 1 receptor (a receptor that facilitates the 
interaction between leukocytes and epithelial cells) (Salek-Ardakani et al., 
2002).  
 
During latency, EBNA1, which is expressed at all latency phases, is known to 
have an internal Gly-Ala repetitive sequence that leads to the prevention of its 
own peptide presentation on MHC I (Dantuma et al., 2002; Levitskaya et al., 
1995; Levitskaya et al., 1997). Various EBV latent proteins and miRNAs have 
been reported to be involved in immune evasion mechanisms; mostly by 
downregulating pro-inflammatory proteins and pathways (reviewed in (Ressing 
et al., 2015)).  
  
1.5.1 The role of BNLF2a in immune evasion 
Major histocompatibility complex class I (MHC I) molecules play a central role in 
host immune recognition of foreign antigens. The primary role of MHC I is to 
present short peptides processed within the cell to CD8 T cells. Circulating 
cytotoxic T lymphocytes (CTL) (CD8 T cells) differentiate between self and non-
self peptides. In a virus-infected cell, processed peptides from virus proteins are 
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presented on MHC I. Such cells are flagged by CTL as foreign antigens and are 
destroyed by CTLs. Thus, CTL immune response is dependent on efficient viral 
peptide presentation by MHC I in infected cells. The antigen processing starts 
with the degradation of intracellular proteins into very short peptides 
(approximately 8-16 aa). Protein degradation is mediated by the proteasome in 
the cytosol and resulting peptides are then transported into the endoplasmic 
reticulum (ER) where they associate with the transporter associated with 
antigen processing complex (TAP) at the ER membrane. Subsequently, 
peptides bound to TAP are translocated to the MHC I molecules. Mature MHC I 
molecules loaded with peptides exit the ER to be presented on the cell surface. 
TAP is a heterodimeric protein consisting of TAP1 and TAP2 subunits, both 
containing an N-terminal transmembrane domain and a C-terminal cytosolic 
nucleotide binding domain. The latter domain is associated with the peptide 
binding. Moreover, ATP molecules binding to TAP is essential for peptide 
transportation (reviewed in (Neefjes et al., 2011)).  
 
Several herpesviruses have developed various mechanisms to target the 
antigen presentation process to evade any immune response. For example, the 
HSV ICP47 protein is known to target TAP molecules by direct binding. CMV 
US6 is also known to inhibit the ATP binding by targeting TAP molecules 
(Røder et al., 2008). 
 
Similarly, EBV BNLF2a, a 60 amino acids protein (6.5 KDa) expressed from the 
BNLF2a (ED-L2) promoter (Hudson et al., 1985), was shown to interfere with 
both peptide and ATP binding to TAP molecules within the ERs compartments 
(Hislop et al., 2007). The BNLF2a protein is a tail-anchored protein composed 
of a hydrophilic N-terminal region and a C-terminal hydrophobic part (20 amino 
acids). The C-terminal tail anchor mediates ER membrane association and 
retention, while its cytosolic N-terminus inhibits peptide and ATP binding to TAP 
(Wycisk et al., 2011).  
 
B cells infected with a mutant EBV, harboring a deletion in the BNLF2a gene, 
showed reduced recognition of viral immediate-early and early antigens by 
specific CD8 T cells. However, the recognition of late lytic antigens was not 
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affected by BNLF2a deletion when compared to wildtype EBV (Croft et al., 
2009). It is worth noting that BNLF2a expression was detected in nearly 50% of 
gastric carcinoma biopsies analysed by (Strong et al., 2015). Low expression of 
Zta was also detected in these samples. However, there was no significant 
correlation between the expressions of both proteins suggesting that BNLF2a 
expression is independent of Zta (Strong et al., 2015). 
 
Although, the role of BNLF2a results in a reduced viral peptide presentation on 
the cell surface, recent findings showed that a peptide from BNLF2a C-terminal 
region is presented on MHC I and recognized by CD8 T cells (Bell et al., 2009). 
This further supports that a collaborative role for EBV proteins in immune 
evasion is critical for viral immune evasion as described in the previous section.  
  
1.6 Project Aims 
A genome-wide ChIP-Seq experiment to detect Zta binding was carried out in 
BL Akata cells previously in our lab. This has identified binding sites for Zta 
across the viral and cellular genome. In this project, we aimed to investigate 
conservation of Zta binding across the viral genome in different cell lines 
including non-B cells.  
 
The genome-wide analysis of Zta binding across the host genome also showed 
that Zta was associated with distal enhancer elements. Therefore, we asked the 
question of whether Zta is able to enhance activation of a minimal promoter 
through distal ZRE element using luciferase reporter constructs.    
 
Zta binding was also observed in the ChIP-Seq data at the viral early lytic gene 
BNLF2a suggesting a role for Zta in regulating this promoter. We set out to 
characterise Zta regulation of this important gene for viral immune evasion and 
use it as a model to broaden our understanding of Zta transcriptional regulation 
of the viral early lytic genes.   
 
2-76 
 
  
Chapter 2 Materials and Methods 
2.1 Materials, and reagents 
2.1.1 DNA constructs (plasmids) 
Plasmid Name Generated by/ Reference Backbone plasmid Application 
pcDNA3 Invitrogen pcDNA3 
Control for 
Zta 
expression 
His-Zta 
(Full-length Zta) 
Previously in the lab 
(Bailey et al., 2009a) 
pcDNA3 
Zta 
expression 
His-GFP- bZIP Zta 
(Zta 168-245 aa) 
Myself with the help of Dr 
Louise Bird at Oxford 
Protein Production Facility 
(OPPF) 
pOPINN-GFP 
(OPPF) 
Protein 
purification 
and DNA 
binding 
PGL3-Control luciferase Promega PGL3 
Zta 
enhancer 
element 
analysis 
 
MinC-Null 
(CIITA -214+53) 
Previously in the lab by 
Nicolae Balan (Balan et 
al., 2016) 
PGL3-Control 
MinC-ZREs 
Undergraduate student: 
Renu Gurung 
PGL3-Control 
MinP-Null Myself PGL3-Control 
MinP-ZREs Myself PGL3-Control 
pCpGL luciferase (Klug and Rehli, 2006) pCpGL 
BNLF2a 
promoter 
analysis 
 
BNLF2a 1-5 
Previously in the lab by 
Kay Osborn 
pCpGL 
BNLF2a Null 
Previously in the lab by 
Kay Osborn 
pCpGL 
BNLF2a 4-5 Myself pCpGL 
BNLF2a 1-3 Myself pCpGL 
BNLF2a 2-5 Myself pCpGL 
BNLF2a 1&3-5 Myself pCpGL 
BNLF2a 1-2&4-5 Myself pCpGL 
BNLF2a 1 Myself pCpGL 
BNLF2a 2 Myself pCpGL 
BNLF2a 3 Myself pCpGL 
BNLF2a 1&2 Myself pCpGL 
BNLF2a 1&3 Myself pCpGL 
BNLF2a 2&3 Myself pCpGL 
BNLF2aTATA M Myself pCpGL 
BNLF2aKLF4 M Myself pCpGL 
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BNLF2a 1FL M Myself pCpGL 
BNLF2a 2FL M Myself pCpGL 
BNLF2a 3FL M Myself pCpGL 
BNLF2a 4FL M Myself pCpGL 
BNLF2a 5FL M Myself pCpGL 
BNLF2a 1-5FL M Myself pCpGL 
Table 2.1: Plasmid DNA constructs used in various experiments. 
 
 
2.1.2 Cell lines 
 
Cell line name Description Reference Application 
LCL#3 
Lymphoblastoid B cells 
transformed using B95-
8 EBV strain 
(Sinclair et al., 1994b) Zta ChIP-qPCR 
293-BZLF1-KO (also 
called 293 Z-KO) 
293 cells stably 
infected with 
recombinant EBV 
lacking BZLF1 gene 
(Semi-adherent cells) 
(Feederle et al., 2000) Zta ChIP-qPCR 
DG75 
EBV-negative Burkitt's 
lymphoma cells 
(Ben-Bassat et al., 
1977) 
 
Zta enhancer 
element analysis, 
and BNLF2a 
promoter analysis 
 
HeLa cells 
Adherent epithelial 
cells 
(Gey et al., 1952) 
BNLF2a promoter 
analysis 
Table 2.2: Mammalian cell lines used in various experiments. 
 
2.1.3  Antibodies 
Antibody Description Application Dilution Supplier 
Zta antibody 
(BZ1) 
Zta primary 
mouse 
monoclonal 
Western Blot 
(WB) 
1:500 
Gift from Martin 
Rowe Lab, 
Birmingham 
Described in 
(Young et al., 
1991c) 
Zta antibody 
(SCZ) 
Zta primary goat, 
polyclonal 
ChIP/EMSA 
10 μg/IP 
2 μg /EMSA 
reaction 
Santa Cruz Biotech 
(sc-17503) 
Normal goat 
IgG 
 
Goat 
ChIP (control 
antibody) 
10 μg/IP 
 
Santa Cruz Biotech 
(sc-2028) 
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ZEB1 
Goat 
polyclonal 
EMSA/WB 
2 μg/EMSA 
reaction 
Santa Cruz Biotech 
(sc-10572) 
ZEB2 (SIP1) Rabbit polyclonal EMSA/WB 
2 μg/EMSA 
reaction 
Bethyl Laboratories 
A302-474A 
β-Actin Rabbit polyclonal WB 1:5000 Sigma (A2066) 
IRDye 680CW  
 
anti-mouse 
secondary 
fluorescent Ab 
WB 1:5000/1:10000 LI-COR 
IRDye 800CW  
anti-rabbit 
secondary 
fluorescent Ab 
WB 1:5000/1:10000 LI-COR 
Table 2.3: Antibodies used in various experiments. 
 
2.1.4 Primers (oligonucleotides) 
2.1.4.1 ChIP-qPCR primers 
EBV gene 
target qPCR primers pair for ChIP (5′ to 3′) 
PCR product genome 
coordinates 
(NC_007605.1) 
BNRF1 
F (1) TGTGACACCAACAGGTGTTGCCTTG 
1501-1570 
R (1) ACCCCAAAGAGGGCAAAGCCTAC 
BCRF1 
F (1) GGGAGGTACATGTCCCCCAGCATT 
9253-9311 
R (1) CTGTGGACTGCAACACAACATTGCC 
BFLF2 
F (2) ATCTGCAGCCAGGCCCTTAGCC 
44985-45015 
R (2) CAAAACACGCTGCTGGATGTGCC 
BLLF3 
F (2) TCCATCTGGGCACTTCTGACGCT 
76463-76542 
R (2) CCGTCAGCAGCGTGTTCACAA 
BLLF2 
F (2) CTCAGTGACATGGAAGAGGTTG 
77863- 77970 
R (2) CCAACCACACCTTAGGAGGA 
BZLF1 
F (2) AGCCAAGGCACCAGCCTCCT 
90943-91018 
R (2) TGCATGAGCCACAGGCATTGCT 
BRRF1 
F (1) CCTGTTGTTTCGGAGAATGG 
92638-92770 
R (1) AATTTACAGCCGGGAGTGTG 
BRLF1 
F (1) GGCTGACATGGATTACTGGTC 
9389-93981 
R (1) TGATGCAGAGTCGCCTAATG 
BKRF4 F (3) CATTGCTCTCTGAGCGGTTA 98591-98667 
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R (3) ACCAGATGCTTCTTGGAGTTG 
BTRF1 
F (3) AGCTACGCAATCGGAGTCA 
126981-127034 
R (3) GGAGGCTCAGTCTAGCAG 
OriLyt-Flank 
F (1) GCGCAACAGTGCCACCAACC 
50517-50590 
R (1) CAGGACCTGGCGGTAGTGCAG 
OriLyt 
F (1) CAGCTGACCGATGCTCGCCA 
41196/144115-
41323/144242 R (1) ATGGTGAGGCAGGCAAGGCG 
BNLF2A 
F (2) GGCCGTGGGGGTCGTCATCA 
167728- 167759 
R (2) ACGCTGCTTTTGGGTTCTTCTGGT 
82Kbp 
F CCTCCGAGCCGTGTGAAGCTC 
82594-82682 
R CAAGAACCTCGGTGGCATCCTGG 
Table 2.4: Primers used in ChIP-qPCR experiments. ChIP-qPCR for EBV target 
genes.  
(1) (Ramasubramanyan et al., 2012b). (2) (Ramasubramanyan et al., 2012a). (3) (Flower et al., 2011). 
 
2.1.4.2 EMSAs primers 
DNA Probe Name 
(5' to 3') 
Sequence 
Fluorescent 
dye 
Primer 
Purificatio
n 
BNLF2a ZRE1 F ACACCTGTCCTCGCTCATCTTTCCACA 5’ IRDye 800 HPLC 
BNLF2a ZRE1 R TGTGGAAAGATGAGCGAGGACAGGTGT None Desalted 
BNLF2a ZRE2 F CACCTGTTGTTGACACATTCTTTGCGC 5’ IRDye 800 HPLC 
BNLF2a ZRE2 R GCGCAAAGAATGTGTCAACAACAGGTG None Desalted 
BNLF2a ZRE3 F CTTTCCATCTTGTGCCAATACACATTT 5’ IRDye 800 HPLC 
BNLF2a ZRE3 R AAATGTGTATTGGCACAAGATGGAAAG None Desalted 
BNLF2a ZRE4 F TCACCTTAACTGGCACACACTCCCTTA 5’ IRDye 800 HPLC 
BNLF2a ZRE4 R TAAGGGAGTGTGTGCCAGTTAAGGTGA None Desalted 
BNLF2a ZRE5 F TAAGCTACTATGACTAACCTTTCTTTA 5’ IRDye 800 HPLC 
BNLF2a ZRE5 R TAAAGAAAGGTTAGTCATAGTAGCTTA None Desalted 
BNLF2aZRE2M F CACCTGTTGTCCCCTTTTTCTTTGCGC 5’ IRDye 800 HPLC 
BNLF2aZRE2M R GCGCAAAGAAAAAGGGGACAACAGGTG None Desalted 
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ZRE2 E-BOX Flank motif 
BNLF2a ZRE2, E-
box F 
AGGAACACCTGTTGTTGACACATTCTT 5’ IRDye 800 HPLC 
BNLF2a ZRE2, E-
box R 
AAGAATGTGTCAACAACAGGTGTTCCT None Desalted 
BNLF2a ZRE2, E-
box M F 
AGGAAGTTTGGTTGTTGACACATTCTT 5’ IRDye 800 HPLC 
BNLF2a ZRE2, E-
box M R 
AAGAATGTGTCAACAACCAAACTTCCT None Desalted 
Table 2.5: Oligonucleotides used to generate EMSA probes.  
The ZRE motif in each oligonucleotide is underlined. The motifs coloured in red represent the 
mutant motif. 
 
 
2.1.5 Solutions and buffers  
 
Method  
 
Name Composition Purpose 
General 
molecular 
biology methods 
Tris-Borate-
EDTA 
(0.5/1XTBE) 
89 mM Tris (pH 7.6), 89 mM boric 
acid, 2 mM EDTA 
 
DNA 
agarose/EMSA 
retardation gel 
running buffer 
General protein 
methods 
WB  
transfer 
buffer 
25 mM Tris-HCl (pH 8.3) ,192 mM 
glycine, 20% (v/v) methanol 
WB 
PBS -Tween 
(PBS-T) 
138 mM NaCl, 2.7 mM KCL, 10 mM 
Na2HPO4, 1.8 mM KH2PO4 (pH 7.4), 
0.1%(v/v) Tween-20 
WB 
Ponceau S 
stain 
0.1% (w/v) Ponceau S in 5% 
(v/v) acetic acid 
Nitrocellulose 
membrane staining 
 
Chromatin 
immunoprecipita
tion-qPCR 
 
100 mM 
PMSF  
Phenylmethylsulfonyl fluoride (174 
mg) in 10 ml of 100% ethanol 
Added to all ChIP 
buffer at a final 
concentration of 
1mM 
IP dilution 
buffer 
0.01%(v/v) SDS, 1.1%(v/v) Triton 
X-100, 1.2 mM EDTA, 16.7 mM Tris 
(pH 8), 167 mM NaCl 
ChIP equilibration 
buffer 
SDS lysis 1% (v/v) SDS, 10 mM EDTA, 50 Chromatin 
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buffer mM Tris (pH 8) 
 
preparation 
Cell lysis 
buffer 
85 mM KCl, 0.5% (v/v) NP-40, 
5 mM PIPES (pH 8) 
 
Cell lysis 
Low salt 
buffer 
0.1% (v/v) SDS, 1% (v/v) Triton X-
100, 2 mM EDTA, 20 mM Tris (pH 
8), 150 mM NaCl 
 
ChIP washes 
High salt 
buffer 
0.1% (v/v) SDS, 1% (v/v) Triton X-
100, 2 mM EDTA, 20 mM Tris pH 8, 
500 mM NaCl 
 
ChIP washes 
Lithium 
chloride 
(LiCl) 
250 mM LiCl, 1%(v/v) NP-40, 
1%(v/v) Na-deoxycholate,1 mM 
EDTA, 10 mM Tris (pH 8) 
ChIP washes 
ChIP TE 
buffer 
10 mM Tris, 5 mM EDTA, 
 
ChIP washes 
Elution Buffer 
10 mM Tris, 5 mM EDTA, 1 mM 
PMSF, 1%(v/v) SDS 
ChIP Elution 
 
Protein 
purification 
 
Lysis Buffer 
pH 7.5 
50 mM Tris-Cl pH 7.5, 500 mM 
NaCl, 0.5 mM TCEP, ~350 units/ml 
Benzonase Nuclease, 0.2%(v/v) 
Tween-20 
His-GFP-bZIP Zta 
recombinant protein 
purification 
 
Equilibration 
buffer 
50 mM Tris-CL pH 7.5, 500 mM 
NaCl, TCEP 0.5 mM 
Washing 
Buffer 
50 mM Tris pH 7.5, 500 mM NaCl, 
30 mM imidazole. 
Elution buffer 
50 mM Tris pH 7.5, 500 mM NaCl, 
150 mM imidazole. 
 
Size 
exclusion 
elution buffer 
50 mM Tris pH 7.5, 300 mM NaCl, 
0.5 mM TCEP 
 
HeLa cells 
nuclear extract 
Cytoplasmic 
extract buffer 
(CE) 
10 mM HEPES pH 7.5, 60 mM 
KCL, 1 mM EDTA, 0.075% (v/v) 
NP40, 1mM DTT, 1 mM PMSF 
EMSA 
Nuclear 
extract buffer 
(NE) 
20 mM Tris-CL pH 8, 420 mM 
NaCL, 1.5 mM MgCL2, 0.2 mM 
EDTA, 1mM PMSF, 25% (v/v) 
glycerol  
EMSA 
EMSA 
Annealing 
buffer 
20 mM Tris-HCL pH 8.0, 1mM 
EDTA pH 8.0, 50 mM NACL 
EMSA 
 DTT 
1 M DTT stock (1.5 g in 10 ml 
nuclease-free water) 
EMSA 
Table 2.6: Solutions and buffers.  
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2.1.6 Kits and reagents  
 
General molecular 
biology methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kit/ reagent Purpose Supplier 
Maxi/Midi preps 
Kit 
Large–scale plasmid 
DNA extraction and 
purification 
Qiagen 
Mini-preps 
Small-scale plasmid 
DNA extraction and 
purification 
Qiagen 
T4 DNA ligase Sub-cloning Invitrogen 
5X T4 ligase 
buffer 
Used in ligation 
reaction 
Invitrogen 
Penicillin 
Bacterial cells 
selection 
Sigma 
 
Zeocin 
Bacterial cells 
selection 
Invitrogen 
 
HindIII restriction 
enzyme 
 
Restriction digest Roche 
BamHI 
restriction 
enzyme 
Restriction digest Roche 
10X Buffer H Restriction digest Roche 
HindIII-HF 
restriction 
enzyme 
 
Restriction digest NEB 
BamHI-HF 
restriction 
enzyme 
Restriction digest NEB 
KpnI-HF Restriction digest NEB 
SalI-HF Restriction digest NEB 
DpnI 
Digesting methylated 
DNA 
NEB 
CutSmart buffer Restriction digest NEB 
rAPid Alkaline 
phosphatase 
Digested Plasmid 
DNA phosphatase 
Roche 
DNA 
Hyperladder 
Bioline 
Agarose gel DNA 
marker 
Bioline 
5X Bioline DNA 
loading blue dye 
DNA agarose gel Bioline 
Gel Red DNA agarose gel Biotium 
Top10 
competent cells 
Plasmid DNA 
transformation 
Invitrogen 
PIR1 competent 
cells 
pCpGL derived 
constructs DNA 
transformation 
Invitrogen 
Rosetta PlysS 
competent cells 
Protein expression Novagen 
Phusion Flash 
Master Mix 
PCR Thermoscientific 
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AMPure XP 
magnetic bead 
PCR purification Beckman Coulter 
Bnzenase 
Nuclease 
Protein purification Sigma 
Luria Broth Bacterial cultures 
LifeSci school 
service department 
Power Broth™ 
Bacterial cultures 
(protein expression) 
Molecular 
Dimensions 
General protein methods 
 
 
 
 
 
 
Odyssey 
blocking buffer 
Diluting fluorescent 
secondary antibodies 
for WB 
LI-COR 
Dried milk 
powder 
WB membrane 
blocking 
co-operative 
NuPAGE Bis-
Tris SDS-PAGE 
(10% and 12%) 
Protein gel (SDS-
PAGE) 
electrophoresis 
Invitrogen 
NuPAGE MOPS 
buffer 
Protein gel (SDS-
PAGE) 
electrophoresis 
Invitrogen 
SeeBlue Pre-
stained protein 
marker 
Protein SDS-PAGE 
gel electrophoresis 
and western blots 
Invitrogen 
2X protein 
sample buffer 
Lamelli 
 
Protein SDS-PAGE 
gel electrophoresis 
Sigma 
SimplyBlue 
SafeStain 
SDS-PAGE staining Invitrogen 
Tissue culture methods 
 
 
 
 
 
 
 
 
 
DMEM medium 
Adherent cells 
culture 
GIBCO, Invitrogen 
RPMI 1640 
medium 
Suspension cells 
culture 
GIBCO, Invitrogen 
Foetal calf 
serum (FCS) 
Cell culture medium 
supplementary 
GIBCO, Invitrogen 
Penicillin, 
Streptomycin, L-
Glutamine 
(PSG) 
Cell culture medium 
supplementary 
GIBCO, Invitrogen 
DPBS Cell washing GIBCO, Invitrogen 
Trypsin-EDTA 
(0.25%), phenol 
red 
Adherent cell 
dissociation 
GIBCO, Invitrogen 
Dimethyl 
sulfoxide 
(DMSO) 
Cell freezing Sigma 
Hygromycin B 
293-BZLF1-KO cells 
selection 
Invitrogen 
 
Effectene Kit 
Adherent cells 
transfection 
Qiagen 
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Chromatin 
immunoprecipitation-
qPCR 
Protein G 
Sepharose 
beads 
Chromatin 
immunoprecipitation 
Sigma 
Protein A 
Sepharose 
beads 
Chromatin 
immunoprecipitation 
Sigma 
Salmon sperm 
DNA 
Sepharose beads 
blocking 
Invitrogen 
GoTaq Syber 
green master 
mix 
Real time 
quantitative PCR 
Promega 
Luciferase reporter 
assay 
 
5x Passive Lysis 
Buffer (PLB) 
Cell lysis Promega 
Luciferase 
reporter assay 
kit 
Luciferase 
measurement 
Promega 
EMSA 
 
10X orange 
loading dye 
EMSA LI-COR 
5X binding buffer 
Consist of (50 
mM Tris-HCl (pH 
7.5), 5 mM 
MgCl2, 2.5 mM 
EDTA, 2.5 mM 
DTT, 250 mM 
NaCl, 0.25μg/ul 
poly (dI-dC), 
20%(v/v) 
glycerol 
EMSA Promega 
Table 2.7: Kits and reagents. 
 
 
2.2 Methods 
2.2.1  General nucleic acid methods 
2.2.1.1 Molecular cloning by restriction enzymes digest 
2.2.1.1.1 Restriction enzyme digestion 
Restriction enzyme (RE) digests were frequently used in the cloning 
experiments. DNA restriction digest reactions were carried out in a total of 30 μl. 
As shown below, the mixture consists of 10 units of restriction enzyme (1μl) / 1 
μg DNA, 3 μl of the recommended enzyme buffer and an appropriate amount of 
DNA. For double-digest reactions, only 0.5 μl of each enzyme was used. 
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 Component of a restriction digest reaction Amount to be added (μl) 
10X restriction enzyme buffer 3 μl 
restriction enzyme (10 Units) 1 μl 
DNA X μl (up to 1 μg) 
H2O Up to a final volume of 30 μl 
 
 
The reaction mixture was incubated for a minimum of 1 hour at 37°C. In 
general, to achieve higher digest efficiency, longer incubation times (up to ~3 
hours) were regularly used. REs were heat-inactivated at 65°C for 20 minutes 
or according to the recommended inactivation conditions provided by the 
enzyme supplier. Although the RE reactions were more or less identical, a 
varied amount of DNA were used to obtain the desired DNA yield. These 
variations will be mentioned in the relevant sections.  
 
2.2.1.1.2 Subcloning 
To generate the reporter assay constructs, promoter and ZREs element inserts 
were ordered as synthetically designed DNA from either Invitrogen GeneArt or 
GeneStrings services. The GeneArt constructs were provided as a pre-cloned 
insert in a basic vector. 1 μg of this plasmid DNA was double digested with the 
appropriate enzymes (restriction sites used for each construct are given in the 
relevant Results chapter). After heat inactivation of the REs, DNA fragments 
were separated using 1.2% (w/v) agarose gel. The insert DNA band was sliced 
from the gel under UV light emission.  Subsequently, to extract the DNA, the gel 
slice was processed using gel extraction kit (Qiagen) according to the 
manufacturer’s protocol. The insert DNA concentration was determined based 
on UV light absorbance using a NanoDrop spectrophotometer (Invitrogen).  
 
Although the promoter constructs ordered using GeneStrings were subcloned in 
largely the same way as GeneArt constructs, there were a few differences. In 
contrast to GeneArt constructs, only 200 ng of Invitrogen GeneStrings was 
used. This was done to minimise the loss of DNA as only a small amount of 
GeneStrings DNA is supplied (between 400-900 ng). Also, the gel extraction 
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step was avoided as these constructs were provided as long double-stranded 
DNA strings. Instead, RE digested inserts were directly purified using the gel 
extraction kit (Qiagen). 
 
Similarly, the destination plasmid (vector) was digested with same enzymes to 
obtain compatible sticky ends with the insert. Furthermore, to reduce 
incompletely-digested vector DNA self-ligating, the vector plasmid was treated 
with rAPid alkaline phosphatase (Roche). The dephosphrylation step 
compatibility with the ligation reaction eliminated the need for further DNA 
purification prior to ligation. 
 
The vector dephosphorylation reaction (described below) was incubated for 10 
minutes at 37 °C followed by phosphatase enzyme inactivation at 75°C for 2 
minutes.  
 
Component of alkaline phosphatase reaction Amount to be added (μl) 
10X Buffer 2 μl 
Enzyme (1 Unit) 1 μl 
DNA X μl (up to 1 μg) 
H2O Up to a final volume of 20 μl 
 
 
2.2.1.1.3 Ligation  
An appropriate amount of the insert DNA and digested destination plasmid 
(vector) was used to set up ligation reaction. Ligation reactions were performed 
using T4 DNA ligase (Invitrogen). Vector and insert DNA were added in a ratio 
of 1:3 (vector: insert); typically, 50 ng of vector DNA was used for each ligation 
while the insert DNA amount was calculated according to the formula below: 
 
ng of vector X kb size of insert                                            insert 
--------------------------------------     X    molar ratio of              ------- 
kb size of vector                                                                  vector 
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The final reaction was made in a total volume of 10-15 μl as follows: 
 
Ligation reaction component Amount to be added (μl) 
10X Ligase Buffer 1 μl 
T4 Ligase 1 μl 
Insert DNA X μl 
Vector DNA X μl (50 ng vector)  
H2O Up to a final volume of 10-15 μl 
 
 
The ligation samples were incubated in ice/water bath overnight. The following 
day, a bacterial transformation reaction using 2-3 μl of the ligation mix was set 
up, as will be explained in the following sections.  
 
 
2.2.1.2 Molecular cloning by In-Fusion ligation 
2.2.1.2.1 PCR reaction 
In order to generate the His-GFP-bZIP Zta expression construct, In-Fusion 
ligation approach was used. These experiments were carried out with the help 
of Dr Louise Bird at Oxford Protein Production Facility (OPPF) as part of a 
collaboration project.  PCR was used to amplify the desired insert from template 
DNA (His-full length Zta plasmid).  Specific PCR primers were designed as 
described in Section 2.2.9.  
 
The lyophilised oligonucleotides were resusepnded in nuclease- free water at 
100 μM and a working stock for each primer was made at 10 μM.  Then, the 
PCR reaction was set as follows:  
 
PCR reaction component Amount to be added (μl) 
2X Phusion Flash Master Mix 25 μl 
Primers (10 μM) F&R 3 μl each 
Template DNA 2 μl (10 ng vector)  
ddH2O Up to a final volume of 50 μl 
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The thermal cycling parameters were as the following:  
98 °C for 10 seconds  
98 °C for 1 second 
60 °C for 5 seconds                   30 cycles          
72°C for 15 seconds  
72°C for 2 minutes 
Hold at 4°C 
A small amount (5 μl) of the PCR reaction was loaded onto 1.6% agarose gel to 
ensure a specific PCR product was obtained. Then, the PCR product was 
treated with DpnI enzyme to digest the template DNA as this DNA could 
interfere with the subsequent transformation procedure. This is due to the fact 
that the template DNA (His-Zta) is a plasmid DNA that shares the same 
antibiotic resistance cassette with the destination vector (pOPINN). DpnI 
enzyme digests only methylated DNA such as the plasmid DNA replicated 
within E. coli, while synthetically generated DNA (e.g. PCR product) remains 
undigested. After the DpnI treatment, the PCR product was purified using 
AMPure XP magnetic bead purification (Beckman Coulter, A63880) according 
to the manufacturer’s protocol.  
 
2.2.1.2.2 In-Fusion Ligation 
In-Fusion Ligation Master Mix was ordered as lyophilised mixture. 
Subsequently, 2 μl of the insert (the PCR purified product) was mixed with a 
100 ng of the destination linearised vector (pOPINN). The volume was brought 
up to 10 μl using nuclease-free water. The mixture was mixed with the ligation 
lyophilised material and was incubated for 30 minutes at 42 °C in a water bath. 
After that, the ligation reaction was diluted with 40 μl using nuclease –free 
water. Only 1 μl of the diluted reaction was transformed into competent bacterial 
cells. Subsequently, the bacterial cells were plated out on agar plates and 
processed as explained in more details in the next sections. 
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2.2.1.3 Bacterial transformation 
For a typical transformation reaction, a small amount of plasmid DNA (<10 ng) 
was mixed with 50 μl of competent E. coli cells. Strains of E. coli used routinely 
in the various experiments with the appropriate antibiotic concentrations are 
listed below:   
 
1- TOP10 E. coli competent cells used for PGL3 and pCDNA3 vectors; 100 
μg/ml ampicillin was used for selection.  
2- PIR E. coli competent cells used for pCpGL constructs; 25 μg/ml Zeocin 
was used for selection).   
3- Rosetta pLysS cells (protein expression strain) used for pCpGL 
constructs; 50 μg/ml of Ampicilin and Chloramphenicol (34 μg/ml) were 
used for selection.   
 
The competent cells aliquot (stored at -80 ºC) was allowed to thaw slowly on ice 
for a few minutes. Then, after the addition of plasmid DNA, the transformation 
mixture was left on ice for another 20 minutes. To facilitate the uptake of the 
plasmid DNA by competent cells, the sample was heat-shocked at 42 ºC for 45 
seconds and placed back on ice for 2 minutes. Soon after, to allow the recovery 
of the heat-shocked competent cells, 1 ml of LB broth was added under sterile 
conditions. The sample was left vigorously shaking (225 rpm) in an orbital 
shaker at 37 ºC for an hour. Under sterile conditions, only 10% of the mixture 
was immediately spread onto an ambient temperature LB agar plate 
supplemented with the appropriate selective antibiotic. The agar plate was 
placed upside down in a 37 ºC incubator overnight (~16 hours). The following 
day, the plate was examined for colonies. Given the presence of colonies, the 
plate was stored at 4 ºC until further use within a few days. 
 
An exception to this protocol was the transformation conducted using a ligation 
reaction. A modified amount of the ligated DNA (2-3 μl) was mixed with 50 μl of 
competent cells. This was based on the ligation reaction final volume; no more 
than 20 % of ligation mixture was used. Furthermore, two different volumes 
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(10% and 90%) of the transformed mixture were plated out onto two agar plates 
for each transformation.  
 
Another exception was in the case of pOPINN vector cloning where agar plates 
were prepared with the addition of X-Gal and IPTG. This allows the detection of 
β-galactosidase activity in order to differentiate colonies that have recombinant 
plasmids (white colonies) from the ones with inefficiently linearised or non-
recombinants plasmids (blue colonies). 
 
To screen for successful ligations, a few single colonies (routinely 2-4 single 
colonies) were picked using sterile tip, and inoculated, under sterile conditions, 
in separate tubes containing 5 ml of LB/PowerBroth culture (starter culture) 
supplemented with the appropriate antibiotic. The inoculated broth samples 
were kept shaking vigorously at 37 ºC for at least 16 hours to allow further 
growth of the transformed E. coli. Samples were stored at 4 ºC until further 
analysis. 
 
2.2.1.4 Subcloning validation 
As described in the previous section, 3 ml of the starter LB broth cultures were 
used to extract plasmid DNA. The obtained plasmid was assessed for the 
presence of the insert either via REs double digest or PCR (For the In-Fusion 
ligated vector) followed by agarose gel electrophoresis. Furthermore, validated 
samples from the RE digest screen were sent for sequencing analysis (MWG 
Eurofins, UK). Subsequently, sequencing data was analysed using BLAST tools 
to validate the ligated DNA by ensuring the presence of the correct insert 
sequence within the relevant vector plasmid. 
 
2.2.1.5 Bacterial glycerol stock 
For long term storage of bacterial stocks, 800 μl of the verified starter culture 
(as described earlier) was mixed with 200 μl of 100% sterile glycerol to achieve 
a final concertation of 20% glycerol. The mixed samples were stored at -80 ºC 
so they can be used as a source of DNA plasmids.  
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2.2.1.6 Plasmid DNA extraction 
2.2.1.6.1 Mini-prep 
Mini-prep plasmid extraction kit (Qiagen) was mainly used to obtain small 
amounts of plasmid DNA which can be utilized in either REs screens or DNA 
sequencing. Using 3 ml of LB broth starter cultures, bacterial cells were 
pelleted, lysed, and subsequently (the lysate) was passed through a DNA 
binding silica column. The plasmid DNA extraction and purification were 
conducted precisely according to the manufacturer’s protocol. 
2.2.1.6.2 Maxi/Midi-prep 
To obtain a high yield of plasmid DNA, a large-scale kit such as Maxi/Midi preps 
extraction were used. 500 μl of the validated 5 ml LB broth culture (as described 
in Section 2.2.1.3) was diluted in 500 ml of LB broth containing the appropriate 
antibiotic and incubated at 37 ºC overnight with agitation (225 rpm). The 
plasmid DNA extraction was carried out according to the manufacturer’s 
protocol (Qiagen).  
 
2.2.1.7 Agarose gel electrophoresis 
DNA gel electrophoresis was used to separate and visualise DNA fragments. In 
most experiments, a concentration ranging from  1-1.4% (w/v) agarose gel was 
used based on the expected sizes of DNA bands. 50 ml of 1x TBE containing 
an appropriate amount of agarose powder was brought to boiling temperature to 
dissolve the agarose completely. The solution was allowed to cool to room 
temperature before adding 10,000X GelRed DNA stain (Biotium) at a final 
concentration of  4 μl/ 50 ml of agarose solution. Subsequently, the agarose gel 
solution was poured into a sealed gel tray fitted with a gel comb. The gel was 
left to set at room temperature for 20 minutes, then, placed into an 
electrophoresis tank submerged with  1x TBE buffer. Samples were mixed with 
blue DNA loading dye (Bioline) and loaded into the wells along with a 1kb DNA 
hyperladder (Bioline) after removing the comb. Electrophoresis running settings 
were regularly performed at 100 V for 1 hour. DNA bands visualisation was 
carried out using LI-COR imaging system (600 channel). 
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2.2.2 General protein methods 
2.2.2.1 Western blots  
2.2.2.1.1 SDS-polyacrylamide gel electrophoresis  
To separate proteins and conduct western blots, commercially available precast 
Bris-Tris SDS-PAGE gels were used (NuPAGE, Invitrogen) along with NuPAGE 
MOPS SDS running buffer. Total protein lysate or cells pellet was boiled for 10 
minutes after the addition of 2X Laemmli protein buffer. Samples were 
subsequently spun down (13,000 rpm, 5 minutes) to precipitate any debris. An 
appropriate volume of each sample was loaded into the gel wells along with a 
pre-stained protein molecular weight marker set (SeeBlue marker, Invitrogen). 
Gel electrophoresis was carried out in a vertical tank at 200 V for 50 minutes.  
 
2.2.2.1.2 Protein transfer and immunoblotting  
After carrying out protein separation by electrophoresis, proteins were 
transferred to a nitrocellulose membrane. This was performed by placing the gel 
and membrane between sponges and filter papers (transfer sandwich). The 
sandwich was placed tightly in a transfer cassette and fitted in a tank filled with 
transfer buffer (25 mM Tris-HCl pH (8.3), 192 mM glycine, 20% (v/v) methanol). 
The transfer was conducted at 75V for 90 minutes in a cooled tank.  
 
Then, to check if successful protein transfer was achieved, the nitrocellulose 
membrane was covered with reversible Ponceau S stain for 2 minutes before 
being washed under running deionized water.  
 
Following the complete transfer of proteins, the nitrocellulose membrane was 
placed in a small dark box covered with 10 ml blocking buffer (5% dried milk in 
PBS-Tween). After 60 minutes of gentle rocking motion at room temperature, 
the blocking buffer was poured down the sink. Subsequently, the membrane 
was incubated (for at least 12 hours gently rocking at 4°C) with diluted primary 
antibodies in blocking buffer at the recommended dilution (A list of the 
antibodies is given in Table 2-3). On the following day, the blotted membrane 
was washed three times (5 minutes each time) in PBS-Tween at room 
temperature. By using fluorescent western blot method, it was sufficient to 
incubate the membrane with fluorescently labelled secondary antibodies 
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(Odyssey, LI-COR) and visualise the protein bands immediately after three 
PBS-T washes. The LI-COR imaging system was employed to visualise the 
protein bands under the 700 and 800 channels. The image capture was allowed 
for 10 minutes to minimise background signal.  
 
2.2.2.2 SimplyBlue SafeStain 
SimplyBlue SafeStain is an alternative Coomassie stain that provides a fast, 
sensitive and safe detection of proteins. The SDS-PAGE gel was rinsed (3 
times) with around a 100 ml of deionized water to remove SDS and buffer salts 
as these can interfere with the binding of the dye to proteins. Subsequently, the 
gel was soaked with around ~20 ml of the stain to cover the gel and left for 1 
hour at room temperature with gentle shaking. After incubation, the stain was 
discarded, and the gel was washed twice with around 100 ml water for 1 hour.  
2.2.3 Tissue culture 
2.2.3.1 Cell lines and culture conditions  
Various cell lines were used in the different experiments. B-cells such as the 
lymphoblastoid cell line 3 (LCL#3) (transformed with B95.8 EBV strain) (Sinclair 
et al., 1994b) and the EBV-negative Burkitt’s lymphoma cells (DG75) (Ben-
Bassat et al., 1977) were maintained as suspension cultures.  These cells were 
fed with RPMI 1640 medium (GIBCO, Invitrogen) supplemented with 10% (v/v) 
foetal calf serum and 100 U/ml of penicillin, 100 μg/ml of streptomycin and 2 
mM of L-glutamine (GIBCO, Invitrogen). Cultures were maintained at cells 
concentration between 3X105 and 3X106 /ml and passaged every 2-3 days 
based on cell density.   
 
293-BZLF1-kockout cells (293-BZLF1-KO) are 293 epithelial cells transfected 
with BZLF1 mutant EBV genome (Feederle et al., 2000). These cells were 
maintained as semi-adherent cells in RPMI 1640 media as described above 
with the addition of Hygromycin at a final concentration of 100 μg /ml for 
selection. To split these cells, it was enough to incubate them with phosphate 
buffered saline (PBS) (GIBCO, Invitrogen) for a few minutes to dissociate the 
cells from the flask. 
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HeLa, epithelial cells derived from cervical carcinoma (Gey et al., 1952), were 
maintained as adherent cells in DMEM media supplemented with 10% (v/v) 
foetal calf serum and 100 U/ml of penicillin, 100 μg/ml of streptomycin and 2 
mM of L-glutamine (GIBCO, Invitrogen). Cells were passaged (1 in 5) after 
reaching 60-70% confluency using trypsinisation.  
 
All cells were kept at 37°C in a humidified incubator containing 5% CO2 and 
handled with tissue culture standard aseptic techniques at all time.  
 
For long term storage of cells, a freezing medium was prepared using the 
cryopreservative agent dimethyl sulfoxide (DMSO) and foetal calf serum (15% 
DMSO (v/v)). Pelleted cells were resuspended in the freezing medium, divided 
in cryo-vials and placed in a freezing chamber which contains isopropanol to 
allow slow freezing at -80°C. After few days, frozen cells were moved from -
80°C to a liquid nitrogen storage.  
 
2.2.3.2 Transient transfections 
2.2.3.2.1 Adherent cells (Effectene transfection kit) 
293-BZLF1-KO and HeLa cells were transfected using a non-liposomal 
Effectene kit (Qiagen). The manufacturer protocol was followed with slight 
changes by reducing the amount of Effectene reagent used to 2.5 μl/ 1 μg DNA. 
For the luciferase reporter assay, on the day before transfection, HeLa cells 
were seeded in 6-well plates at 4x105 cells/well. The cells were transfected with 
a total of 1 μg of DNA (500 ng expression vector DNA with 500 ng reporter 
vector DNA) unless otherwise stated. DNA stock solution at 100 ng/μl was used 
for all 6-well plates transfections to ensure consistency in transfection protocol. 
After 48 hours, HeLa cells were scraped off the plate, washed once with PBS 
and collected into two halves for luciferase and western blots.  
 
On the other hand, 293-BZLF1-KO cells were maintained in large flasks to 
obtain enough cells that can be used in ChIP experiments. Thus, transfection 
DNA and reagent volumes were scaled up to 20 times to suit large flask 
transfections. Cells were harvested and cross-linked 48 hours post-transfection 
as will be described in Section 2.2.5. 
2-95 
 
  
2.2.3.2.2  Suspension cells   
Electroporation was used to transfect DG75 cells used in luciferase reporter 
assays. To ensure healthy cell growth and viability, cells were split 1:3 on the 
day before transfection. For each transfection, around 1.2X 107 cells suspended 
in 300 μl, pre-warmed serum-free medium was electroporated. A total of 10 μg 
of DNA, which contains 5 μg DNA of either pcDNA3 (control) or Zta expression 
vector (HisZta-pcDNA3) with 5 μg of the luciferase reporter vector was used.  
 
Electroporation was conducted in disposable transfection polycarbonate 
cuvettes with 4 mm gap size (VWR) using BIORAD Genepulser II. 
Electroporation conditions were set at 250 voltage and 975 capacitance. 
Transfected cells were immediately resuspended in 1 ml of media and 
transferred in 9 ml of media in a small flask. Transfected cells were incubated 
for 24 hours at 37°C before harvesting. Cells collected (24 hours post-
transfection) into two halves: luciferase assay and western blot. 
 
2.2.4 Luciferase reporter assays 
2.2.4.1 Luciferase reaction 
The firefly luciferase reporter assay (Promega) was used to investigate 
promoters and ZREs constructs activity. Transfected cells (either HeLa or DG75 
cells as described in Section 2.2.3.2) were pelleted and resuspended in 250 μl 
1X Passive Lysis Buffer (Promega). To ensure efficient lysis and 
homogenisation, samples were vortexed for 10 seconds. The cell lysis was 
allowed to take place at room temperature for 20 minutes which was followed 
by centrifugation in a microfuge at 13,000 rpm for 5 minutes at 4°C. For each 
transfection, 10 μl of the lysate was loaded in triplicate into a white 96 well plate. 
The plate was placed in plate reader machine (Promega GloMax multi-detection 
system) which allows the auto-dispensing of luciferase reagent (Promega LAR 
reagent). The plate reader was set to dispense 50 μl of LAR, take a read for 10 
seconds with a delay of 2 seconds after the addition of LAR reagent. Light 
emission was measured in relative light units (RLU). A background value 
representing the average of triplicate reads of the Passive Lysis Buffer was 
subtracted from all reads to account for background signal. 
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2.2.4.2 Normalization 
As previously stated, harvested cells for luciferase assay were divided equally 
into two halves. One-half was used to run a western blot to show Zta 
transfection levels as well as a loading control (β-actin). 
 
Thus, cells were boiled in 125 μl sample buffer Laemelli 2X (Sigma) with only 5 
μl of each sample was loaded onto SDS-PAGE gel.  From the western blot, the 
actin band intensity was quantified for each sample using the LI-COR Image 
Studio software. For each sample, the individual luciferase RLU reads were 
divided by the actin band intensity value for that sample. Then, the average and 
standard deviation were determined for the normalized RLU reads.  
 
2.2.5 Chromatin immunoprecipitation (ChIP-qPCR) 
2.2.5.1 Chromatin preparation 
Zta binding to various sites in the viral genome was determined in B 
lymphocytes and epithelial cells (LCL#3 and 293-BZLF1-KO cell lines) using 
ChIP-qPCR. First, cells were pelleted and resuspended using normal media to 
be at 1x107 cells/ml. To cross-link DNA-binding proteins to their sites, 
formaldehyde was added at a final concentration of 1% (v/v), and samples were 
kept rocking at room temperature for 10 minutes. The cross-linking reaction was 
stopped by the addition of glycine at a final concentration of 0.125 M. 
The cells were pelleted by centrifugation at 1300 rpm for 5 minutes and washed 
twice with PBS.  Pelleted and washed cells were either snap frozen or 
subsequently resuspended in 600 μl per 1x107 cell lysis buffer (85mM KCl, 0.5% 
NP-40, and 5mM PIPES pH 8.0). Cell lysis took place while samples were 
incubated on ice for 10 minutes. Soon after, nuclei were pelleted at 3500 rpm at 
4°C for 10 minutes. The pelleted nuclei were resuspended in 200 μl ChIP SDS 
lysis buffer per 1x107 cells (1% SDS (v/v), 10 mM EDTA, 50 mM Tris pH 8.0) 
after the removal of the supernatant. At this stage, the chromatin was ready for 
physical shearing by sonication. Chromatin fragments were reduced to small 
fragments between 200 and 600 base pairs in length.  Sonication was carried 
out in 1.5 ml Eppendorf tubes in a total volume of 200 μl chromatin aliquots. 
2-97 
 
  
During the sonication, samples were kept in ice water bath to avoid any effect  
the excessive heat generated by the sonication probe. The sonication 
conditions  were set for 12 cycles of 10 second on/off pulses at 30% output 
using Sonics Vibra cell VC 750 sonicator. 
2.2.5.2 Immunoprecipitation 
To prepare the beads, 100 μl of mixed protein A and protein G beads of 50% 
(w/v) bead slurry was used per immune-precipitation (IP). Beads were spun 
down at 3000 rpm at 4 °C for 5 minutes and washed 3 times with ChIP dilution 
buffer (0.01% (v/v) SDS, 1.1% (v/v) Triton X-100, 1.2 mM EDTA, 16.7 mM Tris 
pH 8.0, 167 mM NaCl). After that, the beads were resuspended in ChIP dilution 
buffer at 55 μl per IP. The beads were then blocked by incubation with 55 μl of 
10 mg/ml salmon sperm DNA (Invitrogen), at 4°C and kept rotating for 30 
minutes. Following that, the beads were washed twice with IP dilution buffer and 
resuspended in 55 μl IP dilution buffer.   
The chromatin samples were thawed on ice and then diluted 1:10 with IP 
dilution buffer to a final volume of 1 ml. Chromatin was pre-cleared by adding 45 
μl of bead slurry and incubated at 4°C with rotation for 30 minutes. The samples 
were centrifuged at 3000 rpm at 4°C for 5 minutes, and the supernatant was 
transferred to new tubes.  
 
At this point, 40 μl was removed from each sample (represents 4% input 
sample). Then, 10 μg of antibody to Zta (goat polyclonal antibody, sc-17503, 
Santa Cruz Biotechnology) or control antibody (normal goat IgG, Santa Cruz 
Biotech sc-2028) were added to each sample and incubated at 4°C with rotation 
for at least 1 hour. 55 μl of beads were added per IP and incubated at 4°C with 
rotation overnight. 
The following day, the beads were recovered by centrifugation at 3000 rpm at 
4°C for 5 minutes. The beads were then washed once (unless stated otherwise) 
at different contingency conditions using the following buffers in order:  
1- Low salt buffer (0.1% (v/v) SDS, 1% (v/v) Triton X-100, 2 mM EDTA, 20 
mM Tris pH 8.0, 150 mM NaCl),  
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2- High salt buffer (0.1% (v/v) SDS,1% (v/v) Triton X-100, 2 mM EDTA,20 
mM Tris pH 8.0, 500 mM NaCl)  
3- LiCl buffer (250 mM LiCl,1% (v/v) NP-40,1% (v/v) Na-deoxycholate, 1 
mM EDTA,10 mM Tris pH 8.0)  
4- ChIP TE buffer (0.01M Tris-HCl 5mM EDTA pH 7.5) (two washes). 
Each wash was for 15 minutes at 4°C while samples are rotating ChIP. Also, 
antibodies complex bound to beads were eluted with ChIP elution buffer (0.01M 
Tris-HCl, 5mM EDTA pH 7.5, 1% (v/v) SDS) by incubation at 65°C for 15 
minutes. At this step, input samples were thawed and processed in the same 
way as the IP samples. The supernatant was recovered and was incubated at 
65°C overnight to reverse cross-linking.  
The following day, the samples were diluted 1:2 with 150 μl of ChIP TE buffer 
and 2.5 μl of proteinase K (20 μg/μl) was added. To ensure the removal of all 
the protein, the samples were incubated at 55°C for at least 2-3 hours. Finally, 
the DNA was purified using PCR purification kit (Qiagen) and eluted in 100 μl 
nuclease-free water. 
2.2.5.3 Real time-qPCR 
Absolute quantification qPCR was performed using GoTag (Promega). The 
reaction was set as follows: 
 
 
  
 
 
 
 
2X Promega Master Mix 12.5 μl 
Primers Forward and Reverse mix 
(5 μM each) 
1.25 μl 
Nuclease-free water 8.75 μl 
DNA template 2.5 μl 
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The samples were run in 96-well plates and analysed using Applied Biosystems 
StepOne real-time PCR machine. The standard curves were obtained by 
making up 5 serial dilutions starting with 4% of the input DNA sample.  The 
cycle’s parameters were as the following: 
95°C for 10 minutes 
40 cycles of: 
95°C for 15 seconds 
60°C for 1 minute 
Primers used in the ChIP-qPCR experiments for target regions are listed in 
Table 2.4.  
2.2.6 Protein expression and purification (His-GFP-bZIP Zta) 
To investigate Zta interaction with BNLF2a ZREs, a basic leucine zipper domain 
of Zta tagged with His-GFP vector was cloned and screened for protein 
expression, as previously described.  
 
This vector was used to express bZIP Zta domain (tagged with GFP and poly 
histidine) in E. coli at large scale. Then it was purified using histidine affinity 
column as well as a size exclusion chromatography column.  
 
2.2.6.1 Protein expression 
A single colony of transformed Rosetta PlysS competent cells was inoculated 
into 20 ml of Powerbroth supplemented with the appropriate antibiotics in a 50 
ml tube. After overnight incubation at 37°C, with rigours shaking at 225 rpm, 10 
ml of the overnight culture was added to 500 ml of Overnight Express Instant 
TB Medium (autoinduction media) in 2 L flask supplemented with the 
appropriate antibiotics. The OD was continuously monitored while the culture 
was incubated at 37°C and shaking at 225 rpm. The incubation temperature 
was reduced to 25°C when the OD reached around 0.6-0.8 and the culture was 
incubated for approximately a further 20 hours. 
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2.2.6.2 Protein purification 
Transformed Rosetta PlysS cells from the autoinduced overnight culture were 
harvested at 6,000 g for 15 minutes at 4°C. The pellet was weighed and 
resuspended in an appropriate amount of lysis buffer (based on the weight of 
the pellet (30 ml/10 g of pellet)). This was followed by sonication using 10 
seconds off/on pulse for 10 minutes. The lysate was spun again to remove the 
insoluble fraction at 30,000 g for 30 minutes at 4°C. The clear lysate was 
transferred to a clean tube and kept on ice.   
 
A 1 ml HiTrap TALON Cobalt2+ column (GE Healthcare) was connected to 
FLPC ÄKTA purifier system and washed according to the manufacturer’s 
recommendations. Then, equilibrated with 15 ml of equilibration buffer (50 mM 
Tris-CL pH 7.5, 500 mM NaCl, TCEP 0.5 mM). 50 ml of the lysate was injected 
into the super loop (connected to the ÄKTA system).  The machine was set up 
to inject the lysate through the column at 1 ml/min flow, perform a 10 ml column 
wash using washing buffer, and elute using 10 ml elution buffer by collecting 20 
fractions (0.5 ml each) in a 96 deep well-plate. The fractions under the highest 
UV trace peak were pooled together and concentrated to 1 ml using VIVASPIN 
MWCO 50K spin column.  
 
On the same day, a GF 75 size exclusion chromatography column (GE 
Healthcare) was connected to FLPC ÄKTA purifier system and prepared 
according to the manufacturer’s recommendations. Subsequently, 500 μl of the 
concentrated protein sample (post affinity column purification) was injected into 
the column. The protein molecules were allowed to separate based on size by 
collection 60 fractions (1 ml each) in elution buffer (50 mM Tris-HCL, 300 mM 
NaCl, TCEP 0.5 mM). SimplyBlue stained SDS-PAGE was used to inspect the 
presence of the expected size band of the purified protein in the collected 
fractions in correlation with the UV trace.  
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2.2.7  HeLa cell nuclear extract 
Around 2X107 cells were scraped off the flask in 10 ml ice-cold PBS, pelleted 
and washed in 5 ml cold PBS. Pelleted cells were resuspended in 200 μl 
cytoplasmic extract buffer and kept on ice for 3 minutes to allow the breakage of 
the cells. Then, intact nuclei were pelleted in a microfuge at 1500 rpm for 4 
minutes at 4°C. The pelleted nuclei were washed once in 200 μl cytoplasmic 
extract buffer without NP-40. A 100 μl of nuclear extract buffer was added to the 
pelleted nuclei and kept on ice for 10 minutes with interval vortexing every 2-3 
minutes. The extract was aliquoted into smaller volumes, snap frozen, and 
stored at -80°C. 
 
2.2.8 Electrophoretic mobility shift assay 
EMSA assays were performed to investigate proteins of interest interactions 
with DNA in vitro. This requires the mixture of labelled DNA probes with the 
protein of interest followed by gel electrophoresis. 
 
2.2.8.1 Fluorescent EMSA probes preparation 
The EMSA probes were ordered as 27 bases single-stranded complementary 
oligonucleotides from Integrated DNA Technologies (IDT). Only one strand of 
the complementary oligos was labelled at the 5’ end with an IRDye 800 dye.  
Lypholisised labelled, and non-labelled oligos were resuspended in nuclease- 
free water to make a  100 μM stock of each oligo.  A working stock at 20 μM (20 
pmol/μl) was made by diluting each oligo in 1X EMSA annealing buffer. Then, 
equal volumes were mixed of the labelled complementary oligo and a 3-fold 
molar in excess of the unlabelled strand. To allow annealing of both strands, 
samples were placed in a 100°C heating block for 5 minutes. Subsequently, the 
heating block was turned off and samples were allowed to cool slowly until 
reaching room temperature. An EMSA working solution of the annealed DNA 
strands (EMSA probe) was achieved by diluting the annealed oligonucleotides 
at 1 in 10 ratio using nuclease-free water. EMSA probes were stored protected 
from light at -20 °C until further use. A list of all EMSA oligonucleotide 
sequences is provided  in Table  2-5. 
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2.2.8.2 EMSA binding reaction and gel electrophoresis 
The EMSA binding reaction was carried out as listed below: 
Binding reaction Amount  
5X binding buffer (Promega) 4 μl 
DNA probe (EMSA working stock) 2 μl 
Protein: 
- HeLa nuclear extract (5-30 μg) 
- Zta Purified protein (600 ng) 
 
X μl 
DTT (0.1M) 0.8 μl 
Nuclease -free water X μl 
Total:                                  20 μl 
 
Then, the EMSA binding reaction was allowed to take place for 30 minutes on 
ice/water bath while being protected from light. For the super shift EMSA, HeLa 
nuclear extract was incubated with 2 μg of the relevant antibody for 20 minutes 
prior to the addition of the EMSA reaction mixture.  
Meanwhile, a pre-run of the pre-cast native DNA retardation gel, which consists 
of 6% (v/v) polyacrylamide in 0.5XTBE buffer, was carried out in a pre-chilled 
0.5 X TBE buffer at a constant voltage (e.g. 100 V) for around 30-45 minutes.   
After the incubation, the binding reaction was mixed with 2 μl of loading dye 
(10X orange dye, LI-COR). 10 μl of each sample was loaded onto the gel and 
was allowed to run for 1 hour at 100 V. Once the run is done, the gel was 
imaged in the LI-COR under the 800 channel allowing 10 minutes for image 
acquisition.  
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2.2.9 Computational methods 
2.2.9.1 Primers design 
New primers were designed to investigate Zta binding at specific viral DNA 
regions where previous primers were not available in our lab. These oligos were 
designed using NCBI Primer-Blast web tool (www.ncbi.nlm.nih.gov/tools/primer-
blast). The oligos were created to be around 20 bp and give a product length 
ranging from 90 to 150 bp. Primers specificity was checked against the EBV 
wildtype genome (NC_007605.1) and EBV B95-8 (V01555.2) as well as the 
human genome. Design parameters were adjusted to obtain approximately 
65ᵒC Tm and 55% and 65% GC content for each oligo. On the other hand, 
primers used in the In-Fusion ligation were designed by Dr Louise Bird at 
Oxford Protein Production Facility (OPPF) using their automated primer design 
tool, which is available at https://www.oppf.rc-harwell.ac.uk/Opiner.   
 
2.2.9.2 MEME and TOMTOM motif search 
The conserved ZREs flanking motif was identified in silico by entering each 
BNLF2a core ZRE site (7 bp) and 14 bp flank bases on each side into the 
MEME motif search web tool (MEME Suite 4.10.2 http://meme-suite.org) (Bailey 
et al., 2009b). The significant transcription factor motif that were discovered 
using MEME  was then compared with other transcription factor motifs using the 
motif database scanning algorithm TOMTOM (Bailey et al., 2009b). 
2.2.9.3 ALGGEN-PROMO transcription factor motifs predicting tool 
PROMO web tool was used to search for Zta binding sites (ZREs). This tool 
predicts various transcription factors binding sites (TFBS) based on weight 
matrices defined in the TRANSFAC database (version 8.3) (Farre et al., 2003). 
The web tool is accessible online on: 
http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3 
 
2.2.9.4 Diagram and illustration design  
Thesis diagrams were designed using Adobe Illustrator CS6 and Microsoft 
PowerPoint.   
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Chapter 3 Zta binding across the viral genome 
3.1 Introduction 
As discussed in Chapter 1, upon EBV entry into the cell, the circularised viral 
DNA is maintained as an episome packed in higher order repressive chromatin 
structure in a very similar way to the host genome. This chromatin state is 
essential to maintaining latency by limiting the viral expression program to a 
specific set of genes (reviewed in (Lieberman, 2013).  
 
However, the viral transactivator Zta is capable of disrupting this latency 
(Countryman and Miller, 1985; Grogan et al., 1987). This event takes place in 
spite of the strong association between the viral genome and repressive 
epigenetic marks. Thus, Zta must have evolved with unique characteristics that 
allow it to overcome these repressive marks to induce lytic cycle. In fact, Zta 
plays a vital role in orchestrating many of the early events that take place during 
lytic cycle including the regulation of host and viral genes as well as viral DNA 
replication. These events are achieved by the ability of Zta to bind directly to a 
wide range of binding motifs ( AP-1 and ZREs sites) (Farrell et al., 1989; Urier 
et al., 1989) in methylated and/or unmethylated states (Bhende et al., 2004, 
2005; Wille et al., 2013). Also, Zta interacts with the cellular general 
transcription factors such as TFIID and TFIIA (Lieberman, 1994; Lieberman and 
Berk, 1991; Lieberman et al., 1989; Lieberman et al., 1997). More importantly, 
Zta is known to recruit histone-modifier proteins which lead to a more 
accessible chromatin. For example, Zta is known to directly bind histone 
acetylase CBP (Adamson and Kenney, 1999; Deng, 2003; Zerby et al., 1999). 
Also, Zta is known to associate with the repressive histone mark (H3K9me3) 
across various early lytic cycle promoters (Ramasubramanyan et al., 2012b). 
 
These multifunctional features of Zta have generated much interest in 
investigating its structure and function in the past few years. In line with this, the 
powerful technique of chromatin immunoprecipitation (ChIP), coupled with 
second generation DNA sequencing (ChIP-Seq) was employed to investigate 
Zta binding across the viral and cellular genome (Bergbauer et al., 2010; 
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Ramasubramanyan et al., 2012a; Ramasubramanyan et al., 2015). The 
previous studies have established Zta binding patterns in B cells only.  
 
On the other hand, EBV infects and replicates in epithelial cells (Greenspan et 
al., 1985; Sixbey et al., 1984). EBV latency is not supported in normal terminally 
differentiated epithelial cells (Nawandar et al., 2015; Niedobitek et al., 1991; 
Young et al., 1991c). This could be attributed to Zta continuous expression in 
differentiated epithelial cells (Young et al., 1991c). What is more interesting is 
that epithelial cells growing in organotypic cultures showed a high rate of EBV 
replication (Temple et al., 2014).  To understand the features of EBV lytic cycle 
in epithelial cells, genome-wide Zta binding analysis will be critical. Although 
there is no global data for Zta binding in an EBV epithelial system published to 
date, a genome-wide analysis using ChIP-Seq for Zta binding was carried out 
recently in an EBV-positive NPC cell line by Anja Godfrey, a Ph.D. student in 
our lab.  This will provide an insight into EBV lytic cycle differences between B 
cells and epithelial cells.  
 
Here, we will focus on Zta binding across the viral genome only. In particular, 
differences observed in Zta binding in different EBV-positive cell lines in the 
previously published ChIP-Seq data sets as will be discussed in the next 
sections. Using ChIP coupled with qPCR (ChIP-qPCR), we extend Zta binding 
analysis in two different EBV systems including HEK 293 cells infected with 
EBV genome cloned on a bacterial artificial chromosome (BAC) (Feederle et al., 
2000), a system that has been extensively used in EBV genome mutational 
analysis (Feederle et al., 2010). Furthermore, we address conservation of Zta 
enrichment in different cell lines at novel EBV promoters and genomic regions 
previously described for the first time (Ramasubramanyan et al., 2012a). 
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3.2 Results  
3.2.1  ChIP-qPCR approach to analyse Zta binding to EBV genome  
Our specific aim was to investigate the differences between various Zta binding 
patterns seen in published ChIP-Seq data as described in Section 3.1.  An 
example of these differences is given in Figure 3-1 (A and B) where Zta 
binding to the EBV genome was compared between different cell lines analysed 
in two separate published ChIP-Seq data sets (Bergbauer et al., 2010; 
Ramasubramanyan et al., 2012a). Zta binding peaks across the viral genome 
from the two sets of data (aligned according to B95-8 EBV genome (V01555)) 
were aligned and regions of differences identified.  
 
Two regions that illustrate the major differences in Zta binding are shown in 
Figure 3-1 (A and B).  First, there was an apparent Zta binding peak between  
0-2 kbp in EBV-positive Akata BL cells previously identified by members of our 
lab (Ramasubramanyan et al., 2012a) but not in the other two cell lines (Raji 
and B95-8 cells)(Bergbauer et al., 2010). This binding peak occurs in the region 
of the EBV late lytic BNRF1 promoter.   
 
Similarly, in panel B, a Zta binding peak at ~95 kbp (according to B95-8 EBV 
genome) is seen in Akata BL cells but not in the other two cell lines. A query of 
this site in NCBI genome browser showed that the region is not associated with 
any regulatory function. It is worth to note that this region aligns to a region 
around 82 kbp in the wildtype EBV strain (NC_007605).  This region will be 
discussed further and referred to as ~82 kbp in the following sections.  
 
Thus, there is strong evidence that Zta binds differently across the viral genome 
in different EBV systems derived from B cells despite the strong correlation of 
Zta binding observed at most of the regions across the viral genome.  
 
To investigate the differences seen in Zta binding patterns across the viral 
genome, a ChIP-qPCR approach was taken. Additionally, we expanded this 
investigation of Zta binding in an EBV non-B cell system. Thus, two different cell 
lines, LCL#3 which are lymphoblastoid B-lymphocytes in latency III (Sinclair et 
al., 1994b) and 293-BZLF1-KO cells, a model for EBV non-B cell system 
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(Feederle et al., 2000), were used, as will be seen in later experiments. In 
LCL#3, a small sub-population of these cells continuously goes into lytic phase. 
On the other hand, 293-BZLF1-KO cells, which were made by infecting HEK 
293 cells with recombinant EBV DNA with a deletion in BZLF1 gene, require Zta 
ectopic expression to induce lytic cycle.  
 
The ChIP-qPCR experimental design is illustrated in Figure 3-2. LCL#3 and 
293-BZLF1-KO cells were maintained, as described in Chapter 2. In the case of 
293-BZLF1-KO cells, His-full length Zta plasmid (His-Zta) was transfected 48 
hours prior to harvesting to induce lytic cycle. Zta expression was verified using 
western blotting, as shown in Figure 3-2 (A). 
 
Each cell line was harvested and treated with formaldehyde to cross-link 
proteins to DNA. 293-BZLF1-KO cells were harvested 48 hours post-
transfection. Upon lysis, the cross-linked chromatin was sonicated to shear it to 
small fragments. The sonicated material was reversed cross-linked and a 
sample was checked on 1% agarose gel to assess the shearing efficiency as 
shown in Figure 3-2 (B).  An enriched DNA smear between 200-600 bp 
indicated successful chromatin shearing.  
 
Chromatin immunoprecipitation was performed using protein A and G 
Sepharose beads along with a specific antibody against Zta and a control 
antibody (raised in the same species) in LCL#3 experiment. On the other hand, 
for 293-BZLF1-KO cells, two chromatin preparation were used; one transfected 
with His-Zta plasmid, and a control sample transfected with pcDNA3 plasmid as 
shown in the western blot (Figure 3-2 (A)).  
 
After the immunoprecipitation, samples were reversed cross-linked, and treated 
with proteinase K to remove the protein in the samples. This was followed by 
DNA purification and qPCR to determine whether enrichment for the targets of 
interest had occurred. The primers used for qPCR are listed in a Table 2-4 in 
Chapter 2.   
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The amplification efficiency and specificity of the primers was checked by 
adding a melting curve step in the qPCR protocol. The primers had a range of 
80% and 98% amplification efficiency. In addition, the standard curves used to 
measure the absolute quantity of DNA had slope values between -3.755 to -
3.365 and R2 values around 0.998. This indicates consistency in the 
amplification of the serial dilution samples seen in the standard curves as 
illustrated in the example provided of the melting and standard curves for one of 
the primers (Figure 3-2 (C)). 
 
Overall, a well-established ChIP-qPCR protocol and previously described ChIP-
grade antibody against Zta were used in these experiments. In addition, various 
quality control steps as illustrated in Figure 3-2 were carried out at every step to 
minimise any technical variations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1 Differences in Zta binding to the EBV genome. Zta binding to the EBV
genome was compared between two different published ChIP-Seq data sets. Zta
binding peaks were aligned according to B95-8 EBV genome (V01555) in EBV-
positive Akata (black peaks), Raji (blue peaks) and B95-8 (green peaks) cell lines. (A)
Binding at 0-2 kbp of EBV genome was seen in Akata but not in the other two cell lines
(red box). (B) Similarly, binding between 95-97 kbp of EBV genome (red box) was seen
in Akata but not in the other two cell lines. This region aligns to a region around 82 kbp
in the wildtype EBV strain (NC_007605). It will be referred to as ~82 kbp in the
following sections. ChIP-seq data were taken from: 1- Akata cells (Ramasubramanyan
et al., 2012). 2- Raji and B95.8 cells (Bergbauer et al., 2010).
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Figure 3-2 Experimental design of Zta ChIP-qPCR. (A) Zta binding patterns
were analysed in two EBV systems: the B cells LCL#3, which are spontaneously
lytic and the non-B cells 293-BZLF1-KO, which require Zta ectopic expression to
induce lytic cycle (western blot). Cells were harvested (48 hours post-
transfection for 293-BZLF1-KO) and treated with formaldehyde to cross-link
proteins to DNA. (B) After cell lysis, chromatin was sonicated to produce short
fragments between 200-600 bp (as seen on the agarose gel (Lane 2)). DNA
bound to Zta was precipitated using specific Zta antibody. (C) Finally, qPCR was
used to quantify enriched fragments using specific primers for the target regions.
Along with Zta antibody, a control antibody was used in LCL#3 ChIP. On the
other hand, in 293-BZLF1-KO experiment, a control sample (293-BZLF1-KO
transfected with control plasmid) treated identically to Zta sample was used. A
serial dilution of the input DNA was prepared to generate a standard curve
which was used to quantify enriched DNA fragments. qPCR melting and
standard curves were used as an indicator of product specificity and
amplification efficiency, respectively.
Reverse cross-linking and DNA 
purification
qPCR
Melting and standard 
curves
C
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3.2.2 Zta binds similarly to EBV OriLyt 
To address Zta association with EBV origin of lytic replication (OriLyt) in the two 
cell lines, ChIP-qPCR specific primers for this target region as well as a flanking 
region (negative control) were used. We looked into the OriLyt region because 
the association between Zta and OriLyt is well-established and is essential for 
viral DNA replication. The EBV genome contains two identical OriLyt sites. 
These sites are functionally redundant, as EBV B95-8 strain still goes into full 
lytic cycle despite a deletion spanning one of the OriLyt regions. The primers 
used in the qPCR are specific to both OriLyt sites.  
 
The qPCR data presented in Figure 3-3 showed significant enrichment for Zta 
at OriLyt compared to OriLyt-Flank region for both LCL#3 and 293-BZLF1-KO 
cell lines (Figure 3-3 (A and B)). Also, this enrichment is significant compared 
to the control samples in both cell lines. Zta binding at OriLyt is higher than 
other sites, as will be seen in the following figures.  
 
Our finding indicates that there was no significant variation in Zta association 
with EBV OriLyt during lytic cycle between the two EBV-positive cell lines.   
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Figure 3-3 Zta binding at the origin of lytic replication (OriLyt). ChIP-
qPCR in different EBV cell lines: (A) LCL#3 cells and (B) 293-BZLF1-KO.
Zta binding (red bars) is compared to a control sample (blue bars). The
qPCR assays were performed using primers (provided in Table 2-4) for the
origin of lytic replication (OriLyt), and a negative control region flanking
OriLyt (no binding site). Values represent absolute levels of enrichment
calculated using a standard curve of the input material. Error bars
represent the mean of triplicate readings ± SD for each sample.
A B
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3.2.3 Zta binds similarly to promoter regions of the immediate-early genes  
The association between Zta and promoter regions of the immediate-early 
genes (BZLF1 and BRLF1) was assessed using ChIP-qPCR in two cell lines, as 
previously described.  Zta is known to regulate BRLF1 and its promoter during 
very early lytic events (Sinclair et al., 1991). Also, Zta autoregulates its own 
promoter through two ZRE elements (ZIIIA and ZIIIB) (Flemington and Speck, 
1990a).  Specific primers to these target regions as well as the negative control 
OriLyt-Flank region were used (Table 2-4). 293-BZLF1-KO cell line contains a 
deletion of BZLF1 gene that affects only part of exons 1 and 2 but not the 
promoter site (Feederle et al., 2000).   
 
The qPCR data showed significant enrichment for Zta at BZLF1 and BRLF1 
promoters compared to the OriLyt-Flank control region (no binding site) in both 
LCL#3 and 293-BZLF1-KO cell lines (Figure 3-4 A and B, respectively). This 
enrichment is not as pronounced as what was seen at OriLyt region, but similar 
findings were seen in early and late lytic promoters (Figure 3-5 and Figure 3-
6).  
 
Our findings indicate that there was no significant variation in Zta association 
with EBV immediate-early lytic promoters during lytic cycle between the two 
EBV-positive cell lines used in this experiment.   
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Figure 3-4 Zta binding at the immediate-early lytic promoters. ChIP-
qPCR in different EBV cell lines: (A) LCL#3 cells and (B) 293-BZLF1-KO.
Zta binding (red bars) is compared to a control sample (blue bars). The
qPCR assays were performed using primers (provided in Table 2-4) for no
binding site (OriLyt-Flank) and the immediate-early promoters of BRLF1 &
BZLF1 genes. Values represent absolute levels of enrichment calculated
using a standard curve of the input material. Error bars represent the mean
of triplicate readings ± SD for each sample.
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3.2.4 Zta binds similarly to promoter regions of various early lytic genes 
We further assessed the association between Zta and various promoters of 
EBV early lytic genes. This was of great interest because the association 
between Zta and some of these targets were first described only recently 
(Bergbauer et al., 2010; Ramasubramanyan et al., 2012a). 
 
The qPCR results showed a significant enrichment for Zta across every tested 
promoter compared to the OriLyt-Flank control region (no binding site) (Figure 
3-5 (A and B)). Student t-test was used to calculate the P-values for the weak 
Zta binding at BFRF2, BLLF2, BRRF1 and BNLF2a promoters compared to the 
OriLyt-Flank control region. Statistically significant Zta enrichment was 
observed in LCL#3 (P< 0.001; marked with (***)) and 293-BZLF1-ZKO (P <0.01 
(marked with (**)) (Figure 3-5 A and B, respectively).  
 
Similar to our findings at immediate-early promoters, there was no significant 
variation in Zta association with the tested EBV early lytic promoters between 
the two EBV-positive cell lines used in this experiment.   
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Figure 3-5 Zta binding at the early lytic promoters. ChIP-qPCR in
different EBV cell lines: (A) LCL#3 cells and (B) 293-BZLF1-KO. Zta binding
(red bars) is compared to a control sample (blue bars). The qPCR assays
were performed using primers for no binding site (OriLyt-Flank) and various
early lytic promoters. Values represent absolute levels of enrichment
calculated using a standard curve of the input material. Error bars
represent the mean of triplicate readings ± SD for each sample. (***)
indicates p<0.001 while (**) indicates p<0.01 compared to No binding site.
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3.2.5 Zta binds similarly to promoter regions of various late lytic genes 
The association between Zta and various promoters of EBV late lytic genes was 
also addressed in our ChIP-qPCR investigation. The late lytic promoters differ 
from the immediate-early and early lytic promoters in terms of their regulation, 
TATA box motif, and their temporal expression as described in Chapter 1. Zta 
association with some of these genes suggests a strong possibility that a 
different Zta mechanism is regulating these genes.  
 
The qPCR data showed a significant enrichment for Zta across every tested 
promoter compared to the OriLyt-Flank control region (no binding site) (Figure 
3-6 (A and B)).  Student t-test was used to calculate the P-values for the weak 
Zta binding at BKRF4, and BTRF1 promoters in comparison with the OriLyt-
Flank control region. Significant Zta enrichment was observed in LCL#3 and 
293-BZLF1-ZKO (Figure 3-6 A and B, respectively). P-values were ranging 
from < 0.001 in (marked with (***)), and < 0.01 (marked with (**)). 
 
Our findings indicate that there was no significant variation in Zta association 
with the tested EBV late lytic promoters between the two EBV-positive cell lines 
used in this experiment.   
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Figure 3-6 Zta binding at the late lytic promoters. ChIP-qPCR in different
EBV cell lines: (A) LCL#3 cells and (B) 293-BZLF1-KO. Zta binding (red
bars) is compared to a control sample (blue bars). The qPCR assays were
performed using primers for no binding site (OriLyt-Flank) and various late
lytic promoters. Values represent absolute levels of enrichment calculated
using a standard curve of the input material. Error bars represent the mean
of triplicate readings ± SD for each sample. (***) indicates p<0.001 while (**)
indicates p<0.01 compared to the No binding site.
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3.2.6 Zta binds to a novel site with unknown regulatory function  
The ChIP-qPCR approach, as previously described, was used to evaluate the 
association between Zta and the wildtype EBV strain (NC_007605) genomic 
region between 82462-82962 bp. Specific qPCR primers were designed, as 
listed in Table 2-4 with their genomic coordinates.  This region (referred to as 
~82 kbp) was of interest because it is about 2 kbp away from the closest lytic 
open reading frame (BLLF1 and BLLF2) (Figure 3-7). Furthermore, it was one 
of the primary regions we found to be different in the published Zta ChIP-Seq 
data as explained in Figure 3-1.  
 
Figure 3-7 represents a genome view of this ~82 kbp region taken from the 
publicly available NCBI genome browser. This view shows EBV coding genes in 
close proximity to ~82 kbp region, and the nearest TATA boxes (highlighted in 
red). A Promo web tool search for Zta binding sites (Farre et al., 2003) revealed 
two binding sites TGTCACA (82765-82771 bp) and TGTGTCA (82825-82831 
bp).  The location of these ZREs is shown in Figure 3-7 (B). 
 
Zta binding was observed at this novel region in both cell lines tested in our 
experiment. Statistically significant enrichment for Zta was seen compared to 
the OriLyt-Flank control region. Student t-test was used to calculate the P-
values which were < 0.001 in both cell lines (marked with (***)) (Figure 3-7 (C)).  
 
To investigate if there is any EBV sequence variation that might affect Zta 
binding to this region in Raji EBV strain, a BLAST analysis of the region 
between 82462-82962 bp (NC_007605) was carried out in Akata EBV strain 
sequence (KC207813) and Raji EBV strain sequence (KF717093) (Figure 3-8). 
Although the predicted ZRE sites were identical in both strains, the region 
flanking one of the ZRE in Raji strain was different from the EBV wildtype strain. 
This suggests that EBV strain sequence variations might play a major role in 
Zta binding patterns. 
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Figure 3-7 Zta binding at a region with unknown regulatory function (~82 kbp).
(A) NCBI genome browser overview of the wildtype EBV sequence (NC_007605).
The target region ~82 kbp is marked with a red flag; genes are shown as green
bars. (B) A zoomed-in view of ~82 kbp showing the annotated ORFs in close
proximity to this region. Red bars represent protein coding regions. This site maps
to a region around 95 kb in the EBV B95-8 strain (V01555) as previously described
in Figure 3-1. Nearby TATA box signals are shown as short black vertical lines (red
box). The approximate location of the predicted ZREs (using PROMO web tool) in
this target region is marked with a red flag (C) ChIP-qPCR in different EBV cell
lines: LCL#3 cells (left) and 293-BZLF1-KO (right). Zta binding (red bars) is
compared to a control sample (blue bars). The qPCR assays were performed using
primers (Table 2-4) for no binding site (OriLyt-Flank) and ~ 82 kbp region. Values
represent absolute levels of enrichment calculated using a standard curve of the
input material. Error bars represent the mean of triplicate readings ± SD for each
sample. (***) indicates p<0.001 compared to the No binding site.
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Figure 3-8 Sequence variations between EBV strains at the ~82 kbp region.
NCBI nucleotide BLASTs between the region 82462-82962 of the wildtype EBV
sequence (NC_007605) and the complete sequence of EBV Akata (KC207813) and
Raji (KF717093) strains were carried out. (A and B) show a small region around the
predicted ZREs of the BLAST results in ~82 kbp region. Akata EBV shows 99%
similarity at this region (A) while Raji EBV strain has only 97% sequence similarity
at this region (B). The predicted ZREs in ~82 kbp region are shown in red boxes.
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3.3 Discussion  
Zta plays a critical role in triggering the switch between latency and lytic phase 
by initiating viral DNA replication and regulating various lytic and host genes as 
previously described. There has been much interest in establishing the binding 
sites for Zta across the viral and cellular genome using genome-wide 
approaches such as ChIP-Seq analysis.   
 
Although this highly sensitive technique has revealed a wealth of information 
regarding Zta binding patterns, the overall view of Zta binding is still lacking. 
This is mainly due to the fact that there are different EBV systems with different 
EBV strains. Not to mention that to date there is no global Zta binding study 
published in an EBV epithelial system. Moreover, our observation of differences 
between the published Zta ChIP-Seq data sets in Burkitt’s lymphoma B cells 
across the viral genome (Bergbauer et al., 2010; Ramasubramanyan et al., 
2012a) has raised many questions about Zta binding in different cells, as 
described in Section 3.2.1.  
 
In this chapter, I carried out ChIP-qPCR analysis to compare Zta binding across 
the viral genome in two different EBV cell lines: the spontaneously lytic LCL#3 
(Sinclair et al., 1994a),  and the latent 293-BZLF1-KO cells (Feederle et al., 
2000) chosen as a non-B cell EBV system.  
 
Unlike ChIP-Seq, the ChIP-qPCR approach has a low resolution and is limited 
to individual target sites. However, it is considered as a very efficient, rapid and 
cost-effective way to investigate transcription factors (TFs) binding as well as 
histone modifications in vivo (Gade and Kalvakolanu, 2012).  
 
Using this approach, I aimed to address the variations observed in published 
ChIP-Seq data described earlier. In addition, I considered validating  Zta binding 
at novel EBV promoter sites identified previously by members of our lab 
(Ramasubramanyan et al., 2012b). 
 
The two ChIP-Seq data sets previously described, by Bergbauer et al and 
Ramasubramanyan et al were carefully aligned to identify any differences in Zta 
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binding. Both data sets were largely in agreement; especially at major lytic 
promoters (BZLF1, BRLF1, BALF5, and BMRF1), However, Zta binding was 
clearly different at a few sites. Two examples of these differences are provided 
in Figure 3-1. One of these sites was the promoter of the late lytic gene 
BNRF1, which is one of the major tegument proteins (Cameron et al., 1987).  
 
These differences in Zta binding ChIP-Seq published data could be explained 
by many factors including technical and biological variations. Technical 
variations in ChIP-Seq can be due to differences in experimental conditions 
such as antibodies, chromatin fragmentation, quality of the input DNA, and peak 
calling methods. Such variations may introduce bias which makes it difficult to 
compare data from different labs. Nevertheless, ChIP-Seq remains a very 
powerful and sensitive technique that produces consistent results (Haring et al., 
2007; Kidder et al., 2011).     
  
On the other hand, these differences can occur due to biological variations, 
specifically DNA sequence variations between EBV strains, host cell specific 
variations and viral chromatin structure. For example, Raji BL EBV strain 
harbors a deletion affecting BALF2, which results in defective EBV replication 
(Decaussin et al., 1995; Hatfull et al., 1988). It is worth noting that Zta was 
shown to bind to the BZLF1 promoter in B95-8 but not in Raji cells, suggesting 
that cell or EBV genome variations can influence BZLF1 promoter (Zp) 
regulation (Bergbauer et al., 2010). Also, BZLF1 promoter is not activated 
through the phorbol ester TPA or histone deacetylase (HDAC) inhibitors in Raji 
cells (Murata et al., 2012). Although Raji EBV strain has the sequence of the 
prototype Zp, many sequence variants of Zp were described in other EBV 
strains (Feederle et al., 2015).  
 
Also, cell specific variation in chromatin regulation can influence the chromatin 
structure of EBV. The Akata EBV genome has decreased histone acetylation 
while Raji EBV genome is associated with high H3k27me3 and H4K20me3, 
reviewed in (Lieberman, 2015).  
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B cells have been predominantly used to investigate the epigenome of EBV. On 
the contrary, only limited promoter regions were investigated in EBV epithelial 
systems such as in 293 EBV-BAC cells (Murata et al., 2012). 
 
In addressing these variations, another factor that is worth considering was the 
replacement of Zta transactivation domain by a GFP protein in the ChIP-Seq 
experiments carried out by Bergbaur et al. This GFP-Zta construct included 
amino acids between 149-245 (Kalla et al., 2010) which were shown to have a 
very similar affinity to DNA binding compared to full-length Zta in vitro 
(Flemington et al., 1992). However, DNA binding differences between the full-
length Zta and GFP chimeric bZIP Zta cannot be ruled out in vivo. Zta 
transactivation domain may recruit other partner proteins that are required to 
stabilise or change the chromatin state at certain sites.  
 
In highly lytic EBV systems, Zta can bind to targets across the newly replicated 
EBV genome copies, which are not chromatinised. This could also introduce 
bias in the data. Despite this, similar findings for Zta binding were reported 
under replicated and non-replicated conditions in Akata cells 
(Ramasubramanyan et al., 2012b).  
 
In our ChIP-qPCR experiments, to cover a wide range of targets, various lytic 
promoters were investigated using a similar protocol and Zta antibody used in 
the experiments carried out by Ramasubramanayn et al. These target regions 
include promoters for genes classified as immediate-early, early, and late lytic 
genes. Investigating these different promoters was important because different 
mechanisms for each class is postulated, as described in Chapter 1. 
 
To date most of these target promoters have not been investigated for their 
response to Zta transcriptional regulation with the exception of BZLF1 
(Flemington and Speck, 1990a; Lieberman and Berk, 1990), BRLF1 (Sinclair et 
al., 1991), BRRF1 (Segouffin-Cariou et al., 2000) and the late lytic cycle gene 
BCRF1, a homolog to cellular IL10 (Mahot et al., 2003b). In addition, in the last 
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two chapters, our analysis will show that BNLF2a is a new target regulated by 
Zta. 
 
Furthermore, the ChIP-qPCR was performed in two different EBV systems as 
described earlier. LCL#3 cells are predominantly in latency type III but contain a 
small sub-population of cells that are continuously in lytic form (Bernig et al., 
2014; Sinclair et al., 1994a). The 293-BZLF1-KO cells used in this experiment 
carry a BZLF1 mutant EBV. Thus, to induce lytic in these cells, transient 
transfection with Zta was required. Cells were transfected with His-tagged Zta 
and harvested 48 hours after transfection.  In this system, DNA replication was 
previously shown to start around 96 hours post Zta transfection (Bailey et al., 
2009a). In theory, the number of EBV infected cells that go into lytic cycle in this 
system will be dependent on Zta transfection efficiency.  Although, Zta 
expression was checked by western blots in 293-BZLF1-KO cells, none of the 
two cell lines were analysed for the percentage of cells that contained Zta 
expression, and hence supported EBV lytic induction.  
 
As was shown in Figure 3-3 - Figure 3-7, Zta binding patterns were consistent 
between both cell lines tested, and in agreement with the data reported in Akata 
BL cells (Ramasubramanyan et al., 2012b). Across the various analysed EBV 
regions, Zta enrichment was varied. The strongest enrichment was observed 
within the OriLyt site, which has 7 ZREs (Schepers et al., 1996). It is not clear if 
this enrichment is related to the number of binding sites, as stronger Zta binding 
was also observed in BNRF1 promoter which contains two ZREs, whereas 
weaker Zta enrichment in other regions contained as many as five ZREs. Thus, 
it is very likely that these regions contain low-affinity sites or have open 
chromatin organization that influences Zta binding (Landt et al., 2012).    
 
Interestingly, Zta binding was validated at a region, which contains ZREs, of 
unknown regulatory function (~82 kbp) as described in Figure 3-7. Indeed, 
several other regions for Zta binding at uncharacterised genome sites have 
been reported (Ramasubramanyan et al., 2012a).  These regions (including ~82 
kbp) could be possibly a proximal enhancer element for a gene nearby or play a 
role in Zta genome replication. Similar regions with unknown functions have 
3-128 
 
  
also been shown to be highly co-occupied with several of TFs during latency. 
For example, ATF3 and USF TFs were reported to co-localize at the region 
around 80,655 bp. This site is located within the first EBNA3A transcript internal 
repeat (Arvey et al., 2013). A Zta binding peak is also present at this site in the 
examined ChIP-Seq data by Ramasubramanyan et al and Begrbauer et al. 
Unlike the other regions, Zta binding peak at ~82 kbp was not seen in the Raji 
cell line ChIP-Seq data by Bergbauer et al which suggests this site is very likely 
bound by Zta in a cell line/ EBV strain -specific manner.  
 
 The sequence of this region in Raji strain was only 97% similar to wildtype EBV 
strain. The region flanking one of the predicted ZREs in the ~82 kbp was 
affected by these variations (Figure 3-8). This could affect Zta binding or other 
transcription factors required for Zta binding at this site.  
   
In conclusion, Zta binding to the EBV genome is influenced by many factors 
including sequence variations, viral epigenetic structure, and cell-specific 
factors. Although the differences between Zta binding in the published data will 
require more analysis, I was able to extensively assess Zta binding across the 
viral genome in two completely different EBV systems that were largely unused 
and uncharacterized for Zta binding analysis during EBV lytic cycle.  
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Chapter 4 ZREs as long-distance enhancer elements  
4.1 Introduction 
In eukaryotic cells, gene expression is dependent on the spatiotemporal binding 
of regulatory proteins (e.g. transcription factors (TFs)) to promoter and 
enhancer/silencer elements. This takes place within a very complex dynamic 3D 
chromatin organization that involves the recruitments of transcription factors, 
engagement of chromatin remodelers and modifiers, and interactions between 
different regulatory elements.  These complex processes have one main goal of 
recruiting the general transcription machinery (including Pol II) to the core 
promoter of a specific gene.  This in turn leads to the final outcome which is the 
initiation of mRNA transcription and eventually protein production. 
 
Understanding this 3D organization of the genome has attracted much interest 
in the last few years. Recent advances in genome-wide technologies facilitated 
the deciphering of the complex transcription regulation mechanisms in various 
cells as well as organisms (Chen et al., 2013; Gerstein et al., 2012; Homouz 
and Kudlicki, 2013; Sanyal et al., 2012; Shen et al., 2012). Furthermore, these 
studies have integrated data from various resources and techniques such as 
ChIP-Seq, chromosome conformation capture methods, and RNA-Seq. 
 
To be more specific, we gained more insight into how promoters and long-range 
enhancer elements interact in such a complex chromatin environment. The first 
observation of enhancer activity was observed when a 72 bp repeated 
sequence taken from the SV40 virus was inserted into a recombinant DNA 
plasmid expressing rabbit haemoglobin beta 1 gene. This SV40 DNA resulted in 
an approximately 200-fold change in the transcript levels of that gene  (Banerji 
et al., 1981). 
     
Enhancers are regulatory elements that typically span a few hundred base 
pairs, with clusters of different transcription factors (TFs) binding sites. Their 
main role is to enhance transcription of a target gene or genes in spite of their 
orientation and distance relative to their targets (Spitz and Furlong, 2012).  An 
active enhancer is characterised by open chromatin structure. This is indicated 
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by the low nucleosome occupancy in the enhancer region. Also, nearby 
nucleosomes are commonly associated with the following histone modifications: 
enrichment of monomethylation of histone H3 lysine 4 (H3K4me1) and the 
acetylation or methylation of histone H3 lysine 27 (H3K27). Moreover, CREB-
binding protein (CBP) and its related protein p300, which have histone 
acetyltransferase activity and known to interact with many other TFs and 
histone modifiers, have been shown to be enriched at enhancer elements. On 
the contrary, inactive enhancer elements are associated with histone 
modification H3K27me3, a polycomb protein-associated repressive mark, and 
can be bound by suppressor TF binding, (reviewed in (Ong and Corces, 2011; 
Shlyueva et al., 2014).   
 
Enhancers play a key role in regulating cell-specific expression which is 
important in determining cell differentiation and fate (Heintzman et al., 2009; 
Visel et al., 2007). Also, mutations in enhancer elements have been associated 
with the development of many cancers. A well-known example is Burkitt’s 
lymphoma, a tumour that is associated with EBV.  A translocation that brings 
the c-Myc oncogene under the control of the enhancer region of the 
immunoglobulin heavy chain in B cells, leads to strong overexpression of c-Myc 
(Dalla-Favera et al., 1982) and eventually the development of Burkitt’s 
lymphoma, as described in Section 1.3.6. The role of enhancers in various 
cancers is reviewed in (Herz et al., 2014; Sur and Taipale, 2016). 
 
Recently, the term ‘super enhancers’ have been used to describe atypical 
enhancers. These enhancers are usually associated with a very strong 
enrichment of the master transcription factors in ESCs: Oct-4 Sox2, Nanog, 
KLF4 and Esrrb and were initially identified in embryonic stem cells (Whyte et 
al., 2013). In contrast to typical enhancers, a distinguishing feature of these 
super enhancers is the fact that they span a long region that is enriched for one 
transcription coactivator, Mediator (Med1). This association with the mediator 
coactivator complex facilitate the interaction with the general transcription 
factors and Pol II (Whyte et al., 2013). Further examination of the occupancy of 
these super enhancer sites in different cell types, has associated these 
elements with a wide range of other transcription factors in a cell type specific 
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manner (Hnisz et al., 2013). The intriguing subject of super enhancers is 
recently reviewed in (Pott and Lieb, 2015).   
 
Enhancers are not only bound by cellular factors, but many viral proteins have 
been implicated in gene regulation through enhancers. Recent studies 
described the involvement of EBV proteins in enhancers and super enhancer 
region elements. In particular, EBNA2 has been associated with the regulation 
of various oncogenes such as c-Myc and BCL2 in B cells (Gunnell et al., 2016; 
McClellan et al., 2013; Zhou et al., 2015). 
 
A recent Zta genome-wide study conducted in our lab using ChIP-Seq and 
RNA-Seq in EBV Burkitt’s lymphoma Akata cells revealed that approximately 
75% of the Zta binding peaks were at distal elements (>4 kb) from the 
transcription start sites (TSS) of cellular genes across the genome, while only 
15% were within 2 kb of TSS (Ramasubramanyan et al., 2015). Moreover, 
addressing the functional relevance of Zta binding, the ChIP-Seq data were 
integrated with RNA-Seq data which indicated that around 278 genes 
associated with Zta binding showed change in expression upon Zta induction in 
these cells. Zta binding peaks were observed at variable locations across these 
genes. For example, in some genes such as RASA3 and FOSB, Zta binding 
peaks were found at various long distance locations from the genes including 5’, 
and 3’ and intragenic sites (Ramasubramanyan et al., 2015). 
   
Based on these data, we hypothesised that Zta regulation is possibly mediated 
through long-range enhancer elements. In order to test this hypothesis, we have 
designed a synthetic DNA fragment with 20 CpG-free ZREs (class I), placed 
around 2 kb upstream a heterologous minimal promoter in a luciferase reporter 
construct.  
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4.2 Results  
4.2.1 Luciferase reporter assay to investigate ZREs as potential enhancer 
elements 
Given the recent finding of Zta binding at distal elements within the cellular 
genome (Ramasubramanyan et al., 2015) as discussed in Section 4.1, we took 
a simple approach to evaluate ZREs as potential long-range enhancer 
elements, outlined in Figure 4-1.  
 
A minimal promoter was subcloned into the pGL3-Control luciferase reporter 
plasmid between KpnI and HindIII RE sites, upstream of the luciferase gene.  In 
the same construct, a random 20X ZREs synthetic DNA fragment, with similar 
spacing between each ZRE, was subcloned into the second multiple cloning 
site of pGL3-Control, between BamHI and SalI. This second multiple cloning 
site in the pGL3 vector is around 2.2 kb away from the promoter and designed 
to test potential enhancer elements.  As shown in Figure 4-1, a schematic 
diagram of the designed construct is given in (A) (dark grey plasmid). The 
minimal promoter is shown in orange while the 20XZRE construct is shown in 
blue. 
 
Two constructs (MinP and MinC) were generated using two different promoters 
along with the same 20XZRE insert. This is further illustrated in Figure 4-2 (A 
and B).  
 
The luciferase constructs were co-transfected with either a control vector 
(pcDNA3) or His-Zta expression vector in EBV-negative Burkitt’s lymphoma cell 
line (DG75). This allowed the comparison of luciferase activity in the presence 
and absence of Zta as demonstrated in Figure 4-1 (B).  
 
Figure 4-2 represents schematic diagrams as well as the exact sequences of 
the minimal promoters and 20XZRE inserts for both luciferase constructs (MinP 
and MinC). The sequence of the minimal promoter (Figure 4-2 (A)) in MinP 
construct was adapted from the minimal promoter in Promega luciferase 
construct (pGL4). This 32 bp promoter was ordered as a synthetic double-
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stranded DNA fragment after the addition of compatible restriction enzyme (RE) 
sites at each end to facilitate the subcloning into pGL3-Control plasmid. 
 
Also, the distal 20XZRE element sequence is shown in Figure 4-2 (A) where 
each ZRE motif is underlined. The 20 ZREs used in this synthetic insert were 
class I ZREs, which do not contain a CpG methylation motif, and were 
previously described in various Zta target promoters (Flower et al., 2011). 
 
Figure 4-2 (B) is a schematic diagram of MinC construct and the MinC 
promoter sequence. This construct differs from the MinP construct in the 
promoter sequence. This second construct was generated to ask if the same 
effect of Zta in MinP was reproducible on a different promoter. The MinC 
promoter is part of the cellular gene CIITA promoter (CIITA -214+53) and was 
previously cloned into pGL3 luciferase vector by Dr Nicolae Balan in our lab 
(Balan et al., 2016).  
 
The results of luciferase reporter assay using MinP and MinC, shown in Figure 
4-3 and Figure 4-4, have been recently published (Ramasubramanyan et al., 
2015). 
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Figure 4-1 Investigating a long-range ZRE element effect on promoter
activation. A schematic representation of luciferase reporter assay experiment
carried out to investigate Zta activation through a long-range enhancer
elements. (A) A synthetic DNA fragment containing 20 ZREs (blue) was cloned
between BamHI and SalI restriction sites in pGL3-Control vector (grey plasmid)
(Promega). The ZRE fragment is around 2 kb away from a minimal promoter
(orange). Two different minimal promoter constructs (MinP or MinC) were
generated as will be discussed in Figure 4-2. Promoter sequences were cloned
between KpnI and HindIII upstream the luciferase expression sequence. (B)
The luciferase vector was co-transfected with either a control vector (pcDNA3)
(green plasmid) or His-Zta expression vector (green and red plasmid) in EBV
negative Burkitt’s lymphoma cell line (DG75). Luciferase signal was compared
in the absence and presence of Zta.
A
B
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GGTACCCTTTCTGTCTTCACCAAATTCAGTCCACAGTAAGGAAGTGAAATTAATTTCAGAGG
TGTGGGGAGGGCTTAAGGGAGTGTGGTAAAATTAGAGGGTGTTCAGAAACAGAAATCTGACC
GCTTGGGGCCACCTTGCAGGGAGAGTTTTTTTGATGATCCCTCACTTGTTTCTTTGCATGTT
GGCTTAGCTTGGCGGGCTCCCAACTGGTGACTGGTTAGTGATGAGGCTAGTGATGAGGCTGT
GTGCTTCTGAGCTGGGCATCCGAAAAGCTT 
KpnI 
HindIII 
 
GGTACCAGATCTTAGAGGGTATATAATGGAAGCTCGACTTCCAGAAGCTT KpnI 
HindIII Bgl II 
Same as above
A
B
Figure 4-2 DNA sequences of the 20XZRE element and heterologous
minimal promoters. (A) A schematic representation of MinP luciferase
construct. The sequence and cloning restriction enzyme sites (REs) of the
heterologous minimal promoter are shown. The minimal promoter is a 32 bp
promoter containing a TATA-box motif taken from Promega pGL4 luciferase
vector. The 2.2 kb distal 20XZRE element sequence is shown along with the
cloning restriction enzyme sites (red) where each ZRE is underlined. (B) A
schematic representation of MinC luciferase construct which is similar to (A) but
has a different promoter taken from the host CIITA gene (referred to as MinC).
The sequence and cloning REs sites of the heterologous minimal promoter
(CIITA -214+53) as well as the 20XZRE element are shown below the diagram.
CIITA –214+53 is a known target for Zta shown previously in our lab (Balan et al.,
2016). The 20X ZRE element was cloned into MinC by Ms Renu Gurung (a final
year undergraduate student taking her project under my supervision in our lab).
GGATCCGTCTGCAGAGGCATGAGCCATGCACTTAGCAAATTATGTGTAAGTACTGTGAGCAA
GACGTGTGCAATAAGCTGAGCCATGGCTGTGTCAATCGATGTGCAATGCACATGTGTCAATG
CATGAGTCATCATTGACTAATGCTGATGTGTCAGGATATGTGTCTTTAGCTGAGCAACCTAG
TGGCACAGCTACCTGAGTAATAGAGTTGCAATACGTGAGCAACTAATCTGTGTCATACAGTG
AGCCAACTAGTATGTCGAC 
BamHI 
SalI 
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4.2.2 Zta activates a heterologous minimal promoter through distal ZREs 
As described in Section 4.2.1, a luciferase construct (MinP) was generated to 
test the potential of ZREs to act as potential long-range enhancer elements. 
The luciferase activity of this construct was compared in the presence and 
absence of Zta expression in EBV-negative DG75 cells. 
 
Figure 4-3 (A) represents a luciferase reporter experiment showing a 
comparison of the promoter activity, in normalised luciferase relative light units, 
for three constructs. These three constructs are the pGL3-Control luciferase 
plasmid (empty vector), MinP-Null (construct with heterologous minimal 
promoter, but no distal 20XZRE element), and MinP-ZREs (construct with MinP 
minimal promoter and distant 20XZRE element).   
 
Comparison of the luciferase activity for each construct in the presence and 
absence of Zta showed approximately 73-fold change for MinP-ZREs compared 
to the control sample (in the absence of Zta). On the contrary, a 7 fold-change 
was seen for the MinP-Null construct. It is worth noting that the empty luciferase 
vector (pGL3-Control), which contains the SV enhancer element, showed no 
significant change in response to Zta.  
 
A statistically significant 14-fold increase in MinP-ZREs luciferase activity 
compared to MinP-Null construct in the presence of Zta was seen (P-value 
<0.001).   
 
Figure 4-3 (B) represents a western blot analysis for Actin (loading control) and 
Zta for each sample. Comparable levels of Zta expression can be seen for all 
samples while the absence of Zta is confirmed in the control samples. For each 
sample, the intensity of the actin band was used to normalise the luciferase 
relative light units value for that sample as previously described in Chapter 2.       
 
The data presented in Figure 4-3 strongly supports the emerging theory of a 
role for Zta and ZREs in long-range enhancer elements.  
 
0 100000 200000
pGL3-Control
MinP-Null
MinP-ZREs
Promoter activity (RLU)
Control Zta
Actin
Zta
Control Zta
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Figure 4-3 A long-range ZREs element drives Zta activation of a
heterologous minimal promoter. (A) A comparison of the promoter activity
for three constructs: pGL3-Control luciferase plasmid (empty vector), MinP-
Null (construct with heterologous minimal promoter, MinP, but no distant
20XZRE element), and MinP-ZREs (construct with MinP minimal promoter
and distant 20XZRE element). Constructs features and sequences are
previously shown in Figure 4-2. Activities are compared in the presence (red
bars) and absence (blue bars) of Zta expression in EBV-negative DG75 cells.
Values are presented as the mean of relative light units (RLU) for triplicate
readings ± SD normalised to actin levels. (B) Western blot analysis of the
samples showing similar levels of Zta transfection. (***) indicates p<0.001
compared to MinP-Null in the presence of Zta.
***
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4.2.3 Zta activates a known target promoter through distal ZREs  
To confirm our previous findings, we generated a different luciferase construct 
(MinC) using a cellular Zta target promoter (CIITA), as previously described in 
Section 2.2.1. 
 
Largely similar to the previous experiment in Figure 4-3, the luciferase activity 
of the MinC construct was investigated in the presence and absence of Zta 
expression in EBV-negative DG75 cells (Figure 4-4). 
 
Figure 4-4 shows a comparison of promoter activity, in normalised luciferase 
relative light units, for three constructs: pGL3-control luciferase plasmid (empty 
vector), MinC-Null (construct with CIITA minimal promoter, but no distant 
20XZRE element), and MinC-ZREs (construct with CIITA minimal promoter and 
distant 20XZRE element).   
 
A statistically significant 9-fold increase in luciferase activity was seen in MinC-
ZREs compared to MinC-Null construct in the presence of Zta (P-value <0.001).  
 
Figure 4-4 (B) represents a western blot analysis for actin (loading control) and 
Zta for each sample.  Comparable levels of Zta expression can be seen for all 
samples while the absence of Zta is confirmed in the control samples. For each 
sample, the intensity of the actin band was used to normalise the luciferase 
relative light units value for that sample as previously described in Chapter 2.        
 
The data presented in Figure 4-4 shows consistency in the 20XZRE enhancer 
element response to Zta expression under different promoters.  
 
 
 
 
 
 
139 | P a g e
0 20000 40000
PGL3-Control
MinC-Null
MinC-ZREs
Promoter activity (RLU)
Control Zta
Actin
Zta
Control Zta
B
A
Figure 4-4 A long-range ZRE element drives Zta activation of a known
Zta target promoter. (A) A comparison of the promoter activity for three
constructs: pGL3-Control luciferase plasmid (empty vector), MinC-Null
(construct with MinC minimal promoter but no distant 20XZRE element),
and MinC-ZREs (a construct with heterologous minimal promoter and
distant 20XZRE element). Constructs features and sequences are shown
previously in Figure 4-2. Activities are compared in the presence (red bars)
and absence (blue bars) of Zta expression in EBV-negative DG75 cells.
Values are presented as the mean of relative light units (RLU) for triplicate
readings ± SD normalised to actin levels. (B) Western blot analysis of the
samples showing similar levels of Zta transfection. (***) indicates p<0.001
compared to MinP-Null in the presence of Zta.
***
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4.3 Discussion 
Unlike in the compact EBV genome, previous ChIP-Seq analysis carried out 
across the human genome in our lab showed that Zta binds at distal elements 
(> 4 kb), and these binding sites formed the majority of the total binding sites 
observed. Interestingly, this suggests a new possible regulatory role for Zta 
through long-range enhancer elements.  Thus, to address this question, I used 
a simple and rapid luciferase reporter approach to investigate the ability of Zta 
to enhance the activation of a heterologous promoter in vitro. A luciferase 
construct, pGL3-Control (Promega, USA), designed to test the role of enhancer 
elements, was used in this approach. This vector has two cloning site regions 
allowing the subcloning of elements immediately upstream of the luciferase 
gene as well as another element further away.  
 
A synthetic element containing tandem repeats of 20 different ZREs separated 
by short spacing was subcloned into pGL3-Control vector at a distance from a 
minimal promoter. Synthetic DNA fragments with random multi-ZREs have been 
used previously to investigate Zta regulatory mechanisms (Lieberman and Berk, 
1991). In addition, a similar approach was used to analyse a novel methylated 
AP-1 site (mAP-1) bound by c-Jun/c-Fos heterodimer. A synthetic construct 
containing random five individual sites mAP-1 was cloned upstream of a 
minimal promoter in a luciferase reporter construct (Gustems et al., 2014).  
 
The number of tandem repeat sites selected was considered to be the best 
reflection of enhancer elements. Commonly, enhancers are bound by multiple 
transcription factors where each transcription factor has multiple binding sites 
(Berman et al., 2002). The number of these multiple sites is variable; for 
example, in Drosophila, an enhancer element (eve stripe 2) was found to 
contain binding sites for at least four TFs, one of these TFs (krupple) has six 
multiple binding sites (Ludwig et al., 1998). Also, in SV40 enhancer, dissecting 
this element into shorter segments has resulted in the loss of their enhancer 
ability. However,  when multiple copies of one shorter segment were used 
together, enhancer activity was restored (Schirm et al., 1987). Similarly, super 
enhancers do not only contain clusters for TFs binding sites but are arranged as 
multiple elements  within a long enhancer region (Pott and Lieb, 2015). 
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Our in vitro experiments showed that the 20XZRE fragment mediated enhancer 
effects on both minimal promoters (MinP and MinC) as shown in Figure 4-3 and 
Figure 4-4, respectively. Comparable levels of enhancer activity were observed 
for enhancer constructs ranging between 9- to 14-fold increases compared to 
the Null constructs in the presence of Zta. The fold change in activity levels 
were higher in the MinP than MinC construct when compared to the control 
sample lacking Zta expression (pcDNA3 control). This is attributed to the very 
low baseline activity of the MinP construct. The experiments were carried out in 
EBV-negative Burkitt’s lymphoma (DG75). These cells were selected to 
eliminate any role for other viral TFs in this enhancer activity and to be in 
agreement with Zta ChIP-Seq data (described earlier) which was performed in 
Akata Burkitt’s lymphoma cells.        
 
Our luciferase reporter findings (summarised in Figure 4-5 (A)) provided 
functional evidence for Zta distance enhancement activity in vitro for the first 
time. However, a definitive evidence of Zta activation through long-range 
enhancer elements will require in vivo genome editing of enhancer elements as 
well as evidence of enhancer interaction with Zta regulated promoters. As 
shown in Figure 4-5 (B), we propose a possible DNA looping model, reviewed 
in (Krivega and Dean, 2012), to explain how Zta achieves its regulatory role 
through enhancers. This could be facilitated by Zta direct binding to an 
enhancer element and a target promoter, which subsequently initiate a DNA 
loop and bring the two regions in close proximity. Zta binding partner such as 
the acetyl transferase coactivators CBP/p300 (Adamson and Kenney, 1999; 
Deng, 2003; Zerby et al., 1999) are very likely to be involved in this process. 
Also, as Zta is known to interact directly with TFIID and TFIIA (Lieberman, 
1994; Lieberman et al., 1997), this could suggest a direct interaction between 
Zta and the general transcription factors at the core promoter in the absence of 
Zta binding sites within the promoter element as illustrated in our minimal 
promoters. Currently, the DNA loop model is being investigated in our lab using 
chromosome conformation capture (3C) method by Ijiel B. Naranjo Perez-
Fernandez. This will provide new insights into Zta gene expression regulatory 
mechanisms.  
 
142 | P a g e
Gene
ZREs
Promoter
TFIID
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LuciferasePromoter
LuciferaseZREs Promoter
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Increased activity 
Distal element 
~2.2 kb 
Figure 4-5 Increasing evidence suggesting a role for Zta at enhancer
elements. Zta binding patterns at vast distal regions across the human genome
(Ramasubramanyan et al., 2015) as well as the increased luciferase promoter
activity seen when a distal ZRE element was introduced to the pGL3-Control
construct suggest a role for Zta in transcription regulation through enhancer
elements. (A) A schematic diagram depicting a model summarising the long-
range ZRE element experiment findings. (B) A possible DNA looping model of
how Zta might facilitate the communication between the enhancer and promoter
regions. Zta is likely to promote the interaction of long-range enhancer elements
with core promoters either through the direct interaction with the basic
transcriptional factors or through coactivators (especially in the presence of Zta
response elements within the proximal promoters. Zta is shown as (blue X), co-
activators (green oval), RNA Pol II and basal transcription machinery proteins are
shown as blue circle, and yellow ovals, respectively.
TFIIA
5-143 
 
  
Chapter 5  Zta activates viral immune evasion gene BNLF2a 
through direct binding to proximal promoter ZREs 
5.1 Introduction 
Transcriptional regulation of genes is dependent on transcription factors (TFs) 
binding to cis-regulatory elements, and through specific protein-protein 
interactions, that lead to the recruitment of the basal transcriptional machinery 
at the gene core promoter within an accessible chromatin environment. Thus, 
promoters, the regions immediately upstream of the transcriptional start site of 
genes (TSS), have multiple adjacent TFs binding motifs which are commonly 
working synergistically through protein interactions (reviewed in (Lelli et al., 
2012)). 
 
As discussed in Chapter 1, Zta along with the other EBV important immediate-
early protein Rta (BRLF1) are the master regulator of the events taking place 
during lytic cycle (Feederle et al., 2000; Miller et al., 2007). In particular, Zta is a 
viral site- specific transcription factor which is indispensable for inducing a 
complete EBV lytic cycle as well as initiating lytic viral DNA replication (Askovic 
and Baumann, 1997; Countryman and Miller, 1985; Feederle et al., 2000; 
Fixman et al., 1995; Grogan et al., 1987; Sarisky et al., 1996; Schepers et al., 
1993a). Zta mediates the lytic cycle by inducing the expression of Rta (Sinclair 
et al., 1991), autoregulating its own expression (Flemington and Speck, 1990a; 
Lieberman and Berk, 1990), and inducing various other EBV lytic cycle genes 
(Chevallier-Greco et al., 1986).  
 
Zta regulates its target genes by binding through a degenerate 7 bp motif 
(ZRE). 32 variants of this motif have been identified including the canonical AP-
1 site (Chang et al., 1990; Farrell et al., 1989; Flower et al., 2011; Lieberman et 
al., 1990). These ZREs are present across the viral and cellular genome; in the 
EBV genome, ZREs can be identified in most of lytic cycle promoters within 500 
bp of the TSS (Flower et al., 2011). In addition, Zta forms a highly stable TFIID-
A complex, which is important to stabilise the TFIID binding at the core 
promoter site (Lieberman, 1994; Lieberman and Berk, 1991; Lieberman et al., 
1997). 
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In recent years, not only Zta genome-wide binding to the viral and the cellular 
DNA was investigated (Bergbauer et al., 2010; Flower et al., 2011; 
Ramasubramanyan et al., 2012a; Ramasubramanyan et al., 2015) but Zta 
induced-changes in global cellular gene expression were analysed 
(Ramasubramanyan et al., 2015). This provided an overall view of Zta targeted 
genes. However, there is a lack of a complete understanding of Zta transcription 
mechanisms as only a small number of the viral and cellular promoters known 
to be responsive to Zta have been thoroughly characterised. For instance, as 
previously discussed in Section 1.4, the most widely investigated viral 
promoters are the BZLF1 (Zp) (Flemington and Speck, 1990a) and BRLF1 (Rp) 
promoters (Sinclair et al., 1991). In addition, other viral lytic promoters that have 
been investigated are BMRF1, BHLF1 and BALF2 (Holley-Guthrie et al., 1990; 
Hung and Liu, 1999; Kenney et al., 1989; Lieberman et al., 1989).  
 
Investigating these promoters was very useful not only to understand Zta 
transcriptional regulation but EBV lytic cycle, particularly in EBV lytic semi-
permissive cells (epithelial cells). For example, as described in Section 1.4.4, 
recent reports described the mechanism of Zta and Rta synergistic activation 
which was shown to be mediated by a cellular factor known as MCAF1 at 
BHLF1 promoter (Chang et al., 2010). Another cellular protein Ku80, which is 
known to interact with Zta (Bailey et al., 2009a; Wiedmer et al., 2008), was 
shown to enhance the activation of BHLF1 promoter (Chen et al., 2011).  On 
the other hand, a few promoters were identified to be highly active or 
differentially expressed in a cell-specific manner (Becker et al., 1991; Bogedain 
et al., 1994; Lagenaur and Palefsky, 1999; Lemon et al., 1977; Lieberman et al., 
1989; Young et al., 1991c). For instance, BMRF1 promoter was shown to 
require Zta and Rta to give maximal activity in B cells while in epithelial cells Rta 
was dispensable (Holley-Guthrie et al., 1990).  Another promoter which was 
shown to be highly expressed in oral hairy leukoplakia (OHL) is BMRF2. Unlike 
BMRF1, this promoter is not responsive to Zta but was induced by the phorbol 
ester TPA and characterised by the presence of GC box and TATA element. 
This promoter shows high basal levels in epithelial cells correlating with its high 
abundance in OHL (Lagenaur and Palefsky, 1999). A more detailed description 
of Zta responsive promoters is provided in Section 1.4.4. 
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In light of these studies, in this chapter, I show the analysis of a novel early- lytic 
promoter target for Zta.  This promoter mediates the expression of BNLF2a, a 
small viral protein that plays a vital role in immune evasion, by targeting the 
transporter associated with antigen processing complex (TAP) (Hislop et al., 
2007; Horst et al., 2009; Ressing et al., 2008; Wycisk et al., 2011). The role of 
BNLF2a in immune evasion is discussed in more details in Chapter 1, Section 
1.5.1.   
 
BNLF2a promoter (also known as ED-L2) is of  great interest not only because 
it mediates the transcription of an essential EBV protein to avoid any immune 
response during lytic cycle (Croft et al., 2009; Quinn et al., 2014) but it was also 
described to have constitutive expression in stratified squamous epithelium of 
the tongue and esophagus (Jenkins et al., 1997; Nakagawa et al., 1997a; 
Nakagawa et al., 1997b; Wilson et al., 1990). It has also been employed in 
transgenic mice models to drive the specific expression of the oncogene Cyclin 
D1 and labelling fusion protein histone 2B-GFP in the esophagus cells, in an 
attempt to study the biology and cancer development in the esophagus 
(Nakagawa et al., 1997b; Roth et al., 2012). 
 
Using luciferase reporter assay, a series of mutant constructs to dissect Zta 
response elements within the promoter were generated to investigate Zta 
regulation of this promoter in B cells as well as epithelial cells. A further 
mutation analysis of the promoter to investigate other potential cellular binding 
sites and Zta regulation mechanisms will be described in the next chapter.  
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5.2 Results 
5.2.1 Zta binds at the BNLF2a promoter during lytic cycle 
The ChIP-Seq data (Ramasubramanyan et al., 2012a) revealed two Zta binding 
peaks upstream BNLF2a promoter in Burkitt’s lymphoma Akata cells as shown 
in Figure 5-1 (A). Further in silico analysis of the DNA sequence under the 
binding peaks unfolded five Zta response elements. A large Zta binding peak is 
seen in very close proximity to the transcription start site (TSS) Figure 5-1 (A). 
Under this large peak there is a cluster of three ZREs separated by very similar 
short distances. Around 80 bp separates ZRE1 and ZRE2, while 67 bp 
separates ZRE2 and ZRE3. On the other hand, around 580 bp away from 
BNLF2a transcription start site there is another smaller Zta binding peak above 
another two predicted ZREs within BNLF2a upstream sequence.  
 
Figure 5-1 (B) represents a screen shot of a genome view of EBV wildtype 
strain (NC_007605.1). This view shows the EBV genome region of BNLF2a 
gene, BNLF2a upstream (promoter) region investigated in this project, and 
genes in close proximity (LMP1 and BNLF2b). The TATA box motif of BNLF2a 
is also highlighted. 
 
The start and end of the promoter region (region between 167029-167941 bp) 
used in BNLF2a promoter luciferase reporter assay, which is discussed 
thoroughly in the next few sections, is shown between red flags in Figure 5-1 
(B). The exact location of each ZRE is also marked. The ZREs were given 
numbers from 1-5 where the closest one to the transcription site is ZRE1. The 
location of the primers used in Zta ChIP-qPCR experiment is also highlighted 
Figure 5-1 (B). The coordinates of these oligonucleotides are also given in 
Table 2-4.  
 
As previously shown in Chapter 3, we also looked into Zta binding at BNLF2a 
promoter in different EBV cell lines using ChIP-qPCR, particularly, the EBV non-
B cell model available to us (293-BZLF1-KO cells). The ChIP-qPCR data is 
presented again in this chapter (Figure 5-2 (A & B)) along with ChIP-qPCR 
results in Akata cells (C). 
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Zta association with BNLF2a promoter region was assessed. The primers used 
in this qPCR are specific to a region near the second cluster of ZREs within the 
promoter region (Figure 5-1 (B)). Statistically significant enrichment for Zta at 
BNLF2a promoter was observed in all the investigated cell lines (P-values < 
0.01 compared to the no binding control region).   
 
The ChIP-qPCR data for Zta binding at BNLF2a promoter presented in Figure 
5-1 fall in agreement with the Zta ChIP-Seq data in lytic induced Akata B cells 
presented in Figure 5-1 (A). Moreover, five ZRE motifs were identified within 
around 700 bp upstream of BNLF2a (Figure 5-1 (B)). These findings show 
preliminary evidence of a possible role for Zta in regulating BNLF2a, which is 
essential for the virus to avoid any host immune response during lytic cycle.  
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Figure 5-2. Zta binding at BNLF2a promoter region in three different cell
lines. ChIP-qPCR in different EBV systems: Akata Burkitt’s lymphoma cells
induced into EBV lytic cycle by cross linking surface IgG, LCL3 cells which
are spontaneously lytic lymphoblastoid cells and 293-BZLF1-KO cells which
are HEK 293 cells stably infected with recombinant EBV containing BZLF1
gene knockout. The qPCR assays were performed using primers for lytic
origin of replication (OriLyt), non-binding region (OriLyt-Flank) and BNLF2a
promoter. Values are presented as the mean of triplicate readings ± SD. (***)
indicates p<0.001 while (**) indicates p<0.01 compared to No binding site.
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C
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5.2.2 BNLF2a predicted ZRE sequences.   
Given Zta binding at ZREs within the BNLF2a promoter, we hypothesised that 
this gene is a direct target for Zta. Thus, we wanted to investigate any functional 
relevance to this binding and to shed light on the possible mechanisms for this 
regulation.   
 
We initially examined the predicted ZREs motif within the promoter. This is very 
important to determine what class of ZREs are present (unmethylated or 
methylated dependent ZREs) and whether any of these ZRE motifs were shown 
to bind Zta previously or at least have a role in regulating other viral promoters.  
 
In Figure 5-3, the sequences and features of BNLF2a-predicated ZREs are 
listed as a table.  ZRE1, which is closest to the TSS and separated by 41 
nucleotides from the TATA box, has a CpG motif and is classified as type II 
ZRE. This means that Zta binds better when a methyl group is added to the 
cytosine nucleotide, but methylation is not essential for Zta binding (Flower et 
al., 2011; Karlsson et al., 2008b). The same motif was also described before in 
the EBV BRLF1 promoter (Rp) (Bhende et al., 2004; Dickerson et al., 2009). 
The other four ZREs are class I (Karlsson et al., 2008b), which does not contain 
a CpG motif, and were described before in either other EBV promoters or within 
the OriLyt region. ZRE2 is a canonical AP-1 site  (Lopez et al., 1993) and is 
found in EBV OriLyt (Lieberman et al., 1990). ZRE3 (TGTGCCA) and ZRE4 
(TGGCACA) are a reverse complementary of each other. An identical motif to  
TGTGCCA is found in the EBV BMRF1 promoter (Flower et al., 2011). ZRE5 is 
another known AP-1 site and has been described in various cellular promoters 
(Rani et al., 2009; Thierry et al., 1992) as well as in the EBV lytic BFRF1 gene 
(Granato et al., 2006). 
Given 
Name
5’-3’ 
Sequence
EBV 
(NC_007605.1)
Coordinates 
Frequency 
of site in 
EBV
genome
Description
ZRE1 TCGCTCA 167109-167115 17
ZRE1 is class II 
(contains CpG
motif) (1&2). This 
ZRE motif is the 
same with ZRE2  
in BRLF1 promoter 
(Rp) (3 &4).
ZRE2 TGACACA 167194-167199 31
ZRE2 is the 
canonical AP-1 
site (5) and has no 
CpG motif (class 
I). Also, found in 
EBV OriLyt (6)
ZRE3 TGTGCCA 167266-167272 41
ZRE3 is class I
and found in 
BMRF1 promoter 
(1).
ZRE4 TGGCACA 167609-167603 41
ZRE4 is the 
reverse 
complementary 
sequence of ZRE3  
found in BMRF1 
promoter (1).
ZRE5 TGACTAA 167702-167708 8
ZRE5 is class I
and described  as 
AP-1 binding site 
in EBV BFRF1 (7) 
as well as various 
viral and cellular 
promoters (8&9)
Figure 5-3 Zta response elements (ZREs) upstream of BNLF2a gene. The table
shows the predicted ZREs within 1 kb upstream of BNLF2a along with their genome
coordinates according to the EBV wildtype strain (NC_007605.1). Each ZRE location
is marked (orange flag) in Figure 5-1. Brief description of each individual ZRE is also
given. (1) (Flower et al., 2011), (2) (Karlsson et al., 2008), (3) (Bhende et al., 2004),
(4) (Dickerson et al., 2009), (5) (Lopez et al., 1993), (6) (Lieberman et al., 1990), (7)
(Granato et al., 2006) (8) (Rani et al., 2009), (9) (Thierry et al., 1992).
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5.2.3 BNLF2a promoter constructs to investigate each ZRE function 
We investigated the functional relevance of the identified ZREs using luciferase 
reporter assay.  A 913 bp fragment immediately upstream of the start codon of 
BNLF2a that included the TATA box and all five ZREs was analysed in our 
reporter assay. Also, it is worth noting that the last part of this fragment overlaps 
with part of LMP1 (3’) end, as shown in Figure 5-1 (B).  
 
The BNLF2a promoter sequence (DNA fragment illustrated in Figure 5-1 (B)) 
was obtained as synthetic dsDNA fragment and was subcloned into the 
luciferase reporter assay plasmid pCpGL-basic upstream of the luciferase gene 
between BamHI and HindIII restriction enzyme sites, as demonstrated in the 
schematic diagram in Figure 5-4. 
 
Mutant ZRE promoter variants were similarly subcloned to generate 12 mutant 
luciferase constructs, the details of which are provided later in Figure 5-7. 
 
Each luciferase construct was co-transfected with either a control vector 
(pcDNA3) or His-Zta expression vector into EBV-negative Burkitt’s lymphoma 
cell line (DG75) and/or human cervical carcinoma epithelial cells (HeLa cells).  
This approach allowed the comparison of luciferase activity in the presence and 
absence of Zta as demonstrated in Figure 5-4 (B).  
 
Figure 5-5 represents the full DNA sequence of the wildtype BNLF2a promoter 
DNA insert (5’-3’) used in our luciferase reporter analysis. Each predicted-ZRE 
sequence is highlighted in the figure along with the canonical TATA motif, which 
is 30 bp away from the transcription start site (TSS).   
 
Furthermore, in Figure 5-6 (A), a schematic cartoon of the promoter reporter 
constructs showing the sequence and location of each ZRE in relative to the 
gene start is given. Also, these locations are listed in a table (Figure 5-6 (B)). 
 
As described earlier, the main aim was to map the ZRE motifs within the 
promoter that would possibly contribute to the promoter activity.  To achieve 
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this, we generated a series of mutant promoter luciferase constructs as 
explained in the experimental design illustration in Figure 5-4. In each 
construct, either one or a different combination of ZREs were replaced each 
time by a random mutant motif (CCCCTTT). 
 
The rationale of each mutant construct will be given in the relevant results 
section. Briefly, Figure 5-7 provides a list of these mutant constructs consisting 
of the name given to the construct, a brief description of the mutated sites, and 
a small schematic for each construct that will be presented again in the relevant 
results section. 
 
Our luciferase reporter assay approach allowed a simple and rapid analysis of 
BNLF2a promoter. This was facilitated by the technological advances in DNA 
fragment synthesis which enabled us to generate numerous mutant promoter 
constructs to investigate Zta regulation of BNLF2a.  
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Figure 5-4 Investigating BNLF2a promoter activity. A schematic
representation of the luciferase reporter assay experiment carried out to
investigate BNLF2a transcriptional regulation. (A) A synthetic DNA
fragment (orange) spanning around 900 bp upstream of BNLF2a gene start
was cloned between BamHI and HindIII restriction enzyme sites in pCpGL-
basic luciferase vector (black plasmid). Additionally, 20 mutant BNLF2a
promoter variants were cloned in pCpGL vector. (B) Each promoter variant
luciferase vector was co-transfected with either a control vector (pcDNA3)
(green plasmid) or His-Zta expression vector (green and red plasmid) in
EBV-negative Burkitt’s lymphoma cell line (DG75) and/or epithelial cells
(HeLa cells). Luciferase signal was compared in the absence and presence
of Zta.
A
B
 
GGATCCCATAGCCCTAGCGACTCTGCTGGAAATGATGGAGGCCCTCCACAATTGACGGA
AGAGGTTGAAAACAAAGGAGGTGACCAGGGCCCGCCTTTGATGACAGACGGAGGCGGCG
GTCATAGTCATGATTCCGGCCATGGCGGCGGTGATCCACACCTTCCTACGCTGCTTTTG
GGTTCTTCTGGTTCCGGTGGAGATGATGACGACCCCCACGGCCCAGTTCAGCTAAGCTA
CTATGACTAACCTTTCTTTACTTCTAGGCATTACCATGTCATAGGCTTGCCTGACTGAC
TCTCCCTCCATTTACTGGGAATGCCTTAGCTAATCACCTTAACTGGCACACACTCCCTT
AGCCACACTGTCTGTCTAGGCTGAAAAGCCACATTCATATTCTATTTCAAAACAAGGGG
AAAGGAGGACATGCGAGAATTGGCAGACACCTTTACCCAGCCCTTAACACACCACACAG
GTAGCAAGGACCCGGGCGTTGCCAGACTCCGCCACCAACGCCCCTGCGTTGAACCCACC
CCTCCTACACACATCAGACCTCTGCACAACACAACTACCAGGCAGATGAGGCCCCTTAC
TTCCACAGGGTACTGGCATACCAGCGGGGGACCACATACATCCCTGTCTCCCACCCAGT
AACTCCAGCAACTTTGCTTTCCATCTTGTGCCAATACACATTTGGATTCAGCCCAAGCC
ACACCTAACTCATGCCAGCAGAGGCAGGAACACCTGTTGTTGACACATTCTTTGCGCAT
AAGCACTTTAATCCCTCTCTCACACCCAGAAACTAAGAGCTAGCCCAAAACCTCCACAC
CTGTCCTCGCTCATCTTTCCACATTCCTCTGGCCTTCTTTCCTTGTCCTTACTGTATAA
AAGTCCACGAAAACAGCTGTGCCTCACTCTCGAGAAGCTT 
 
ZRE1 
ZRE2 
ZRE3 
ZRE4 
ZRE5 
Transcription start site 
TATA box 
(ATG) BNLF2a 
155 | P a g e
Figure 5-5 BNLF2a promoter sequence along with the predicted ZRE motifs. A
schematic illustration of the sequence used in BNLF2a promoter constructs. A 913 bp
sequence with the genome coordinates 167029-167941 based on EBV wildtype strain
(NC_007605.1) was used to analyse BNLF2a promoter activity. Sequence analysis
revealed five Zta response elements (ZREs) (highlighted in yellow) distributed within
700 bp upstream of BNLF2a gene. A canonical TATA box motif (highlighted blue) is
located 30 bp upstream of the transcription start site. The gene start and transcription
start site (TSS) are indicated with arrows. The restriction enzyme sites used in cloning
are highlighted in grey.
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Promoter 
construct name Description Schematic diagram
BNLF2a 1-5 5 ZREs left intact
BNLF2a Null
None of the 
ZREs left 
intact
BNLF2a 1-3 ZREs 1-3 left intact
BNLF2a 4-5 ZREs 4-5 left intact
BNLF2a 2-5 ZREs 2-5 left intact
BNLF2a 1&3-5 ZREs 1 and 3-5 left intact
BNLF2a 1-2&4-5 ZREs 1-2&4-5 left intact
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Promoter 
construct Name Description Schematic diagram
BNLF2a  1 Only ZRE1 left intact
BNLF2a 2 Only ZRE2 left intact
BNLF2a 3 Only ZRE3 left intact
BNLF2a 1&2 ZREs 1&2 left intact
BNLF2a 1&3 ZREs 1&3 left intact
BNLF2a 2&3 ZREs 2&3 left intact
Figure 5-7 BNLF2a ZREs luciferase promoter constructs. All the luciferase
reporter constructs generated to address ZREs contribution to promoter activity
are listed. The construct given name, ZRE mutations and a schematic diagram
of each constructs are given. To mutate each ZRE motif, the wildtype ZRE motif
was replaced with a generic sequence (CCCCTTT).
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5.2.4 Zta activates BNLF2a through promoter ZREs in different cell lines 
Various BNLF2a promoter reporter constructs were generated to investigate Zta 
activation of BNLF2a promoter and to identify the individual ZRE/s responsible 
for this activation, as explained in the previous sections.   
 
We initially investigated whether Zta alone is capable of activating BNLF2a and 
whether this activation is dependent on the direct binding of Zta through its 
response elements (ZREs). Thus, we compared the activity of wildtype BNLF2a 
promoter (BNLF2a 1-5) against a construct with mutated ZRE sites (BNLF2a 
Null). This comparison was carried out in the presence and absence of Zta 
expression in EBV-negative DG75 B-cells as well as HeLa cells. A 
representative data of the BNLF2a 1-5 and BNLF2a Null promoter luciferase 
relative activity is shown in Figure 5-8. The data is presented as fold change of 
the activity in the presence of Zta over the absence of Zta (pcDNA3 control 
sample).   
 
The relative activity of the wildtype promoter construct (BNLF2a 1-5) was at 
least 7-fold greater than BNLF2a Null in which all the predicted ZRE sites were 
mutated (Figure 5-8 (A and C)). This finding was consistent between EBV- 
negative DG75 cells (A) and HeLa cells (C). Using student t-test, a statistically 
significant difference in promoter activity between BNLF2a 1-5 and BNLF2a Null 
construct in the presence of Zta was observed (P-value <0.001). 
 
Figure 5-8 (B and D) represents a western blot analysis for actin (loading 
control) and Zta for each sample. Comparable levels of Zta expression can be 
seen for all samples while the absence of Zta is confirmed in the control 
samples. For each sample, the intensity of the actin band was used to 
normalise the luciferase relative light units value for that sample as previously 
described in Chapter 2.     
 
Clearly, the data presented in Figure 5-8, strongly indicates that Zta, with no 
other viral proteins, activates BNLF2a promoter in both cell lines tested. This 
activation is dependent on the presence of intact ZREs, as the promoter activity 
was massively attenuated when these sites were mutated.    
160 | P a g e
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BNLF2a Null
Promoter relative activity
DG75 cells 
Control Zta
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BNLF2a 1-5
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B
Figure 5-8 Zta activates BNLF2a through ZREs. The figure shows luciferase
reporter assay analysis of the wildtype BNLF2a construct (BNLF2a 1-5) and
mutated ZREs (BNLF2a Null) construct co-transfected with either Zta expression
vector (red bars) or control vector (blue bars) in EBV-negative Burkitt's lymphoma
cells (DG75 cells) (A) and epithelial cells (HeLa cells) (C). (B and D) Western blots
show similar levels of Zta transfection in each cell line. Values are normalised to
actin levels and presented as fold change in relative to the control for each sample.
Error bars represent the mean of triplicate reads ± SD. (***) indicates p<0.001
compared to BNLF2a Null in the presence of Zta.
BNLF2a 1-5
BNLF2a Null
Control Zta
+ +
+ +
Actin
Zta
Actin
Zta
BNLF2a 1-5
BNLF2a Null
Control Zta
+ +
++
***
***
C
D
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5.2.5 The proximal ZREs to the TSS are essential for BNLF2a activation. 
Following our first intriguing observation where Zta activated the promoter 
through ZREs, the following logical questions were raised: Which ZREs are 
contributing to the promoter activity? Does the arrangement of the ZREs relate 
to their function?  
 
To better understand these questions, we were equally interested in what 
appears to be two cluster regions of ZREs separated by around 330 bp. This 
was largely based on the observation that there were two Zta binding peaks in 
the ZRE regions ChIP-Seq data, as shown in Figure 5-1.  
 
Thus, we generated two mutant BNLF2a promoter constructs containing either 
the first three proximal ZREs (ZRE1-3) (BNLF2a 1-3) or the last two distal ZREs 
(ZRE 4-5) (BNLF2a 4-5) in the wildtype form.  
 
The promoter activity of BNLF2a 1-3 and BNLF2a 4-5 reporter constructs was 
investigated in a luciferase reporter assay experiment, as explained in the 
previous sections. This analysis was carried out in the presence and absence of 
Zta expression in EBV-negative DG75 B-cells as well as HeLa cells.  
 
Figure 5-9 shows a representative experiment, in which wildtype BNLF2a 1-5, 
BNLF2a Null, BNLF2a 1-3 and BNLF2a 4-5 constructs were compared. The 
data are presented as promoter relative activity (fold change) in the presence of 
Zta over the absence of Zta.   
 
Interestingly, the BNLF2a 1-3 construct was still activated in the presence of Zta 
at levels that were very comparable to the levels seen in the wildtype BNLF2a 
1-5 construct in both cell lines tested (Figure 5-9 (A and C)).  
 
The relative promoter activity of BNLF2a 1-3 was at least 9-fold greater than 
BNLF2a Null. This finding was consistent between EBV-negative DG75 cells 
(A) and epithelial cells (HeLa cells) (C).  
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On the other hand, the relative promoter activity of BNLF2a 4-5 construct, which 
included the intact two distal ZREs, showed a very reduced activity in DG75 
cells and a completely insignificant change in HeLa cells, when compared to 
BNLF2a Null.  
 
Figure 5-9 (B and D) represents a western blot analysis for actin (loading 
control) and Zta for each sample. Comparable levels of Zta expression can be 
seen for all samples while the absence of Zta is confirmed in the control 
samples. For each sample, the intensity of the actin band was used to 
normalise the luciferase relative light units value for that sample, as previously 
described in Chapter 2.     
 
Clearly, the data presented in Figure 5-9, strongly indicate that BNLF2a 
promoter response to Zta is largely driven from the first three ZREs (ZRE 1-3) 
promoter in both cell lines tested (DG75 and HeLa cells).  
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Figure 5-9 The proximal ZREs contribute the most to BNLF2a activity. The
figure shows luciferase reporter analysis of the wildtype BNLF2a construct (BNLF2a
1-5), mutated ZREs (BNLF2a Null) construct as well as a construct with only the
three proximal ZREs left (BNLF2a 1-3) and a construct with the two distal ZREs left
(BNLF2a 4-5). BNLF2a promoter luciferase constructs were co-transfected with
either Zta expression vector (red bars) or control vector (blue bars) in EBV-negative
Burkitt's lymphoma cells (DG75 cells) (previous page) (A) and epithelial cells (HeLa
cells) (C). (B and D) Western blots show similar levels of Zta transfection in each
cell line. Values are normalised to actin levels and presented as fold change in
relative to the control for each sample. Error bars represent the mean of triplicate
reads ± SD. BNLF2a 4-5 is significantly different from BNLF2a Null (p<0.001) in
DG75 cells but not in HeLa cells . (***) indicates P< (0.001).
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5.2.6 ZREs functional redundancy 
Based on our previous finding where the first three ZREs were shown to be 
critical for BNLF2a promoter response to Zta activation, we asked the question 
whether all of the three ZREs are needed, or is it possible to further identify the 
individual ZREs responsible for the promoter activity. To address this question, 
we used the same luciferase approach and generated additional mutant 
BNLF2a promoter constructs that accounted for all combinations of the first 
three ZREs.  
 
Initially, we generated the three separate luciferase promoter constructs 
BNLF2a 2-5, BNLF2a 1&3-5 and BNLF2a 1-2&4-5, where each contained a 
mutant form of one ZRE out of the first three.  This was to determine whether 
any single ZRE was essential for BNLF2a activation.  
 
Figure 5-10 shows a representative experiment in which the promoter activity of 
BNLF2a 1-5, BNLF2a Null, BNLF2a 2-5, BNLF2a 1&3-5 and BNLF2a 1-2&4-5 
constructs were compared. The data is presented as fold change of the activity 
in the presence of Zta over the absence of Zta (control) in EBV-negative DG75 
cells as well as HeLa cells.  
 
The BNLF2a 2-5 construct, containing ZREs 2-5 and mutated ZRE1, showed 
promoter activity in the presence of Zta but at slightly reduced levels compared 
to the wildtype promoter construct BNLF2a 1-5 in both cell lines (EBV negative 
DG75 cells and HeLa cells) (Figure 5-10 A and C, respectively).  
 
The BNLF2a 1-2&4-5 construct, containing ZREs 1-2&4-5 and mutated ZRE3, 
showed a similar level of activation compared to BNLF2a 2-5 in the presence of 
Zta in both cell lines (Figure 5-10 A and C, respectively). 
 
On the other hand, the BNLF2a 1&3-5 construct, containing ZREs 1&3-5 and 
mutated ZRE2, was still largely activated in the presence of Zta, but to a much 
lower degree than the levels reported for BNLF2a 2-5 construct and BNLF2a 1-
2&4-5 construct. 
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Figure 5-10 (B and D) represents a western blot analysis for actin (loading 
control) and Zta for each sample, as discussed in the previous figure. 
Comparable levels of Zta expression can be seen for all samples while the 
absence of Zta is confirmed in the control samples. For each sample, the 
intensity of the actin band was used to normalise the luciferase relative light 
units value for that sample, as previously described in Chapter 2.     
 
The data presented in Figure 5-10, suggests that no single ZRE of the first 
proximal ZREs is key motif in Zta activation of BNLF2a.  
 
This initial finding suggested a possible functional redundancy of ZREs but did 
not eliminate whether the wildtype activity of BNLF2a promoter requires one or 
more ZREs.  
 
We therefore generated additional constructs to determine whether one or more 
ZRE were enough to induce the wildtype promoter activity. A list of all 
constructs is provided in Figure 5-7. Also, based on the fact that there were no 
major differences in the results between the two cell lines used in our 
experiments, a decision was made to proceed with transfecting the new 
constructs into HeLa cells only. Unlike DG75 cells, HeLa cells provided a much 
more consistent transfection efficiency as electroporation was not required.  
 
Figure 5-11 (A), represents data showing the relative promoter activity of the 
BNLF2a promoter constructs BNLF2a 1, BNLF2a 2 and BNLF2a 3, which 
contains only one intact ZRE in HeLa cells only.  Comparing the relative activity 
of these constructs to the wildtype promoter construct (BNLF2a 1-5) suggested 
that no single ZRE was capable of driving the wildtype promoter activity.  
 
The BNLF2a 3 construct containing intact ZRE3 only was not responsive to Zta 
induction, while BNLF2a 1 and BNLF2a 2 constructs containing intact ZRE1 
and ZRE2 respectively showed a reduced but statistically significant activation 
when compared to BNLF2a Null. This activation was slightly more prominent in 
BNLF2a 2. These results are in agreement with the results presented in Figure 
5-10 where mutating one of the three proximal ZREs showed no adverse effects 
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on the promoter activity. Also, ZRE2 had a more prominent effect, suggesting a 
potential dominant role for ZRE2. 
 
As previously discussed, Figure 5-11 (B) shows a western blot analysis of the 
levels of Zta transient expression along with actin (loading control).  
 
We hypothesised that the wildtype promoter activity is very likely to be derived 
from at least two functional ZREs of the proximal ZREs based on the findings 
presented in Figure 5-10 and 5-11. To test this hypothesis, we additionally 
generated the BNLF2a promoter constructs BNLF2a 1&2, BNLF2a 1&3 and 
BNLF2a 2&3. Each of these constructs contains two different intact ZREs of the 
first three proximal ZREs within BNLF2a promoter.  
 
 Figure 5-12 (A), represents data demonstrating the promoter activity in the 
presence of Zta for BNLF2a 1&2, BNLF2a 1&3 and BNLF2a 2&3 constructs. 
Interestingly, leaving two ZREs each time has restored the promoter activity to 
levels similar to the level of the wildtype promoter activity (BNLF2a 1-5). These 
levels were at least 6- fold greater than BNLF2a Null. Noticeably, the BNLF2a 
1&3 construct, containing intact ZRE1, ZRE3 and mutated ZRE2, resulted in a 
slightly significant reduced activation when compared to BNLF2a 1&2 and 
BNLF2a 2&3 constructs (P <0.05). This supports ZRE2 key role in the promoter 
activation. Furthermore, the results presented in Figure 5-12 have majorly 
reproduced the findings in Figure 5-10.  However, unlike in Figure 5-10, the 
constructs presented in Figure 5-12 contained mutated ZRE4-5. This confirms 
our initial observation of a less important role for ZRE 4-5 in BNLF2a promoter 
activation, as shown in Figure 5-9 (C). 
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Figure 5-10 Mutating one ZRE of the proximal ZREs has no profound effect on
promoter activity. The figure shows luciferase reporter analysis of the wildtype
BNLF2a construct (BNLF2a 1-5), mutated ZREs (BNLF2a Null) construct as well as
constructs with only one of the three proximal ZREs is mutated each time. BNLF2a
promoter luciferase constructs were co-transfected with either Zta expression vector
(red bars) or control vector (blue bars) in EBV-negative Burkitt's lymphoma cells
(DG75 cells) (previous page) (A) and epithelial cells (HeLa cells) (C). (B and D)
Western blots show similar levels of Zta transfection. Values are normalised to actin
levels and presented as fold change in relative to the control for each sample. Error
bars represent the mean of triplicate reads ± SD. (***) indicates p<0.001, (**)
indicates p<0.01 and (*) indicates P< (0.05) compared to BNLF2a 1&3-5 in the
presence of Zta.
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Figure 5-11 The effect of leaving one ZRE of the proximal ZREs on promoter
activity. The figure shows luciferase analysis of the wildtype BNLF2a construct
(BNLF2a 1-5), mutated ZREs (BNLF2a Null) construct as well as constructs with
only one of the three proximal ZREs remaining each time (A). BNLF2a promoter
luciferase constructs were co-transfected with either Zta expression vector (red
bars) or control vector (blue bars) in epithelial cells (HeLa cells). (B) Western blot
shows similar levels of Zta transfection. Values are normalised to actin levels and
presented as fold change in relative to the control for each sample. Error bars
represent the mean of triplicate reads ± SD. (***) indicates p<0.001, and (**)
indicates p<0.01 compared to BNLF2a Null in the presence of Zta.
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Figure 5-12 The effect of leaving two ZRE of the proximal ZREs on promoter
activity. The figure shows luciferase analysis of the wildtype BNLF2a construct
(BNLF2a 1-5), mutated ZREs (BNLF2a Null) construct as well as constructs with
only two of the three proximal ZREs remaining each time (A). BNLF2a promoter
luciferase constructs were co-transfected with either Zta expression vector (red
bars) or control vector (blue bars) in epithelial cells. (B) western blot shows similar
levels of Zta transfection. Values are normalised to actin levels and presented as
fold change in relative to the control for each sample. Error bars represent the mean
of triplicate reads ± SD. (*) indicates P< (0.05) compared to BNLF2a 1&3 in the
presence of Zta.
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5.2.7 In vitro analysis of Zta binding to BNLF2a ZREs 
We further investigated Zta binding to each ZRE in vitro in an attempt to 
complete a simple model for Zta activation of BNLF2a promoter. To do this, we 
carried out electrophoresis mobility shift assay (EMSA) using fluorescently 
labelled probes of each BNLF2a ZRE, as previously described in Chapter 2. 
Furthermore, we generated a recombinant Zta expression vector and expressed 
this recombinant protein, which resembles a His-GFP tagged basic leucine 
zipper (bZIP) domain of Zta, in E. coli.  
 
5.2.7.1  bZIP Zta recombinant protein expression and purification 
Prior to the EMSA, we needed to produce purified Zta protein to address Zta 
binding specificity to BNLF2a ZREs. As a part of a collaboration project with 
Oxford Protein Production Facility (OPPF), several recombinant expression 
plasmids were generated to test Zta expression in E. coli as well as insect cells. 
Upon initial expression screens in E. coli, a recombinant plasmid for a GFP- 
tagged Zta bZIP domain (DNA binding domain) showed promising protein 
expression. Therefore, this recombinant protein plasmid was selected to be 
expressed and purified at a large-scale and subsequently used in the EMSA 
experiment.  
 
The methods used in generating this plasmid and expressing Zta recombinant 
protein are briefly outlined in Figure 5-13 and Figure 5-15. By utilising the 
OPPF high-throughput methods, the plasmid was generated using In-Fusion 
ligation where the bZIP domain (168-245 aa) DNA sequence was subcloned 
into the pOPINN-GFP expression plasmid, which has N-terminus tag sequence 
for His-GFP.  
 
To have a suitable insert to be used in the In-Fusion ligation reaction, PCR 
primers were designed to add overlapping regions with the expression plasmid.   
Figure 5-13 represents a schematic diagram of the cloning process. The PCR 
product is illustrated along with the overlapping regions (Figure 5-13 (A)). The 
destination plasmid pOPINN-GFP along with the location and orientation of the 
tag sequence (His-GFP) are shown in Figure 5-13 (B). Subsequently, the 
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ligated DNA was transformed into competent cells as shown in Figure 5-13 (C). 
A more detailed description of the In-Fusion ligation is given in Chapter 2.  The 
generated plasmid (referred to as His-GFP-bZIP Zta plasmid) was tested for its 
expression of His-GFP-bZIP Zta recombinant protein in E. coli, as previously 
mentioned.   
 
Figure 5-14 (A) shows the DNA sequence for bZIP Zta (168-245 aa) PCR 
product along with the PCR primers and the cloning overlapping regions. 
Figure 5-14 (B) represents the protein sequence of the expected recombinant 
protein sequence His-GFP-bZIP Zta (168-245 aa). The tag sequences and 
cleavage site along with bZIP Zta are highlighted in different colours. Similarly, 
Figure 5-14 (C) represents a schematic cartoon of the expressed recombinant 
protein His-GFP-bZIP Zta (168-245 aa). 
 
Figure 5-15 (A-C) shows a flow diagram of the major steps of this process. The 
newly generated His-GFP-bZIP Zta plasmid was used to express and purify the 
recombinant protein His-GFP-bZIP Zta at a large scale in Rosetta pLysS E. coli, 
as described in Chapter 2. We undertook a two-step purification approach 
utilising an affinity column followed by size exclusion chromatography (gel 
filtration column). The purification steps were carried out in collaboration with 
Ms Montse Vega (a Master’s degree student in our lab).  
 
After the protein was eluted from the affinity HisTrap column, a few fractions 
were pooled together, concentrated and loaded into a size exclusion 
chromatography column, as described in Chapter 2. Figure 5-16 (A) shows the 
UV 280 trace (mAU) of the eluted material after the size exclusion column. The 
highest-point peak in the graph represents our expressed recombinant protein 
(His-GFP-bZIP Zta) in its native state (a dimer). A small amount of each 
collected fraction under the largest peak was separated on a denaturing SDS-
PAGE gel stained with SimplyBlue. The band observed immediately above 38 
KDa represents the expected size of His-GFP-bZIP Zta Figure 5-16 (B). This 
enriched band is seen in the fractions under the centre of the main peak, as 
shown in Figure 5-16 (A). The expression and purification of His-GFP-bZIP Zta 
resulted in a sufficient amount to be used in BNLF2a ZREs EMSA analysis. 
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Figure 5-13 Generating His-GFP-bZIP Zta expression vector.
The bZIP domain of Zta (168-245 aa) tagged with His-GFP at the N terminus was
expressed in E.coli. The expression vector was generated as a collaboration
project with Oxford Protein Production Facility (OPPF). Utilising their high-
throughput protein expression technologies, this plasmid as well as other
expression plasmids were generated using In-Fusion cloning technology and
screened for protein expression. The schematic diagram illustrates the major
cloning steps. (A) Primers to amplify Zta target DNA sequence were designed
with overlap regions (blue colour) between the insert (PCR product) (orange
colour) and the expression vector (dark grey) at each end. 6x Histidine-EGFP
coding sequence is shown in light grey and green, respectively (B) The PCR
generated insert and the linearized plasmid were fused together using In-Fusion
ligation master mix. (C) A transformation in E.coli was carried out using the
ligated material. All the steps were carried out with the help of Dr Louise Bird at
the OPPF.
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EGFP bZIP Zta (168-245 aa)6X His
3CN C
Figure 5-14 His-GFP-bZIP Zta sequences. (A) The DNA coding sequence for
bZIP Zta (168-245 aa). Primers (forward and reverse) shown in red were designed
to amplify Zta target DNA sequence with the addition of overlap regions at each end
(dark and light blue colour). The overlapping sequence between the insert (PCR
product) and the expression vector (described in previous figure) facilitates the In-
Fusion cloning. (B) The full protein sequence of the expected expressed protein (
His-GFP-bZIP Zta). The N terminus 6 X histidine and GFP tags sequences are
shown in dark grey and green, respectively. PreScission protease cleavage site
(3C) sequence is underlined in black. Zta bZIP domain sequence (168-245 aa) is
shown in red. The protein has a theoretical molecular weight of 38.12 KD (C) A
cartoon highlighting the recombinant protein sequences in similar colours to the
sequence above.
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Expected expressed protein sequence: 6x His-GFP- bZIP Zta (168-245 aa) 
 
MAHHHHHHVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLK
FICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTI
FFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVY
IMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQ
SALSKDPNEKRDHMVLLEFVTAAGITLGMDELYKSSGLEVLFQGPLEECDSEL
EIKRYKNRVASRKCRAKFKQLLQHYREVAAAKSSENDRLRLLLKQMCPSLDVD
SIIPRTPDVLHEDLLNF* 
Amplified bZIP Zta DNA sequence 
 
AAGTTCTGTTTCAGGGCCCGCTGGAGGAATGCGATTCTGAACTAGAAATAAAG
CGATACAAGAATCGGGTGGCTTCCAGAAAATGCCGGGCCAAGTTTAAGCAACT
GCTGCAGCACTACCGTGAGGTCGCTGCTGCCAAATCATCTGAAAATGACAGGC
TGCGCCTCCTGTTGAAGCAGATGTGCCCAAGCCTGGATGTTGACTCCATTATC
CCCCGGACACCAGATGTTTTACACGAGGATCTCTTAAATTTCTAAAGCTTTCT
AGACCAT 
176 | P a g e
A
B
C
Figure 5-15. Large scale purification of His-GFP-bZIP Zta protein. (A) His-
GFP-bZIP Zta expression vector ( as previously described in Figure 5-13) was
transformed into E.coli expression strain (Rosetta pLysS) (B) Transformed
Rosetta cells were allowed to grow in Autoinduction media for 16 hours.
Subsequently, cells were pelleted and resuspended in lysis buffer. (C) First , the
protein was purified using His-tag affinity column and eluted using high imidazole
concentration. Then, the purified material was passed through size exclusion
column to allow the removal of the imidazole and high salt concertation. All the
purification steps were carried out in collaboration with Ms Montse Vega (a
Master’s degree student undertaking her project in our lab).
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Figure 5-16 Purified His-GFP-bZIP Zta. (A) The size exclusion
chromatography UV280 trace (mAU) of His-GFP-bZIP Zta. (B) A small amount
of each collected fraction (under the largest peak in (A)) was separated on
denaturing SDS-PAGE gel stained with SimplyBlue. The fractions under the
largest peak were pooled together, aliquoted and stored at -80 C for further
use in electrophoretic mobility shift assay (EMSA). The large molecular weight
proteins elute first in the size exclusion chromatography.
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5.2.7.2   BNLF2a ZREs interaction with His-GFP-bZIP Zta 
The ability of Zta bZIP domain tagged with GFP to bind in vitro to fluorescently 
labelled probes containing each BNLF2a ZRE sequence with a 10 bp flanking 
on both sides was examined by electrophoretic mobility assay (EMSA). 600 ng 
of purified protein His-GFP-bZIP Zta was allowed to interact with each probe, 
then loaded into a DNA retardation gel.  
 
Figure 5-17 (A) represents an EMSA gel showing each BNLF2a ZRE probe 
interaction with or without His-GFP-bZIP Zta.  A shifted band of the same size 
was observed for all ZREs, which indicates a His-GFP-bZIP Zta-DNA complex. 
The binding strength was varied among the different ZREs (ZREs 1-5). ZRE2 
showed the strongest affinity to His-GFP-bZIP Zta, as indicated by the 
increased amount of shifted probe. As previously shown in Figure 5-3, ZRE2 is 
a canonical AP-1 site and found in EBV OriLyt. BNLF2a ZREs features and 
sequences are shown in Figure 5-3 and Figure 5-5.   
 
To confirm if the specificity of the binding between His-GFP-bZIP Zta and ZRE2 
was due to the direct interaction with the ZRE core motif, a mutant ZRE2 probe 
(ZRE2 M) was used (Figure 5-17 (B)). In this probe, the core motif of ZRE 2 
sequence was replaced to the same mutant sequence used in the luciferase 
reporter assay analysis (CCCCTTT). A list of all BNLF2a ZREs oligonucleotides 
used to generate the EMSA probes is given in Table 2-5. 
 
Figure 5-17 (B), shows the EMSA gel where wildtype ZRE2 probe (ZRE2 WT) 
was compared with mutant ZRE2 probe. A band shift was observed for ZRE2 
WT but not ZRE2 M indicating a specific interaction to the ZRE core motif.  
 
The successful expression and purification of a recombinant Zta protein (His-
GFP-bZIP Zta) facilitated the in vitro interactions analysis of bZIP Zta with 
BNLF2a ZREs. This analysis revealed a very strong affinity of His-GFP-bZIP 
Zta to BNLF2a ZRE2, while weaker binding was seen for the rest of BNLF2a 
ZREs. 
 
− + − + − + − + − +
Figure 5-17 Interaction of Zta with BNLF2a ZREs in vitro. (A) The ability of Zta
bZIP domain tagged with GFP to bind in vitro to fluorescently labelled probes
containing each BNLF2a ZRE with the 10 bp flanking region on both sides was
examined by electrophoretic mobility shift assay (EMSA). 600 ng of purified protein
was used with each probe in the presence of Poly dI-dC. (B) The specificity of the
binding was investigated by using ZRE2 M probe where the ZRE core motif was
changed from TGACACA to CCCCTTT. EMSA retardation gel was imaged using
LI-COR imaging system at 800 channel.
− + − +
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5.3 Discussion 
In agreement with the Zta binding peaks at BNLF2a promoter seen in the Zta 
ChIP-Seq data, five Zta responsive elements (ZREs) were predicted in silico 
upstream of the early lytic gene BNLF2a (Ramasubramanyan et al., 2012a).  
These findings suggested that BNLF2a might be a novel target for Zta.  Thus, a 
series of luciferase reporter constructs were generated not only to address Zta 
activation of BNLF2a promoter but also to dissect further which functional ZREs 
are contributing to BNLF2a promoter activation.  
 
The luciferase reporter assay is considered as an efficient, rapid, and highly 
sensitive technique to investigate regulatory sequences (de Wet et al., 1987; 
Nguyen et al., 1988). A limitation of this method is the low-throughput outcome, 
which means that regulatory elements need to be investigated one at a time. 
Also, this approach does not necessarily reflect the regulation within the 
chromatin context. However, reporter assays have been employed in global 
studies by generating thousands of constructs containing variants of regulatory 
elements downstream of a sequence-specific tagged reporter gene. Upon 
transient transfection of these constructs into mammalian cells, the specific 
tagged transcripts for each construct is measured using genome-wide 
technologies such as RNA-Seq. This approach is known as massively parallel 
reporter assay (MPRA) (Arnold et al., 2013; Inoue and Ahituv, 2015; 
Kheradpour et al., 2013; Melnikov et al., 2012; Patwardhan et al., 2012; Sharon 
et al., 2012). 
 
Unlike most strictly late lytic promoters which are dependent on DNA replication 
and have a distinct TATA box (Serio et al., 1997; Yuan et al., 2006), BNLF2a 
promoter is similar to other early lytic promoters. These promoters are 
characterised by the presence of a typical TATA box motif within 30 bp from the 
transcription start site, mostly regulated by Zta and Rta (Chevallier-Greco et al., 
1986) and have multiple ZREs. Interestingly, many of the promoters known to 
be responsive to Zta contain multiple ZREs. For example, BZLF1 (Zp) contains 
two adjacent ZREs (ZIIIA and ZIIIB) (Flemington and Speck, 1990a), and 
BRLF1 promoter contains ZRE1, 2 and 3, ZRE 2-3 have a CpG motif (Bhende 
et al., 2004; Sinclair et al., 1991). Similarly, BMRF1 promoter contains three 
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ZREs (Holley-Guthrie et al., 1990), BALF2 promoter contains at least two ZREs 
(Hung and Liu, 1999), and BHLF1 promoter contains four ZREs (Lieberman et 
al., 1989). Also, we showed 5 ZREs within BNLF2a promoter.  
 
One explanation for the role of multiple adjacent sites for Zta comes from a 
previous study by (Carey et al., 1992). This study showed that Zta acts in a 
synergistic way to achieve activation. This was suggested when constructs 
containing either one ZRE or multi ZREs were compared in a chloramphenicol 
acetyltransferase (CAT) reporter assay. A construct containing one ZRE gave 
only trace activity, while a construct with two ZREs showed an 18-fold change 
when compared to the one ZRE construct. A proportional relation between 
measured transcription and Zta sites (ZREs) was also reported using in vitro 
transcription assay (Carey et al., 1992). A similar finding was reported in (Sato 
et al., 1992) where Zta failed to activate collagenase and c-Jun promoters which 
contained a single consensus AP-1 site in a CAT reporter assay. However, 
adding the AP-1 site (TGAGTCA)  and the ZRE motif (TGTGCAA) upstream of 
the collagenase promoter resulted in Zta activating the promoter (Sato et al., 
1992). Also, the work by Carey et al showed that promoters with more ZREs are 
activated with less Zta concentration. Therefore, more ZRE sites will require 
less amount of Zta to induce activation.   
 
In BNLF2a promoter luciferase assay, I was able to show Zta activation in the 
presence of all intact ZREs. When all the ZREs were mutated only 15% of the 
wildtype promoter activity was detected. This observation was consistent in 
EBV-negative Burkitt’s lymphoma B cells (DG75) and cervical carcinoma cells 
(HeLa cells), as shown in Section 5.2.4 (Figure 5-8). Strikingly, this activity was 
dependent on the proximal ZREs while the more distal ZREs (ZRE 4-5) had a 
marginal effect on the promoter (Figure 5-9).   
 
Constructs designed to further dissect the promoter, leaving one of the proximal 
ZREs resulted in much reduced activity, although this reduction was slightly 
more prominent when ZRE2 was left (Figure 5-11). It is worth noting that ZRE1 
has a CpG motif, but the methylation effect on Zta transcription activation or 
binding was not investigated in this project. Zta is known to strongly and 
5-182 
 
  
preferentially bind methylated ZREs present in the viral genes BRLF1, BMRF1 
and cellular gene EGR1 promoters (Bhende et al., 2004, 2005; Flower et al., 
2011; Heather et al., 2009; Karlsson et al., 2008a; Sinclair et al., 1991). 
 
Leaving out two ZREs in each construct of the BNLF2a constructs BNLF2a 
1&2, BNLF2a 1&3, and BNLF2a 2&3 rescued most of the wildtype promoter 
activity (Figure 5-12). There was no difference in promoter activation for the 
combination of ZRE1-ZRE2 and ZRE2-ZRE3. However, the combination of 
ZRE1 and ZRE3 with mutant ZRE2 resulted in a marginally lower activity 
compared to the former two combinations. Interestingly, these findings were 
consistent between BNLF2a promoter constructs (BNLF2a 2-5, 1&3-5, and 1-
2&4-5) and (BNLF2a 1&2, 1&3 and 2&3) in spite of mutating ZRE 4-5 in the 
latter constructs. This also further confirms the minor role for ZRE4-5 in BNLF2a 
activation. The activity level of each generated BNLF2a construct is 
summarised in Figure 5-18. 
 
Our data supports a synergy for Zta by binding at two adjacent ZREs, in 
agreement with a previous report (Carey et al., 1992). This synergy could be 
dependent on cooperative DNA binding as Zta binding affinities were different 
for the different ZRE motifs, as was shown in the EMSA analysis (Figure 5-17). 
In a cooperative DNA binding, the role of one transcription factor (TF) would be 
to interact with a second TF to facilitate its binding to an adjacent binding site 
(Janson and Pettersson, 1990).   
 
Cooperative DNA binding could be possible through coactivators such as CBP 
which could indirectly facilitate the interactions between two Zta molecules at 
adjacent sites. The histone acetyltransferase protein CBP and Zta are known to 
co-localise at the immediate-early promoters Zp and Rp (Deng, 2003).  
However, a direct interaction between Zta molecules bound at adjacent sites is 
also possible.  
 
On the other hand, Zta synergy could be the result of simultaneous contact of 
multiple Zta molecules with the basic transcription machinery proteins. Thus, 
the level of activity is possibly proportional to the number of Zta molecules that 
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are within an appropriate distance to interact with the transcription machinery 
factors.  
 
It is not conclusive whether ZRE2 plays a greater role in BNLF2a regulation 
despite the observation that ZRE2 had the highest affinity for Zta in vitro. Also, 
BNLF2a promoter constructs with mutant ZRE2 showed lower activity than 
constructs with mutant ZRE1 or ZRE3.  We cannot rule out whether the 
distance between each two ZREs and/or the distance of each ZRE and the 
TATA box is a factor in BNLF2a regulation. The distance between ZRE1-ZRE3 
was around 160 bp while it was 78 bp between ZRE1-ZRE2 and 67 bp between 
ZRE2-ZRE3.   
  
It is generally believed that the cooperative activation of two factors is most 
effective when the two factors are on the same face of the DNA helix. Also, the 
distance between the binding sites affects the formation of DNA-protein-protein 
DNA complex (Huang et al., 2012).  
 
The distance effect on Zta synergistic transcription activation between two Zta 
binding sites was addressed by Huang et al. In a series of luciferase constructs 
containing two identical ZREs (ZIIIB) placed 23 bp from a TATA box and 
separated by increasing distance (adding 2 bp every time), Zta transcription 
activation was generally reduced with the increasing distance between the two 
ZREs. However, in a construct where two Zta molecules were bound on 
opposite faces of the DNA double helix (ZREs separated by 8 bp) showed 
higher activity than the construct where Zta molecules were bound on the same 
DNA helix face  (ZREs separated by 4 bp) (Huang et al., 2012).  
 
In addition, the distance between the transcription factors and the TATA box 
influence their activation ability. However, none of the previous reports (Carey 
et al., 1992; Huang et al., 2012) addressed changes in the distance between 
the ZREs and the TATA box.  
 
The role for ZRE 4-5 remains unclear as the mutant of ZRE 4-5 had little impact 
on the promoter activity in both cells (DG75 and HeLa cells) (Figure 5-9). 
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Nevertheless, there was a clear Zta binding peak spanning the region of these 
two ZREs in the ChIP-Seq data in Akata cells (Figure 5-1). In other early 
promoters such as BHLF1, a second ZRE region between -644 to -902 was 
shown to affect BHLF1 transcription independently from a more proximal ZREs 
region (-7 to -155) with some variations in a cell-specific manner (Lieberman et 
al., 1989).  
 
Based on our luciferase reporter assay and EMSA findings, we propose a 
speculative model suggesting functional redundancy (fail-safe mechanism) of 
Zta regulation of BNLF2a, explained in Figure 5-19. In this model, any two of 
the proximal ZREs (located within 250 bp upstream of the TSS) can drive 
promoter activity. However, given the high binding affinity and close distance of 
ZRE2 to BNLF2a TSS, ZRE2 may either be more effective in facilitating the 
cooperative binding between Zta molecules or the interactions with the TFIID-A 
complex leading to a more stable preinitiation complex.  
 
BNLF2a promoter will be further examined to investigate the role of other 
regulatory elements, as will be described in the next chapter. 
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Promoter
construct
name
Promoter schematic diagram
Contribution to
promoter 
activity in 
response to 
Zta
BNLF2a 1-5 +++++
BNLF2a Null +
BNLF2a 4-5 +/++*
BNLF2a 1-3 ++++
BNLF2a 2-5 +++
BNLF2a 1&3-5 ++
BNLF2a 1-2&4-5 ++++
BNLF2a  1 ++
BNLF2a  2 +++
BNLF2a  3 +
BNLF2a 1&2 +++
BNLF2a 1&3 ++
BNLF2a 2&3 +++
Figure 5-18 The ZREs contribution to the promoter activity. The variant BNLF2a
promoter luciferase constructs generated to address BNLF2a 5 ZREs contribution
to the promoter activity are listed along with a schematic representation of each
constructs and the activity. * BNLF2a 4-5 showed a slightly more activity in DG75
cells than HeLa cells .
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TBP
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Figure 5-19 A fail-safe mechanism for BNLF2a promoter activation. Zta
transcriptional activity is known to be mediated through Zta response elements as well as
interacting with the basal transcription machinery through the TATA binding protein and
general transcription factor II D. In BNLF2a promoter, the three proximal ZREs are
essential for the promoter activity. However, only two are required for activation at the
same time where ZRE2 is the key mediator of this activation each time. This is supported
by Zta strong binding to ZRE2 in vitro. Additionally, the distribution of the three ZREs
could be a critical factor as the distance between (ZRE1 and ZRE2) and (ZRE2 and
ZRE3) is very similar; 78 and 67 nt, respectively. Scenario (A): All ZREs are intact, thus,
the promoter is activated through ZRE1 and ZRE2. Scenario (B): Failure of ZRE1 leads
to Zta being recruited to ZRE3. Scenario (C): in case of ZRE2 failure, the promoter is
still activated in a less efficient way through ZRE1 and ZRE3. In each case, Zta
molecules closest to the TSS interacts with the TFIID-A complex. Zta is represented as
blue X. The basal transcription machinery shown as ovals (yellow and blue) RNA Pol II
shown as blue circle.
A
C
B
TFIIA
TFIIA
TFIIA
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Chapter 6 Other elements play a role in BNLF2a gene regulation  
6.1 Introduction 
As previously discussed in Chapter 5, I identified the viral early lytic gene 
BNLF2a as a direct target for Zta. However, to completely understand the 
mechanisms that govern the regulation of this target and the role of other 
transcription factors, a comprehensive characterisation of the promoter is 
required.  
 
BNLF2a expression can be detected within 4 hours post-lytic cycle induction, 
and high expression levels were reported at 24 hours after inducing lytic cycle in 
Akata BL cells (Tierney et al., 2015). Similarly, BNLF2a expression was 
detected within 4 hours, reached the peak level at 8 hours and remained 
detectable at 20 hours (Croft et al., 2009) in the Akata derivative cells AKBM 
(Ressing et al., 2005a).   
 
BNLF2a plays a crucial role in evading the host immune response by inhibiting 
antigen presentation on the cell surface major histocompatibility complex I 
(MHC I). A comparison between wildtype EBV and delta-BNLF2a EBV in LCLs 
revealed that wildtype EBV-infected cells had a much-reduced recognition by 
specific CD8+ T cells to the immediate-early protein BZLF1. This highlighted the 
critical need for early expression of BNLF2a at early stages in EBV lytic cycle 
(Croft et al., 2009). EBV viral immune evasion and BNLF2a role in antigen 
presentation is previously discussed in Chapter 1. 
 
Like most early lytic promoters, BNLF2a promoter (also known as EBV ED-L2) 
contains a canonical TATA-box motif 30 base pairs upstream of the 
transcription start site (TSS) (Baer et al., 1984; Farrell et al., 1983). This 
promoter was also shown to be activated by the phorbol ester TPA (Farrell et 
al., 1983; Jenkins et al., 1997). As previously mentioned in Section 5.1, this 
promoter showed tissue-specific expression in stratifying squamous epithelia 
(keratinocytes), which are found in the tongue, esophagus, and skin tissues 
(Nakagawa et al., 1997a; Nakagawa et al., 1997b; Wilson et al., 1990). In 
addition, BNLF2a promoter was employed to express Cyclin D1 in a tissue--
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specific manner in a transgenic mice model to investigate oncogenesis in the 
esophagus (Nakagawa et al., 1997b; Roth et al., 2012).  Immunohistochemistry 
staining for the transgene cyclin D1 showed that expression was restricted to 
the basal and suprabasal layers of stratified squamous epithelia, but was not 
detected in simple epithelium layers (Nakagawa et al., 1997b). Likewise, a 
BNLF2a promoter luciferase construct showed constitutive expression of in the  
human esophageal squamous carcinoma cell line TE-11, but not in other cell 
lines of simple epithelial origins (Nakagawa et al., 1997a). This has attracted 
much interest in BNLF2a promoter to understand its tissue-specific expression.  
 
A previous mutational analysis of the promoter using luciferase reporter assays 
showed that a CACCC box-like motif (CACACCT), located between -212 to -
105 bp from BNLF2a gene start, was critical for basal level expression of 
BNLF2a promoter in TE-11 cells (Nakagawa et al., 1997a). Also, the E-box 
motif (CACCTG), located between -181 to -175 bp, and a CACACCC motif, 
located between -132 to -125 bp, were identified to be essential for the phorbol 
ester TPA induction of the promoter (Jenkins et al., 1997). The CACACCC motif 
was suggested to be a keratinocyte-specific factor and was shown to form a 
complex in vitro with the kruppel like factor KLF4, also known as gut-enriched 
kruppel-like factor (GKLF). This was demonstrated by transiently expressing 
KLF4 which leads to BNLF2a promoter activation and by showing direct binding 
of recombinant KLF4 to the CACACCC motif EMSA experiment (Jenkins et al., 
1998).  
 
In this chapter, I focus on analyzing the mechanism of Zta regulation of 
BNLF2a.  To achieve this, I examined the promoter for TFs binding sites using 
an in silico approach, and carried out further mutational analysis using 
luciferase reporter assays. As will be discussed in subsequent sections, several 
regulatory elements, including a novel motif that we identified, were addressed 
to shed light on Zta regulation of BNLF2a promoter. 
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6.2 Results 
6.2.1 The conservation of a motif flanking BNLF2a ZREs  
As previously described in Chapter 5, Zta direct regulation of BNLF2a through 
ZREs in the promoter was established.  
 
Our specific aim in this chapter was to elucidate a complete model for Zta 
activation of BNLF2a promoter. Therefore, investigating all regulatory elements 
in the promoter and any possible interacting cellular partners for Zta will be 
critical. To achieve this, we examined the published literature regarding BNLF2a 
regulation, as described in Section 6.1, and conducted in silico promoter 
sequence analysis using the motif discovery tool MEME (Bailey et al., 2009b).  
 
Each BNLF2a ZRE sequence along with 14 bp on each side of the ZRE motif 
was submitted to the MEME motif prediction tool. The submitted sequences are 
shown in Figure 6-1 (A).  Interestingly, this approach predicted a 15 bp ZREs 
flanking/overlapping sequence which was conserved between all BNLF2a 
ZREs. Figure 6-1 (B) shows the position weight matrix of this conserved ZRE 
flanking motif.  
 
The core bases of the identified motif flanking ZRE1 and ZRE2 overlaps a 
canonical E-box motif (Atchley and Fitch, 1997). The E-Box flanking ZRE2 is 
previously identified as one of the essential elements for TPA induction (Jenkins 
et al., 1997).    
 
This newly identified motif was also submitted to the motif comparison web tool 
TOMTOM (Bailey et al., 2009b). Interestingly, this identified two significant 
transcription factors that are known to bind to a similar position weight matrix. 
These transcription factors are members of T-box binding proteins (TBX) and 
ZEB1 proteins. Figure 6-1 (C) represents the binding site sequence logos of 
these two transcription factors. 
 
This discovery led to further mutational analysis of BNLF2a promoter to 
understand the role of this motif using luciferase reporter assays as will be 
discussed in Section 6.2.2, 6.2.4 and 6.2.5.  
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>BNLF2a ZRE1
CTCCACACCTGTCCTCGCTCATCTTTCCACATTCC
>BNLF2a ZRE2
GGAACACCTGTTGTTGACACATTCTTTGCGCATAA    
>BNLF2a ZRE3
TTTGCTTTCCATCTTGTGCCAATACACATTTGGAT
>BNLF2a ZRE4
CAAATCACCTTAACTGGCACACACTCCCTTAGCCA
>BNLF2a ZRE5
CTGCTAAGCTACTATGACTAACCTTTCTTTACTTC
MEME (no SSC) 05.05.2015 11:35
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Figure 6-1 Position weight matrices (PWMs) of a conserved ZRE flanking
motif. A MEME-predicted ZRE flanking motif is conserved between all BNLF2a
ZREs. (A) BNLF2a ZRE sequences along with 14 bp at each ZRE side entered in
the MEME motif prediction tool. (B) The binding sequence logo revealed by
MEME from the entered sequences. (C) Submitting the motif shown in (B) to the
motif comparison tool TOM-TOM revealed two significant transcription factors
match: T-box TBX family and ZEB1. The TOMTOM binding sequence logos for
these transcription factors are also shown.
C
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6.2.2 Investigating other regulatory elements within BNLF2a promoter 
To investigate the functional relevance of the various regulatory elements in 
BNLF2a promoter, we undertook the same luciferase reporter assay approach, 
as described in Chapter 5.  A further series of BNLF2a promoter constructs that 
did not involve any alteration of Zta response elements (ZREs) were generated 
using the luciferase plasmid pCpGL-basic. 
 
Figure 6-2 shows the full DNA sequence (5’-3’) of the wildtype BNLF2a 
promoter insert, that was previously described in Figure 5-5, this time with each 
ZRE sequence, the KLF4 site, and the predicted flanking region described in 
Section 6.2.1 highlighted. In addition, the canonical TATA motif (30 bp away 
from the transcription start site) is also highlighted.  
 
A series of 8 new reporter constructs were generated mutating the highlighted 
regulatory elements in Figure 6-2. These constructs were generated in an 
identical way to that explained in Figure 5-4. In each construct, either one or a 
different combination of elements were replaced by a random mutant motif, as 
shown in Figure 6-3. 
 
Figure 6-4 represents a schematic cartoon of the promoter constructs showing 
the location of each ZRE as well as the other regulatory elements to be 
examined in this series of experiments.  
 
As in Chapter 5, the rationale of each mutant construct will be given in the 
relevant results section. A list of these mutant constructs including the given 
name and a brief description of the mutated sites is given in Figure 6-5. A small 
schematic cartoon is also shown for each construct in Figure 6-5. This cartoon 
will be presented again in the relevant results section. 
 
The newly generated reporter constructs were very effective in contributing to 
our understanding of the possible mechanisms of how Zta activates BNLF2a. 
By utilising luciferase reporter assays, we were able to analyse various cis-
acting elements in BNLF2a promoter rapidly.   
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Figure 6-2 BNLF2a promoter and the predicted ZREs flanking motif sequence. A
schematic illustration of the sequence used in BNLF2a promoter constructs as
described in the previous chapter. A 913 bp sequence with the genome coordinates
167029-167941 based on EBV wildtype strain (NC_007605.1) was used to analyse
BNLF2a promoter activity. A MEME motif analysis (described in the previous figure)
revealed a conserved motif flanking/ overlapping each ZRE in BNLF2a promoter
(highlighted in dark grey). The five Zta response elements (ZREs) are highlighted in
yellow). In addition, the two motifs described previously in (Jenkins et al.,1998) are
highlighted; KLF4 in grey and an E-box motif in red (CACCTG). The E-box is part of the
ZRE2 flanking motif. ZRE1 flanking motif is also an identical E-box motif to ZRE2 flank.
The canonical TATA box motif (highlighted blue) is located 30 bp upstream the
transcription start site. The gene start and transcription start site (TSS) are indicated
with arrows. The restriction enzyme sites used in cloning are highlighted in grey.
GGATCCCATAGCCCTAGCGACTCTGCTGGAAATGATGGAGGCCCTCCACAATTGACGGA
AGAGGTTGAAAACAAAGGAGGTGACCAGGGCCCGCCTTTGATGACAGACGGAGGCGGCG
GTCATAGTCATGATTCCGGCCATGGCGGCGGTGATCCACACCTTCCTACGCTGCTTTTG
GGTTCTTCTGGTTCCGGTGGAGATGATGACGACCCCCACGGCCCAGTTCAGCTAAGCTA
CTATGACTAACCTTTCTTTACTTCTAGGCATTACCATGTCATAGGCTTGCCTGACTGAC
TCTCCCTCCATTTACTGGGAATGCCTTAGCTAATCACCTTAACTGGCACACACTCCCTT
AGCCACACTGTCTGTCTAGGCTGAAAAGCCACATTCATATTCTATTTCAAAACAAGGGG
AAAGGAGGACATGCGAGAATTGGCAGACACCTTTACCCAGCCCTTAACACACCACACAG
GTAGCAAGGACCCGGGCGTTGCCAGACTCCGCCACCAACGCCCCTGCGTTGAACCCACC
CCTCCTACACACATCAGACCTCTGCACAACACAACTACCAGGCAGATGAGGCCCCTTAC
TTCCACAGGGTACTGGCATACCAGCGGGGGACCACATACATCCCTGTCTCCCACCCAGT
AACTCCAGCAACTTTGCTTTCCATCTTGTGCCAATACACATTTGGATTCAGCCCAAGCC
ACACCTAACTCATGCCAGCAGAGGCAGGAACACCTGTTGTTGACACATTCTTTGCGCAT
AAGCACTTTAATCCCTCTCTCACACCCAGAAACTAAGAGCTAGCCCAAAACCTCCACAC
CTGTCCTCGCTCATCTTTCCACATTCCTCTGGCCTTCTTTCCTTGTCCTTACTGTATAA
AAGTCCACGAAAACAGCTGTGCCTCACTCTCGAGAAGCTT 
 
ZRE1 
ZRE2 
ZRE3 
ZRE4 
ZRE5 
Transcription start site 
TATA box 
(ATG) BNLF2a 
KLF4* 
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Sequence 
Name Sequence Mutant sequence
TATA box TATA GATA
KLF4 CACACCC ACGTAGA
ZRE1 flanking CACACCTGTCCTCGC CAGTTTGGTCCTCGC
ZRE2 flanking AACACCTGTTGTTGA AAGTTTGGTTGTTGA
ZRE3 flanking GCCAATACACATTTG GCCAATACCAAACTG
ZRE4 flanking ATCACCTTAACTGGC ATGTTTGTAACTGGC
ZRE5 flanking CTAACCTTTCTTTAC CTGTTTGTTCTTTAC
Figure 6-3 BNLF2a promoter wildtype and mutant elements. The figure shows
the wildtype sequences of the various elements investigated in this chapter. The
mutations we introduced in each motif to generate the luciferase reporter assay
constricts are also listed (red color).
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Promoter 
construct Name Description Schematic diagram
BNLF2a 1-5 Wildtype sequence
BNLF2a Null 1-5 ZREs mutant
BNLF2a TATA M 
TATAAA motif 
replaced with 
GATAAA
BNLF2a KLF4 M
KLF4 site
(described in 
(Jenkins et al., 
1998) mutant
BNLF2a 1FL M ZRE1 flanking motif mutant
BNLF2a 2FL M ZRE2  flanking motif  mutant  
BNLF2a 3FL M ZRE3 flanking motif mutant  
BNLF2a 4FL M ZRE4 flanking motif  mutant  
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Promoter 
construct Name Description Schematic diagram
BNLF2a 5FL M ZRE5 flanking motif  mutant  
BNLF2a 1-5 FL 
M
ZREs 1-5  flanking
motif mutant  
Figure 6-5 BNLF2a luciferase promoter constructs. A previously described
element (Jenkins et al.,1998), A TATA box variant and the MEME predicted
elements were investigated using luciferase reporter assays. The construct given
name, mutation site and a schematic diagram of each constructs generated are
listed as a table.
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6.2.3 A single point mutation in the TATA box enhances Zta activation of 
BNLF2a 
As a first step towards understanding the various means of Zta transcriptional 
activation, we examined the effect of changing the TATA motif to GATA motif on 
Zta activation of BNLF2a promoter. This was of great interest as TFIID, in 
particular, TBP has a weaker affinity to the non-canonical TATA box (GATA). 
This results in a reduced preinitiation complex recruitment to the core promoter. 
However, as described in Section 6.1, Zta is known to stabilise the general 
transcription factor binding to GATA motif through direct interaction with TFIID-
TFIIA complex, which compensates for the inefficient recruitment of the 
preinitiation complex (Lieberman and Berk, 1991; Lieberman et al., 1997). 
Furthermore, a GATA motif is present in one of the highly responsive promoters 
for Zta, which is the promoter of the early lytic gene BHLF1 (Lieberman et al., 
1989). Thus, we investigated whether or not the non-canonical TATA box 
(GATA) might provide EBV with a functional transcription advantage over 
cellular promoters. 
 
A mutant reporter construct (BNLF2aTATA M) was generated containing a 
GATA motif instead of TATA motif using the luciferase reporter assay plasmid 
(pCpGL-basic), as described in Chapter 5.   
 
The activity of this construct was compared to the wildtype BNLF2a construct 
BNLF2a 1-5 and the mutant ZREs construct BNLF2a Null. Each luciferase 
construct was co-transfected with either the control vector pcDNA3 or His-Zta 
expression vector into EBV-negative Burkitt’s lymphoma cell line (DG75 cells) 
(Figure 6-6) and HeLa cells (Figure 6-7).   
 
Figure 6-6 and 6-7 (A) represent a comparison between promoter activity for 
the constructs BNLF2a 1-5, BNLF2a Null and BNLF2aTATA M presented in 
luciferase relative light units (RLU) for both cell lines. As shown in the previous 
chapter, Zta activates the promoter in the presence of intact ZREs; however, 
this activity disappears largely for BNLF2a Null construct, which contains 
mutant ZREs. The promoter in BNLF2aTATA M construct was significantly 
activated in the presence of Zta, despite the decrease in the basal promoter 
6-198 
 
  
activity observed in the absence of Zta. The basal promoter activity was 
depicted solely in Figure 6-6 and 6-7 (B). The relative activity of the promoter 
for BNLF2aTATA M construct, represented by the promoter activity in the 
presence of Zta over the activity in absence of Zta (control), showed a nearly 2-
fold statistically significant increase (P-value <0.001) compared to the relative 
promoter activity for the wildtype BNLF2a 1-5 construct (Figure 6-6 and 6-7 
(C)). These findings were consistent between EBV-negative DG75 cells (Figure 
6-6) and epithelial cells (HeLa cells) (Figure 6-7).  
 
Figure 6-6 & 6-7 (D) represents a western blot analysis for actin (loading 
control) and Zta for each sample. Comparable levels of Zta expression can be 
seen for all samples while the absence of Zta is confirmed in the control 
samples. For each sample, the intensity of the actin band was used to 
normalise the luciferase relative light units value for that sample, as previously 
described in Chapter 2.     
 
The ability of Zta to induce the promoter in the presence of a non-canonical 
TATA box agrees with the aforementioned published data. However, the more 
important observation was that the relative promoter activity for BNLF2aTATA 
M construct was higher than the relative activity of wildtype BNLF2a 1-5. This 
was in spite of the reduced basal level activity for BNLF2aTATA M.    
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Figure 6-6 BNLF2a activation in the presence of a non-canonical TATA-box in
DG75 cells. The canonical TATA box motif was changed from TATA to GATA. (A)
The figure shows the luciferase analysis of the wildtype BNLF2a construct (BNLF2a
1-5), mutated ZREs construct (BNLF2a Null), and TATA-box mutant construct
(BNLF2a TATA M) co-transfected with either Zta expression vector (red bars) or
control vector (blue bars) in EBV-negative Burkitt's lymphoma cells (DG75 cells). (B)
promoter activity in the absence of Zta (basal activity) is shown in luciferase relative
light unites. (C) Values are plotted as fold change values over control sample for
each construct. Error bars represent the mean of triplicate reads ± SD. (***) indicates
p<0.001, compared to BNLF2a 1-5 in the presence of Zta. (D) Western blot shows
similar levels of Zta transfection in both cell lines.
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Figure 6-7 BNLF2a activation in the presence of a non-canonical TATA-box in
HeLa cells. The canonical TATA box motif was changed from TATA to GATA. (A)
The figure shows the luciferase analysis of the wildtype BNLF2a construct (BNLF2a
1-5), mutated ZREs (BNLF2a Null) construct, and TATA-box mutant construct
(BNLF2a TATA M) co-transfected with either Zta expression vector (red bars) or
control vector (blue bars) in epithelial cells (HeLa cells). (B) Promoter activity in the
absence of Zta (basal activity) is shown in luciferase relative light unites. (C) Values
are presented as fold change values over control sample for each construct. Error
bars represent the mean of triplicate reads ± SD. (***) indicates p<0.001, compared
to BNLF2a 1-5 in the presence of Zta. (D) Western blot shows similar levels of Zta
transfection in both cell lines.
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6.2.4 The KLF4 site plays a role in BNLF2a promoter regulation 
As previously described in Section 6.1, KLF4 is a zinc transcription factor that 
was recently associated with Zp and Rp promoters (Murata et al., 2013; 
Nawandar et al., 2015). A previous report (Jenkins et al., 1998)  showed that 
transient expression of KLF4 is capable of activating BNLF2a promoter through 
a CACACCC motif between ZRE1 and ZRE2, as highlighted in Figure 6-2.   
 
To expedite our analysis of BNLF2a promoter, we investigated the effect of 
mutating the CACACCC regulatory element, that was shown to be bound by 
KLF4 in vitro (Jenkins et al., 1998), using a luciferase reporter construct. Thus, 
the BNLF2aKLF4 M construct was generated containing a mutant motif 
(ACGTAGA) instead of the SP-1 like motif CACACCC.   
 
The activity of BNLF2aKLF4 M construct was compared to the wildtype BNLF2a 
1-5 construct and the mutant ZREs construct BNLF2a Null. Each luciferase 
construct was co-transfected with either the control vector pcDNA3 or His-Zta 
expression vector into epithelial cells (HeLa cells) (Figure 6-8).   
 
Figure 6-8 (A) represents a comparison between promoter activity for the 
constructs BNLF2a 1-5, BNLF2a Null and BNLF2aKLF4 M presented in 
luciferase relative light units (RLU) for both cell lines.  
 
As shown in the previous chapter, Zta activates the promoter in the presence of 
intact ZREs; however, this activity disappears for BNLF2a Null construct that 
contains mutant ZREs. The promoter in BNLF2aKLF4 construct was activated 
in the presence of Zta. Remarkably, the promoter basal level has nearly 12-fold 
increase compared to BNLF2a 1-5, in the absence of Zta (Figure 6-8 (B)). 
 
The relative activity of the promoter for BNLF2aKLF4 M construct, represented 
by the promoter activity in the presence of Zta over the activity in the absence of 
Zta (control), showed a substantial decrease in the activation of BNLF2aKLF4 
M compared to BNLF2a 1-5. Nevertheless, this activation was slightly higher 
than BNLF2a Null (P-value <0.001) (Figure 6-8 (C)). 
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Figure 6-8 (D) represents the western blot analysis for actin (loading control) 
and Zta for each sample, as previously described.  
 
By mutating the KLF4 site the basal activity level of the BNLF2a promoter was 
highly elevated, which suggests a possible role for a repressor factor. These 
findings are interesting and could suggest a possible diminishing in the ability of 
Zta to induce the promoter in the presence of mutant KLF4 site, as shown in 
Figure 6-8 (C).  
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Figure 6-8 KLF4 binding site has an effect on basal promoter activity. A
previously identified binding site for KLF4 (Jenkins et al.,1998) is mutated to
investigate its effect on BNLF2a promoter activation. The motif was changed from
CACACCC to ACGTAGA. (A) The figure shows luciferase analysis of BNLF2a
wildtype construct (BNLF2a 1-5), mutated ZREs (BNLF2a Null) construct, and KLF4
site mutant construct (BNLF2aKLF4 M) co-transfected with either Zta expression
vector (red bars) or control vector (blue bars) in epithelial cells (HeLa cells). (B)
Promoter activity in the absence of Zta (basal activity) is shown in luciferase relative
light unites. (C) Values are presented as fold change values over control sample for
each construct. Error bars represent the mean of triplicate reads ± SD. (***) indicates
p<0.001, compared to BNLF2a 1-5 in the presence of Zta. (D) Western blot shows
similar levels of Zta transfection in both cell lines.
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6.2.5 Mutational analysis of the motif flanking ZREs revealed a repressor 
binding site 
This section shows the investigation of the in silico predicted motifs flanking 
BNLF2a ZREs, as described in Section 6.2.1. We investigated this highly 
conserved motif which is either adjacent to or overlaps with the ZREs within the 
BNLF2a promoter. Further analysis using TOMTOM transcription factor 
comparison web tool identified the transcription factors TBX family and ZEB1 as 
potential binding factors to this flanking motif.   
   
To analyse this motif flanking the ZREs a similar way to the previous luciferase 
reporter analysis, 5 new constructs (BNLF2a 1FL M - BNLF2a 5FL M) were 
generated containing mutations in each motif. Additionally, a construct 
containing a combination of all mutant motifs was generated (BNLF2a 1-5FL 
M).  
 
A list of all the generated constructs in this chapter was given previously in 
Figure 6-5. In addition, the mutant motif sequences for each construct are also 
shown in Figure 6-4. 
 
Figure 6-9 and Figure 6-10 shows the activity of these constructs compared to 
the wildtype BNLF2a 1-5 and BNLF2a Null constructs.  Each luciferase 
construct was co-transfected with either a control vector (pcDNA3) or His-Zta 
expression vector in HeLa cells.   
 
Figure 6-9 (A) represents the promoter activity for all mutant flanking motif 
constructs compared with the BNLF2a 1-5, BNLF2a Null in normalised 
luciferase light units (RLU).  
 
For the motif constructs, there was no single construct that completely impaired 
Zta activation.  Unlike the rest of the mutant motif constructs, BNLF2a 2FL M 
had nearly five times more activity when compared to BNLF2a 1-5   in the 
presence of Zta. This motif is only 3 nucleotides upstream of ZRE2 and 
resembles a canonical E-box motif (Atchley and Fitch, 1997). Interestingly, the 
basal activity level in this construct was around 44-fold increase than the basal 
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activity level in BNLF2a 1-5 construct. This can be clearly seen in Figure 6-10 
(A), where the basal promoter activity was plotted solely. Although, BNLF2a 1-
5FL M construct which contains a mutant sequence for all flanking motifs, it did 
not show similar basal level activity to BNLF2a 2FL M construct. 
 
Figure 6-10 (C) shows the relative activity of the promoter for all ZREs flanking 
motif constructs, represented by the promoter activity in the presence of Zta 
over the activity in the absence of Zta (control). Noticeably, this showed a 
reduced activation in BNLF2a 2FL M and BNLF2a 1-5FL M when compared to 
BNLF2a 1-5 construct. However, the activation levels for these two constructs 
were slightly higher than BNLF2a Null (P-value< 0.001).  
 
Figure 6-9 and Figure 6-10 (B) show a western blot analysis blotted for a 
loading control (actin) and Zta for each sample is shown as previously 
described. 
 
Our luciferase reporter analysis of the ZREs flanking motif has revealed an 
important site next to ZRE2.  By mutating this site, a marginal increase in 
BNLF2a promoter basal level was reported which strongly suggests a possible 
role for a cellular repressor. These findings along with the prominent role 
observed for ZRE2, as discussed in chapter 5, will require further investigation 
to elucidating Zta activation mechanism of BNLF2a.  
 
 
 
 
 
 
 
 
206 | P a g e
Figure 6-9 ZREs flanking motif effects on Zta activation of BNLF2a promoter.
(A) The figure shows luciferase analysis of BNLF2a wildtype construct (BNLF2a 1-
5), mutated ZREs (BNLF2a Null) construct as well as flank mutants constructs.
BNLF2a promoter luciferase constructs were co-transfected with either Zta
expression vector (red bars) or control vector (blue bars) in epithelial cells (HeLa
cells). ZRE2 flank mutant (E-box motif) shows high level of activation compared to
BNLF2a 1-5 (wildtype). (B) Western blot shows similar levels of Zta transfection for
Zta samples. Values are normalised to actin levels and represented as luciferase
relative light units. Error bars represent the mean of triplicate reads ± SD.
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Figure 6-10 ZRE2 flanking motif has a profound effect on promoter basal
activity. The figure shows the basal promoter activity in HeLa cells of BNLF2a
wildtype construct (BNLF2a 1-5), mutated ZREs (BNLF2a Null) construct as well as
constructs where the ZREs flank are mutated. Mutation of an E-box flanking ZRE2
increased the promoter basal level (B). Western blot shows the loading control actin
for control samples. Control values are normalised to actin levels and represented
as luciferase relative light units as seen in the previous page. (C) Values are
presented as fold change values over control sample for each construct. Error bars
represent the mean of triplicate reads ± SD. . (***) indicates p<0.001, compared to
BNLF2a Null in the presence of Zta.
0
20
40
60
80
100
120
140
P
ro
m
ot
er
 re
la
tiv
e 
ac
tiv
ity
Control Zta
C
*** ***
6-209 
 
  
6.2.6 Zta binding to ZRE2 is not affected by mutation in the flanking motif  
As described in Section 5.2.7, ZRE2 had the strongest binding affinity to Zta 
bZIP domain in vitro. Given the close proximity of the newly identified flanking 
motif to ZRE2 core motif, the question of whether Zta binding is affected by the 
flanking motif or not was addressed.   
 
Therefore, Zta binding to ZRE2 was investigated in vitro with an EMSA probe 
containing the wildtype or mutated flanking motif (E-box motif).  Although, the 
EMSA experiment described here was carried out in largely a similar way to the 
EMSA experiment described in Section 5.2.7, different probes for ZRE2 were 
used (Figure 6-11 (A)). This was because in the previous probes, the E-box 
motif was at the end of the probe used in the previous experiment, which could 
give false negative results. Thus, new probes were designed to ensure that both 
ZRE2 and the flanking E-box motif is within acceptable distance from the ends 
of the probe.  Accordingly, fluorescently labelled probes were designed and 
ordered as described in Chapter 2; these new probes are referred to as 
BNLF2a ZRE2 E-BOX probes. The sequences for all EMSA probes are listed in 
Table 2-5. 
 
600 ng of a recombinant Zta protein resembling His-GFP tagged basic leucine 
zipper (bZIP) domain of Zta (His-GFP-bZIP Zta) was used in our EMSA analysis 
as previously described in Section 5.2.7.  Figure 6-11 (A) shows the 5’-3’ 
strand of the probe used in this experiment with the ZRE and E-box flanking 
motif highlighted. Figure 6-11 (B) represents an EMSA gel showing the BNLF2a 
ZRE2 E-box and BNLF2a ZRE2 E-box M interaction with or without His-GFP-
bZIP Zta. 
 
A band of the same size representing the shifted DNA-protein complex was 
observed for both probes. The very small difference observed in the shifted 
band for ZRE2 E-BOX M was not taken into account as the ratio of the shifted 
band intensity over the free probe band was similar for both probes.  
 
In conclusion, a purified His-GFP-bZIP Zta was shown to bind to ZRE2 
independently of the adjacent E-box motif (ZRE2 flanking motif).  
Figure 6-11 Interaction of Zta with the mutant motif flanking ZRE2. The ability
of Zta bZIP domain tagged with GFP to bind in vitro to fluorescently labelled probes
containing a mutant of the E-box motif adjacent to BNLF2a ZRE2 ( 3 bp away) was
examined by electrophoretic mobility assay (EMSA). (A) The 5’-3’ sequence of
ZRE2 flanking motif EMSA probes is shown. The wildtype and mutant motifs of the
E-box are coloured in red. ZRE2 motif is given in blue. (B) 600 ng of purified
protein was used with each probe in the presence of Poly dI-dC. The E-box (ZRE2
flanking core motif) was changed from CACCTG to GTTTGG. EMSA retardation
gel was imaged using LI-COR imaging system at 800 channel.
− + − +GFP-bZIP Zta
His-GFP-bZIP Zta
-DNA complex
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BNLF2a ZRE2 E-box WT AGGAACACCTGTTGTTGACACATTCTT
BNLF2a ZRE2 E-box M AGGAAGTTTGGTTGTTGACACATTCTT
A
B
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6.2.7 Specific complex binds to ZRE2 flanking sequence (E-box) in HeLa 
cells nuclear extract 
Given the effect of mutating the E-box motif flanking ZRE2, as described in 
Section 6.2.5, we attempted to identify any possible target protein that may 
bind to this motif in HeLa cell nuclear extract.  
 
Using EMSA approach, we incubated the BNLF2a ZRE2 E-box and BNLF2a 
ZRE2 E-box M, as described in the previous section, with increasing amount of 
nuclear extract (Figure 6-12 (A)).   
 
Two shifted bands were observed indicating two different complexes binding to 
this probe. The upper complex was found to be specific to the flanking motif (E-
box site) as this complex disappeared in the probe with mutated E-box (BNLF2a 
ZRE2 E-box M).  
 
We hypothesised that the two-related zinc finger E-box binding homeobox 
proteins ZEB1 and ZEB2 could be potential proteins binding to the E-box motif. 
ZEB1 and ZEB2 are known to repress Zta promoter (Zp) through E-box sites in 
ZV and ZV’ elements within Zp (Ellis et al., 2010). Therefore, we investigated if 
a supershift band will form with any of the antibodies against ZEB1 or ZEB2 
(Figure 6-12 (B)).  
 
There was no observation of any supershift band or the disappearance of the 
shifted band for both ZEB1 and ZEB2 antibodies, as shown in Figure 6-12 (B).   
 
Thus, the specific complex binding to the motif flanking ZRE2 in HeLa nuclear 
extract remains to be identified.  
 
 
 
 
 
Figure 6-12 EMSA using HeLa nuclear extract. HeLa nuclear extract was
incubated with the fluorescently labelled wildtype and mutant ZRE2 flanking motif (E-
box) probes to examine for any DNA-protein complex presence using EMSA (A)
Increasing amount by 5 μg of HeLa nuclear extract was used. 30 μg was used with
ZRE2 E-box M probe. (B) 2 μg of each different antibody was used to test for
potential binding targets (ZEB1 and ZEB2). Zta antibody (SCZ) was used as a
control antibody. Super shift or disappearance of the shifted band was not observed.
An arrow points to a specific complex to the flanking motif. EMSA retardation gel
was imaged using LI-COR imaging system at 800 channel.
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6.3 Discussion 
In the previous chapter, I showed Zta regulation of BNLF2a was through the 
direct binding to ZREs within the promoter using luciferase reporter assays. 
Here, I extend the analysis of the promoter to identify new regulatory elements 
and address the role of various other motifs in the context of Zta regulation.   
 
Initially, we examined the TATA motif, as mentioned in Section 6.2.3. a TATA 
variant motif (GATA) is present in BHLF1 promoter which is the strongest 
known EBV promoter in terms of Zta activation (Lieberman et al., 1989). Also, it 
is one of the most abundant transcripts during lytic (Metzenberg, 1989). Zta 
binding partner Ku80 has been reported to enhance Zta activation of this 
promoter (Chen et al., 2011). BHLF1 transcript is essential to initiating EBV lytic 
DNA replication (Rennekamp and Lieberman, 2011). However, the benefit of 
having a non-canonical TATA box motif (GATA) in BHLF1 regulation remains 
unclear. 
 
In the cellular gene erythropoietin, the promoter contains a highly conserved 
non-canonical TATA-box (GATA). This motif plays a role in selectively 
expressing this gene during hypoxia, while the promoter remains repressed in 
normoxia (Tsuchiya et al., 1997). A similar finding was reported in the chicken 
beta-globin promoter where a GATA motif instead of a TATA motif (referred to 
as a specialised TATA element), was found to restrict the expression of this 
gene in erythroid cells. A mechanism was proposed in which an erythroid-
specific protein (GATA-1) facilitated the transcription of this promoter with the 
aid of another GATA-1 binding site at 3’ enhancer element (Fong and Emerson, 
1992; Penner and Davie, 1994).  
 
Although, the TATA-binding protein (TBP) recruitment, a rate-limiting step in 
transcription activation (Xiao et al., 1995), does not form a stable complex with 
a GATA motif (Lieberman et al., 1997; Tsuchiya et al., 1997), Zta is known to 
stabilize the TFIID-A complex binding to GATA motif (Lieberman, 1994; 
Lieberman and Berk, 1991; Lieberman et al., 1997). I used BNLF2a promoter 
as a model system to probe the role of GATA versus TATA on transcriptional 
activation. To ask if a GATA motif would provide any advantages in terms of Zta 
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promoter activation, a single point mutation in BNLF2a promoter TATA motif 
was introduced as explained in Section 6.2.3. As shown in Figure 6-6 and 6-7, 
when the TATA motif was replaced with a GATA motif, the basal level was 
reduced compared to BNLF2a 1-5 construct, which is expected given the low 
affinity of TBP to GATA motif. However, in the presence of Zta, the promoter 
activity was restored confirming the ability of Zta to stabilise the TFIID-A 
complex, thus initiating transcription. Interestingly, comparing the fold change 
between BNLF2a 1-5 and BNLF2aTATA M, the promoter activity of 
BNLF2aTATA M was at least twice the activity in BNLF2a 1-5 in both DG75 and 
HeLa cells. Thus, a GATA motif might provide a more efficient mechanism to 
restrict and highly express viral genes during EBV lytic cycle.  
 
In Figure 6-8, the role of a CACACCC motif (referred to as KLF4 site) located 
between ZRE1 and ZRE2 was investigated. As described previously in Section 
6.1, a Kruppel-like factor (KLF4) recombinant protein was shown to bind this 
motif. Furthermore, transient expression of KLF4 leads to BNLF2a promoter 
activation in 293 cells (Jenkins et al., 1998). KLF4 was also employed in 
inducing EBV lytic cycle by binding and upregulating BZLF1 promoter (Zp) and 
BRLF1 promoter (Rp) (Murata et al., 2013; Nawandar et al., 2015). KLF4, a zinc 
finger transcription factor related to Sp proteins, is highly expressed in the 
epidermal layer of the skin and epithelial cells of the tongue, esophagus and 
stomach (Garrett-Sinha et al., 1996) and it plays a critical role in epithelial cells 
proliferation and differentiation (Yori et al., 2010).  Knockout mice harboring a 
deletion for KLF4 fail to develop skin and die shortly after birth (Segre et al., 
1999). KLF4, which binds to a GC-rich motif or a CACCC motif, is known to 
activate various promoters such as the human Keratin 4 promoter through direct 
binding (Okano et al., 2000). On the other hand, KLF4 was implicated in 
negatively regulating other promoters such as Cyclin D1 through binding to an 
SP-1 motif (GGGCGGG). Competition between SP-1 and KLF4 was suggested 
to be critical for this negative regulation (Shie et al., 2000).  
 
In the luciferase reporter assay data shown in Figure 6-8, mutating the KLF4 
site resulted in a substantial increase in BNLF2a promoter basal activity in HeLa 
cells. This indicates that this site is possibly bound by a repressor protein. 
6-215 
 
  
Although KLF4 has a role in repressing certain promoters, BNLF2a KLF4 site is 
likely to be occupied by a different factor in HeLa cells. This is based on the fact 
that transient expression of KLF4 was shown to upregulate the BNLF2a 
promoter in 293 cells.  
 
KLF4 is known to be expressed in HeLa cells (Yang and Zheng, 2012), 
However, competition with other factors from the SP/KLF proteins family cannot 
be eliminated as many SP/KLF factors bind to similar motifs. Many KLF proteins 
are known to have a repressor domain or negatively regulates target promoters 
by recruiting co-repressors. For example, KLF8 and KLF3 associates with the 
co-repressor CtBP (Kaczynski et al., 2003; Vliet et al., 2000). Given the fact that 
Sp proteins have lower affinity to CACCC motif than other KLF proteins 
(Kaczynski et al., 2003).  Such competition between Krupple like factors has 
been reported in other cell lines. For example, KLF3 was shown to repress 
KLF1 target promoters in erythroid cells (Funnell et al., 2012). Even though an 
attempt to identify an overlapping motif with the KLF4 CACACCC or adjacent 
repressor sites was not fruitful, such possibility of the presence of an 
overlapping motif cannot be completely ruled out.   
 
It is worth noting that in the BZLF1 promoter (Zp), KLF4 was shown to activate 
the promoter through the SP1 binding sites present in (ZIA, ZIC, and ZID 
elements) (Murata et al., 2013).  On the contrary, KLF4 is reported to activate 
BRLF1 promoter (Rp) through two different KLF4 consensus motifs (CACCC 
and GGGTG) separated by nearly 50 bp. Mutating one of the sites resulted in 
partial decrease in the promoter activity (Nawandar et al., 2015). This indicates 
a possible synergistic role for KLF4 in activating these promoters.  
 
Another point to consider in Figure 6-8, by examining the promoter fold change 
activity in Figure 6-8 (C), Zta activation was impaired in the KLF4 M construct 
compared to the wildtype (BNLF2a 1-5). This suggests a critical role for this 
element in Zta activation. 
 
In conclusion, CACCC acts as a repressor element in HeLa cells and affects 
Zta activation largely. However, addressing how this element affects Zta, what 
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repressor TFs are likely to be involved, and what role does KLF4 play in the 
promoter activation will require more investigations.  
 
On the other hand, the promoter was subjected to in silico motif search through 
the web tool MEME followed by TOMTOM search as was discussed in Figure 
6-1. The MEME search tool is useful to compare different DNA 
sequences/elements (e.g. promoters) that are believed to be regulated in the 
same way or at least contain the same binding motifs (Bailey et al., 2009b). 
MEME sequence analysis of BNLF2a ZRE 1-5 revealed a 15 bp conserved 
motif flanking all BNLF2a ZREs. This flanking motif overlaps a canonical E-box 
motif in both ZRE1 and ZRE2 flanks. The E-box adjacent to ZRE2 was 
previously shown to be important for TPA induction of the promoter (Jenkins et 
al., 1997).  
 
Interestingly, our mutation analysis of this site in HeLa cells has resulted in a 
sharp increase in the basal activity level in the absence of Zta suggesting a 
strong role for a repressor protein. The construct BNLF2a 1-5FL M, which 
contains mutant sequences for all the flanking motifs, has also showed high 
basal level activity but lower than that seen in ZRE2 flanking mutant. This 
suggests a further role for other flanking sequences or ZREs in the promoter 
basal activity level.  
 
Whether the repressor site flanking ZRE2 has a role in Zta activation or not is 
not clear. We hypothesised that Zta activation is not dependent on this 
repressor as similar levels of activation were never observed between BNLF2a 
1-5 and BNLF2a 2FL M. Also, the relative promoter activity in BNLF2a 2FL M 
and BNLF2a 1-5FL M was greatly reduced compared to the wildtype BNLF2a 1-
5 construct. Thus, it is very likely that the repressor bound at this site is 
regulated by a different mechanism (Figure 6-13). 
 
Based on TOMTOM motif analysis, which allows the comparison of this motif 
with other position weight matrices of known TFs (Bailey et al., 2009b), two  
protein TBX and ZEB1 were identified as possible proteins binding to the 
identified flanking motif (p-value= 1e-4 and p-value= 4.7e-4, respectively).  
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ZEB1 and ZEB2 are known to be involved in the repression of Zp through E-box 
sites within the promoter (Ellis et al., 2010) while TBX represents a large family 
of proteins that share a conserved DNA binding domain and bind to either full or 
half the T site palindromic motif, which consists of 24 bp (AATTTCACACCT-
AGGTGTGAAATT) (Najand et al., 2012). Thus, this protein family is more likely 
to be associated with the longer flanking motif. 
 
Although we showed a specific complex binding to ZRE2 flanking motif in HeLa 
nuclear extract, this complex is not likely to be ZEB1/2. Thus, further 
investigation will be required. Another potential target is the E-box binding 
protein E2-2 that was shown to be involved in Zp silencing (Thomas et al., 
2003). 
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Figure 6-13 A model for the possible role of ZRE2 flanking motif (E-box). (A)
The ZRE2 flanking motif bound by a repressor does not prevent or compete with
Zta binding to ZRE2. Zta is able to overcome the repressing of the promoter. (B)
When this site is mutated the repressor is no longer able to bind which results in an
increased basal level but this repressor does not stop Zta activation.
B
TBP
TFIID
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TBP
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Chapter 7 General discussion 
Gene expression regulation takes place at three different levels in higher 
eukaryotes: the transcriptional, post-transcriptional and post-translational level. 
To make sure only the set of required genes are expressed at a certain time 
and in certain cells, this complex process of transcription is tightly regulated 
temporally and spatially. The synchronous control over gene expression is 
important to determine cell fate, response to external stimuli (signals) and 
function. Moreover, alterations in this regulation lead to diseases (Maston et al., 
2006). 
 
The initiation of mRNA transcription, which requires the recruitment of the 
preinitiation complex (PIC), is mostly dependent on transcription factors, 
regulatory elements, and chromatin accessibility. Transcription factors (TFs) are 
site-specific DNA molecules that bind to various regulatory elements. These 
elements include the core and upstream promoters as well as distal enhancers. 
The core promoter is the site at which the PIC is assembled to execute the 
initiation of mRNA (Smale and Kadonaga, 2003). The upstream promoter 
contains multiple cis-elements for the binding of various TFs, which interact with 
the PIC at the core promoter (Lee and Young, 2000; Maston et al., 2006). 
Enhancers can be located at 5’ or 3’ sites and in distal or proximal distances 
from a given gene. Enhancers play an important role not only to enhance the 
expression but in many cases to determine tissue specificity of gene expression 
(Maston et al., 2006). 
 
Given that the genome is highly packed around histones molecules, 
accessibility to the various elements is not plausible unless these transcription 
factors work cooperatively to facilitate a more open chromatin state that allows 
the recruitment of other TFs. A special class of TFs known as the pioneer TFs, 
have the ability to engage with a nucleosome dense chromatin and recruit 
histones modifiers (Soufi et al., 2015; Zaret and Carroll, 2011). An example for 
such pioneer factors is the PU.1 protein, a key regulator in B cell development. 
This protein is capable of mediating local histone modifications and expanding 
the linker region between nucleosomes which make it more accessible for other 
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TFs to bind DNA (Ghisletti et al., 2010). In addition, the key proteins in 
embryonic stem cell reprogramming Oct4, Sox2 and KLF4 are also classified as 
pioneer TFs (Ghisletti et al., 2010). Interestingly, the ability of a TF to bind 
methylated CpG sites has been suggested to be a key feature in characterising 
pioneer TFs (Zhu et al., 2016). A pioneering TF role was also suggested for the 
AP-1 protein as this protein was reported to assist in glucocorticoid receptor 
(GR) binding, by keeping chromatin in an open state (Biddie et al., 2011; Spitz 
and Furlong, 2012).  
 
Viruses have evolved to highjack and mimic host cell mechanisms to be able to 
infect and survive within these cells. Upon EBV entry into the cell, the viral DNA 
becomes circular, and it is packed in higher order repressive chromatin 
structure, in a very similar way to the host genome. This chromatin state is 
essential to maintain latency by silencing most of the viral genes (Lieberman, 
2013).  
 
Zta which lacks a methyl-CpG binding-domain, has the ability to bind 
methylated CpG sites. Only a few mammalian proteins are known to bind 
methylated DNA without methyl-CpG binding-domain, such as the basic leucine 
zipper (CEBPα) and the zinc-finger protein ZFP57 (Zhu et al., 2016). 
Additionally, the AP-1 heterodimer c-Jun/c-Fos was also found to bind a new 
class of methylated sites (called meAP-1 sites) (Gustems et al., 2014).  
 
The ability of Zta to induce EBV reactivation and reverse the epigenetic 
repression of the viral genome during latency, through direct binding to 
methylated ZREs at key viral promoters suggested that Zta may act as a 
pioneer transcription factor (Woellmer et al., 2012). However, it is not known 
how Zta is recruited to the densely chromatinised EBV genome and whether Zta 
has a direct role in chromatin remodeling during lytic cycle (Hammerschmidt, 
2015).  
 
As previously discussed in Chapter 1, Zta is also essential to recruit the viral 
DNA replication complex at OriLyt and play a vital role in the regulation of many 
viral and cellular genes. Zta also interferes with the function of many cellular 
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pathways that are important to induce apoptosis or host immune response. Zta 
diverse function strongly suggests a vital pioneering role for this viral 
transactivator.  
 
To obtain a complete overview of Zta role during EBV lytic cycle, genome-wide 
studies were carried out previously in our lab and by other groups to detect Zta 
binding across the viral and cellular genome (Bergbauer et al., 2010; 
Ramasubramanyan et al., 2012a; Ramasubramanyan et al., 2015).   
 
As previously discussed in Chapter 3, I carried out ChIP-qPCR to detect Zta 
binding across various regions in the viral genome in two different cell lines that 
are commonly used as a model to study cell transformation and EBV biology.  
In our experiments, we aimed to address differences observed in Zta binding at 
different EBV cell lines which will broaden our understanding of the biology and 
features of each EBV system. For example, we hypothesise that the differences 
in Zta binding at ~82 kbp region are likely to be caused by EBV strain variations 
between Raji and B95-8 strains. We also showed Zta binding at several 
promoter regions in the spontaneously lytic cells (LCL#3). EBV LCLs vary in 
terms of their surface markers and EBV copy number, which could influence the 
regulation of the EBV latency-lytic switch (Davies et al., 2010). Similarly, we set 
out ChIP-qPCR in 293-BZLF1-KO cells (Feederle et al., 2000) in an attempt to 
understand how Zta binding and the lytic cycle is regulated in a non-B cell 
system.  
 
To understand the role of Zta in EBV lytic cycle regulation in each EBV cell line, 
a global approach will be required to investigate Zta binding at the EBV and 
cellular genome. A thorough analysis of EBV strain variations, EBV copy 
number, EBV genome chromatin structure, viral and cellular expression profiles 
will also be crucial. Zta binding data can be integrated with publicly available 
data for other transcription factors and histone modifications. A similar approach 
was used to map the binding of various cellular TFs and the chromatin structure 
organisation in the latent EBV genome (Arvey et al., 2013; Arvey et al., 2012). 
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The genome-wide analysis for Zta binding across the cellular genome 
(Ramasubramanyan et al., 2015) has also provided a new insight of Zta 
transcription regulation at enhancer elements. As previously discussed in 
Chapter 4, we showed the first evidence of the ability of Zta to activate a 
minimal promoter and drive the expression of the luciferase gene in pGL3-
Control construct through a distal ZRE element. Zta transcriptional activation 
through enhancer elements may suggest different regulation mechanisms for 
Zta that remain to be elucidated.  
 
In this project, we also used the viral promoter BNLF2a as a model to broaden 
our knowledge of Zta transcriptional regulation of viral early lytic genes. As 
shown in Chapter 5, the activation of BNLF2a promoter was dependent on 
three proximal ZREs. Further analysis of these proximal ZREs showed that any 
combination of two ZREs of the proximal three could drive expression from the 
promoter. This supports a role for Zta synergy to achieve promoter activation. 
However, whether the distance between any two ZREs affects this Zta synergy 
is not clear. Although a previous report showed a general decrease in a 
luciferase activity when the distance between two ZREs was increased (Huang 
et al., 2012), the distance between each ZRE and the promoter TSS was not 
addressed. We hypothesise that if Zta synergy activation is mediated by the 
simultaneous interaction between the PIC and multiple Zta molecules, the 
active ZREs should be in close proximity of the core promoter. This also could 
explain why the distal ZREs in BNLF2a promoter did not activate the promoter.  
 
We also addressed the effect of a non-canonical TATA motif (GATA) on Zta 
activation using BNLF2a promoter. Interestingly, the construct containing the 
GATA motif was around 2-fold higher in relative promoter activity than the 
wildtype construct. It is not clear whether the presence of such a TATA box 
variant in the viral gene BHLF1 would provide any regulation advantages over 
host or other viral genes. To what extent this TATA variant is present and 
conserved in other viral or cellular promoters is worth investigating. 
Furthermore, with the current advances in genome-editing methods, it is 
possible to generate stable cell lines to investigate the role of GATA motif on 
the expression of various cellular promoters. 
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We further attempted to identify and decipher other regulatory elements within 
BNLF2a promoter, as described in Chapter 6. In silico sequence analysis 
predicted a 15 bp conserved motif flanking all BNLF2a ZREs. Interestingly, 
when the motif flanking ZRE2 was mutated in our promoter mutational analysis, 
there was a sharp increase in the basal promoter activity in the absence of Zta 
which suggests a role for a repressor protein. This flanking motif overlaps a 
canonical E-box site that was shown before to be important for TPA induction 
(Jenkins et al., 1997) . A specific DNA-protein complex to this E-box motif was 
observed in EMSA analysis using HeLa cell nuclear extract. Although we 
attempted to identify any potential target in this complex, this protein remains to 
be identified.  
 
Our BNLF2a promoter analysis findings open up many interesting questions to 
address. For example, whether the ZRE2 flanking motif is conserved in other 
regulatory elements containing ZREs will require genome-wide DNA sequence 
analysis. This motif may also represent a certain class of promoters or is 
regulated differently in other cells. Nevertheless, BNLF2a regulation may only 
represent one mechanism of Zta regulation.  
 
Serial deletion analysis of BNLF2a promoter will help in identifying the minimal 
region required for Zta activation. This will also help in identifying other TF 
binding sites that are required for this activation. On the contrary, Zta is involved 
in the down regulation of other genes as described earlier. How Zta facilitates 
the down regulation of such promoters remains to be largely unknown.  
 
Zta activation is also achieved through synergy with other viral proteins such as 
Rta (BRLF1) and BMRF1. Previous data carried out in our lab by Dr Kay 
Osborn comparing BNLF2a promoter response to Zta in EBV-negative and 
positive Burkitt’s lymphoma cell lines showed similar levels of promoter 
activation. Although, this may indicate that there is no significant role for other 
EBV proteins, a synergistic activation between Zta and Rta cannot be ruled out 
in other cell lines. In fact, Zta and Rta synergy was reported to be more 
prominent in certain cell lines such as HEK 293 cells (Liu and Speck, 2003). Zta 
and Rta synergy is widely reported for various lytic cycle promoters such as 
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BHLF1, BHRF1, and BRLF1 (Chang et al., 2010; Liu and Speck, 2003; 
Ragoczy and Miller, 1999; Yang et al., 2015). Also, it was shown that this 
synergy is dependent on the direct binding of Zta to the promoter (Chang et al., 
2010).  
 
Moreover, it is of great interest to investigate if BNLF2a promoter is also 
responsive to Rta. The immediate early protein Rta is known to transactivate 
various promoters either directly through its responsive element or indirectly 
through SP1 sites (Chang et al., 2005).  As described in Chapter 6, the KLF4 
motif within BNLF2a promoter is a CC (GG) rich motif which could be bound by 
Sp1 protein.    
 
The variant mutant constructs generated in this project will be a very valuable 
tool to look into Zta, Rta, or Zta/Rta transactivation mechanisms. If Zta and Rta 
synergy is observed in BNLF2a promoter, BNLF2a various ZRE mutant 
constructs could be used to identify the sites contributing to this synergy. Also, 
our purified His-GFP tagged bZIP Zta protein will allow addressing Zta binding 
to DNA/protein in vitro using simple approaches such as EMSA and pull down 
assays. 
 
Understanding Zta regulation mechanisms is crucial to understand EBV lytic 
cycle regulation. This will have a wider impact on developing various agents 
that either inhibit or induce EBV lytic cycle.     
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ABSTRACT
Lytic replication of the human gamma herpes virus
Epstein-Barr virus (EBV) is an essential prerequisite
for the spread of the virus. Differential regulation of
a limited number of cellular genes has been reported
in B-cells during the viral lytic replication cycle. We
asked whether a viral bZIP transcription factor, Zta
(BZLF1, ZEBRA, EB1), drives some of these changes.
Using genome-wide chromatin immunoprecipitation
coupled to next-generation DNA sequencing (ChIP-
seq) we established a map of Zta interactions across
the human genome. Using sensitive transcriptome
analyses we identiﬁed 2263 cellular genes whose
expression is signiﬁcantly changed during the EBV
lytic replication cycle. Zta binds 278 of the regulated
genes and the distribution of binding sites shows
that Zta binds mostly to sites that are distal to tran-
scription start sites. This differs from the prevailing
view that Zta activates viral genes by binding exclu-
sively at promoter elements. We show that a syn-
thetic Zta binding element confers Zta regulation at
a distance and that distal Zta binding sites from cel-
lular genes can confer Zta-mediated regulation on
a heterologous promoter. This leads us to propose
that Zta directly reprograms the expression of cellu-
lar genes through distal elements.
INTRODUCTION
Epstein–Barr virus represents a serious health threat both in
the developing world and in western economies and is a sig-
nificant risk factor forHodgkin’s lymphoma (HL), Burkitt’s
lymphoma (BL) and nasopharyngeal carcinoma (NPC) (1–
4). Primary infection with EBV is also responsible for the
development of infectious mononucleosis (5). Infection of
resting primary B-lymphocytes by EBV generates a popu-
lation of cells that are effectively immortal. This represents
the first step in the establishment of life-long viral latency
in vivo and generates precursors that can develop into lym-
phoid malignancies (6,7).
EBV genes fall primarily into two groups, depending on
their patterns of expression, and are classified as either la-
tent or lytic (6,7). During latency, the majority of the vi-
ral genome is silenced and only a restricted set of genes
is expressed (6,7). Once EBV lytic cycle replication is ini-
tiated, the lytic cycle genes are transcriptionally activated
(8,9). Some lytic cycle genes are also expressed following in-
fection of B-lymphocytes by EBV, but this does not result
in a full lytic replication cycle (10–13) and has been termed
a pre-latency phase (14).
The switch from viral latency to the lytic replication cycle
is critical for virus spread. A key executioner of this pro-
cess is the transcription and replication factor Zta (BZLF1,
ZEBRA, EB1, Z) (9,15). This AP-1-like viral protein is
a member of the bZIP family and interacts with a seven
base-pair DNA sequence element termed Zta-response el-
ement (ZRE), for which at least 32 sequence variants are
known (16,17). A sub-set of ZREs contain a CpGmotif and
are only recognized as ZREs when the DNA is methylated
(11,18,19). DNA binding analyses across the EBV genome
by ourselves and others revealed that Zta interacts exten-
sively with viral promoters and with the viral origins of lytic
replication (16,20). The current model of Zta function is
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that it acts at promoter-proximal regions to recruit RNA
polymerase II and associated factors (15).
As well as regulating viral genes, Zta has the potential
to alter the patterns of gene expression in the host cell. Zta
is known to regulate the expression of a few cellular genes
such as FOS (21), E2F1 [23], EGR1 (22,23), IL8 (24), IL10
(25) and IL13 (26). Furthermore, attempts have been made
to obtain a global map of cellular genes regulated during
EBV replication using an EBV-positive BL cell line induced
to initiate viral replication (27,28). However, as only a mi-
nority of the cells in a given population responds to the acti-
vating stimulus, this approach detected only themost highly
activated genes.
Here, we undertook an unbiased genome-wide survey to
map cellular genes that are bound by Zta. We then gener-
ated a cell system that allows enrichment of cells undergo-
ing lytic cycle to perform sensitive transcriptome analyses of
changes in expression of cellular genes during the lytic cycle.
Integrating these data-sets led us to propose that Zta is able
to regulate the expression of cellular genes through interac-
tions with distal elements as well as through promoters, and
we present further evidence to support this hypothesis.
MATERIALS AND METHODS
Cell lines
The Akata group I EBV-positive BL cell line (29), an EBV-
immortalized lymphoblastoid cell line, LCL#3 (30) and an
EBV-negative BL cell line, DG75 (31), were maintained in
RPMI medium supplemented with 10% (v/v) fetal bovine
serum, 100 units/ml penicillin, 100g/ml streptomycin and
2 mM L-glutamine (Life Technologies) at 37◦C with 5%
CO2. For EBV lytic induction, Akata cells were seeded in
log phase growth at 5×105cells/ml. After 24 h, the cells were
concentrated to 2 × 106 cells/ml and treated with 0.125%
rabbit anti-human IgG (DAKO) or Dulbecco’s phosphate
buffered saline (DPBS) for the indicated times, in the pres-
ence or absence of acyclovir (Sigma) to capture both early
and late lytic stages of viral replication (20). HONE1-EBV
cells were maintained in the same medium and the pres-
ence of EBV within the cells was maintained by selection
with 600 g/ml G418. For EBV lytic replication cycle in-
duction, HONE1-EBV cells were grown to 70% confluence
and induced with 10 M suberoylanilide hydroxamic acid
(SAHA) for 48 h.
The expression vector pRTS-CD2-BZLF1, which drives
expression of Zta, non-functional NGFR and GFP from
a bi-directional doxycycline-regulated promoter and CD2
from a constitutive promoter or a control vector in which
the BZLF1 sequences are cloned in the reverse orientation
(32), were introduced into the Akata cell line by electro-
poration. Cells harboring the plasmids were physically en-
riched on the basis of CD2 expression, generating Akata-
Zta and Akata control cells as described (32). Expression
of the doxycycline-regulated promoter was induced by ad-
dition of 500 ng/ml doxycycline for 4–24 h and NGFR-
expressing cells were isolated with anti-NGFR antibodies
coupled to paramagnetic beads as described (32). Viable cell
counts were assessed by trypan blue (Sigma) exclusion.
FACS and protein analyses
GFP-positive cells were detected using multi-parameter
fluorescent activated cell analysis (FACs) (Facs Canto-
Beckton Dickinson). Intracellular staining of Zta was un-
dertaken with the mouse monoclonal antibody BZ1 (33),
with anti-mouse IgG coupled to Donkey F(ab’)2 as a sec-
ondary reagent (anti-mouse IgG -Alexa Fluor R© 647) and
the FIX & PERMR© Cell Permeabilization Kit (LifeTe-
chologies). Intracellular staining of VCA was undertaken
with themousemonoclonal antibodyVCA-gp125 (clone L2
MAB8184, Millipore) and the same secondary reagent and
conditions. Dual parameters of GFP and Alexa-fluor 647-
coupled staining were collected and the double positive cells
identified using BDFACSDivaTM Software (BecktonDick-
inson).
Cells were harvested in sample buffer (4% SDS, 20% glyc-
erol, 10% 2-mercaptoethanol, 0.004% bromophenol blue
and 0.125 M Tris–HCl, pH 6.8.) and total proteins were
fractionated by SDS-PAGE in a 12% gel (Novex). After
transfer to nitrocellulose membrane, Zta and actin were de-
tected by immunoblotting with the BZ1 mouse monoclonal
antibody against Zta (33) and a rabbit antibody against -
actin (Sigma). Species-specific IR-labeled anti-mouse and
anti-rabbit antibodies (Licor) were used in the second layer
and the resulting signal was detected on an Odyssey Fc Im-
ager and quantified using Odyssey Image Studio (Licor).
Luciferase reporter assays
A 239 bpDNA element comprising 20 non-CpGZREs (17)
with a spacing element of 4–6 nucleotides between each
was synthesized as complimentary oligonucleotides (Gene
Strings––Life Technologies) and inserted between the SalI
and BamH1 sites at the enhancer cloning site of the pGL3-
enhancer reporter vector (Promega). Two minimal promot-
ers, one from the cell CIITA gene (−214/+54) and the mini-
mal promoter from the pGL4.23 reporter vector (Promega)
(Supplementary Figure S4) were cloned upstream of the
firefly luciferase sequences between the HindIII and Kpn1
restriction enzyme sites. The sequences of the cloned ele-
ments were verified (Eurofins). The viral BHLF1 promoter
with the ZREs mutated was cloned upstream from the lu-
ciferase reporter gene in pCpGL luciferase reporter vector
(34) and the Zta binding sites from the cellular FOSB gene
and another region of cellular DNA were cloned upstream
from it (Supplementary Figure S4). Zta binding sites≥40kb
downstream from the TSS of RASA3 were cloned into
pGL3-enhancer reporter vector (Promega) and the mini-
mal promoter from the pGL4.23 reporter vector was added
(Promega) (Supplementary Figure S4).
Different DNA combinations comprising 5 g of the rel-
evant reporter construct and 5 g of an expression vec-
tor for His-tagged Zta, or the corresponding empty vector
control (35), were introduced into 1.2 × 107 DG75 cells,
an EBV-negative BL line (31), by electroporation with the
Gene pulser II (Biorad). After 24 h, half of the cells were
harvested into 250 l of 1× passive lysis buffer (Promega),
and luciferase activity was determined using the luciferase
assay system (Promega). Light emission was measured in
relative light units (RLU) using theGloMaxmulti detection
system (Promega). The remaining cells were harvested into
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Table 1. Primers used for Q-PCR assays
5′ flank Zta peak 3′ flank
SCIMP Forward primer
CCCTCGTGCAATACTGTGAGA
Forward primer
TTGCACAGCAAGTTCAAGCC
Reverse primer
ACAACTCATTCGCTCTGGGC
Reverse primer CTTTCTTGAAGG
CAGATGGCAA
BCL2A1 Forward primer
AGGAATTTGGCCTCCCAATCA
Forward primer
TCTTGAGCTGGCTCACCTTG
Forward primer ACAGTGGTTACC
TCTTGGGAGA
Reverse primer
TTTCTCCAGCGACCATGAGTT
Reverse primer
AAACACAGCCTACGCACGAA
Reverse primer CCTGTGTTGAAA
CTCATGTTGGTA
A 
7.5E-094    
Non CpG ZRE 
9.5E-035 
CpG ZRE 
≤2 kb 2-4 kb ≥4 kb 
B 
Figure 1. Zta binding across the human genome. ChIP-Seq was undertaken with an antibody against Zta protein using chromatin from Akata BL cells
induced to enter EBV lytic replication cycle by cross-linking the B-cell receptor with anti-IgG. The DNA bound by Zta was aligned to the human genome
and peaks of Zta binding were identified using model-based analysis of ChIP-seq (MACS). (A) The proportions of genes associated with proximal (<2
kb from TSS), intermediate (2–4 kb) and distal (>4 kb) Zta binding sites is shown. (B) The presence of common DNA sequence motifs within the Zta
binding sites was determined usingMEME-ChIP. The enriched motifs are colored together with the significance of the enrichment. The related ZREmotif
is shown below each in black (17).
protein sample buffer and the levels of Zta were determined
by immunoblotting (as described above). For each sample,
relative promoter activity was determined from the ratio of
luciferase activity to protein level and the assays were per-
formed in triplicate.
ChIP
Surface IgG on Akata cells was cross-linked by application
of anti-IgG and 48 h later chromatin was prepared from 1×
108 cells. An additional sample was treated with acyclovir to
halt viral replication prior to EBV genome replication. The
chromatin was fixed by application of 1% (v/v) formalde-
hyde for 15 min at 20◦C, extracted as described in Bark-
Jones et al. (36) then sonicated on ice (10 × 10 s-pulses;
30% amplitude output) on a Bransonmodel 250Microtip at
setting 5 (Sonics Vibacell). The chromatin was pre-cleared
with protein A/G-sepharose bead slurry (Sigma) that had
been pre-blocked in 0.5% (w/v) fraction V BSA (Sigma)
in DPBS. 2% (v/v) of the pre-cleared extract was retained
as the input control sample while the remainder was incu-
bated with 10 g of Zta-specific goat antibody (Santa Cruz
# sc-17503) or control goat IgG for 1 h at 4◦C as described
in Ramasubramanyan et al. (20). The input control sample
and the precipitatedDNAwere sequentially treatedwith 0.2
g/ml RNAseA and 0.2 g/ml Proteinase K and the DNA
purified. Sequencing libraries were prepared using 10 ng of
the input and ChIP DNA using a ChIP-seq sample prepa-
ration kit (Illumina) following the manufacturer’s protocol,
except that the library (150–350 bp fragments) was puri-
fied from the gel using a gel extraction kit (Qiagen) after
PCR-amplification. The libraries were sequenced (single-
end, 36 bp) using an Illumina Genome Analyzer IIx. Initial
processing of sequencing images was carried out using the
CASAVA pipeline. Base calling, and quality control statis-
tics were performed using GOAT and Bustard modules. Se-
quence reads were aligned to the hg19 release of the human
genome with ELAND. Bigwig files were generated by cal-
culating tag density in 10-bp window, normalizing per mil-
lion total reads and subtracting input signals using in-house
R scripts. Peak calling (P < 10−7) was performed from a
merged Bed file generated from the twoChIP-datasets using
MACS (37), with a merged input Bed file acting as back-
ground (GSE57732). Distances between binding sites and
the transcription start site annotated in RefSeq (38) were
calculated. Genes within 2 kb of a peak were scored as pro-
moter proximal. The Zta binding sequences associated with
peakswere analyzed for commonDNA-sequencemotifs us-
ing MEME-ChIP (39,40). Matches with both P and q val-
ues of <1.0E−034 were selected and common microsatel-
lite repeat sequences omitted. Functional gene enrichment
analysis was undertaken using the DAVID bioinformatics
resource at the National Institute of Allergy and Infectious
Diseases (NIAID) (41,42).
ChIPwas undertaken from chromatin generated from the
spontaneously lytic LCL cell line LCL#3. Enrichment was
quantified using Q-PCR spanning Zta binding peaks iden-
tified in the Akata cell line and flanking regions ∼2 kb 5′ or
3′ to them. The DNA sequences of each of the primers is
shown in Table 1.
 b
y
 g
u
est o
n
 Jan
u
ary
 1
9
, 2
0
1
7
h
ttp
://n
ar.o
x
fo
rd
jo
u
rn
als.o
rg
/
D
o
w
n
lo
ad
ed
 fro
m
 
4 Nucleic Acids Research, 2015
Figure 2. Comparison of Zta binding patterns in BL, LCL and NPC cells. (A) Examples of ChIP-seq data from Akata cells aligned to the human genome
surrounding the SCIMP locus (chr17:5 096 004–5 154 368, hg19) is shown using the UCSC genome browser. The depth of sequencing reads from Zta-
enriched DNA is plotted per million background-subtracted total reads. The scale bar and genome location are shown, together with the Zta binding
profile. Beneath this are the peaks of Zta binding identified using MACs (P < 10−7), with the RefSeq gene mapping shown below that. (B) The presence
of Zta binding in LCL#3 is shown at the SCIMP locus using Q-PCR with primers corresponding to the Zta binding sites (peak) and a flanking region 2
kb distant (flank). The data from triplicate analyses show the percentage of binding relative to input chromatin. The DNA binding associated with Zta is
shown in black and the control antibody in gray. A horizontal line marks the baseline for the assay. (C) The presence of Zta binding in HONE1-EBV at the
SCIMP locus is shown (as in B). (D) Examples of ChIP-seq data from Akata cells aligned to the human genome surrounding the BCL2A1 locus (chr15:80
241 085–80 275 791, hg19) is shown using the UCSC genome browser as in (A). (E). The presence of Zta binding in LCL#3 is shown at the BCL2A1 locus
using Q-PCR with primers corresponding to the binding sites and to two flanking regions 2 kb distant either side of the site as in (B). (F) The presence of
Zta binding in HONE1-EBV cells at the BCL2A1 locus is shown.
Table 2. Ten most enriched Gene Ontology biological process terms in the set of Zta-up regulated genes
GO term
Accession
number P Value Bonferroni Benjamini FDR
Cell projection organization GO:0030030 3.84E−14 1.34E−10 1.34E−10 7.04E−11
Cell morphogenesis GO:0000902 5.75E−14 2.01E−10 1.01E−10 1.05E−10
Cellular component
morphogenesis
GO:0032989 1.03E−13 3.62E−10 1.21E−10 1.89E−10
Biological adhesion GO:0022610 1.08E−13 3.79E−10 9.48E−11 1.98E−10
Neuron projection development GO:0031175 1.62E−13 5.67E−10 1.13E−10 2.97E−10
Cell adhesion GO:0007155 2.27E−13 7.95E−10 1.33E−10 4.16E−10
Cell morphogenesis involved in
differentiation
GO:0000904 7.67E−13 2.69E−09 3.84E−10 1.40E−09
Neuron projection morphogenesis GO:0048812 1.28E−12 4.49E−09 5.62E−10 2.35E−09
Cell projection morphogenesis GO:0048858 3.15E−12 1.10E−08 1.23E−09 5.77E−09
Cell morphogenesis involved in
neuron differentiation
GO:0048667 7.83E−12 2.74E−08 2.74E−09 1.43E−08
Reverse transcription and qPCR
Total RNA was prepared from Akata-Zta and Akata
control cells 24 h after addition of doxycycline using
RNAeasy Kit (Qiagen) and treated with RQ-DNAse
(Promega) and quantitated using a Nanodrop spectrome-
ter. First strand cDNAwas prepared using random primers
(Roche). Viral transcripts were amplified using absolute
quantitation with Sybrgreen Go-Taq Q-PCR (Promega)
with the following primers: BMLF1 (GACCGCTTCGAG
TTCCAGAAT; ACTCTCCCGAACTAGCAGCAT
and BDLF3 (TCGGTGGCAGTGATGTTCTG;
TTCCAACGCATCCACCATCA). Host cell RNAs
were also analyzed using TaqMan relative quantitation
RT-PCR in a high-throughput format using Gene cards
(Life Technologies, UK). Signals were normalized to
GAPDH expression and the relative difference in the
presence and absence of doxycycline determined. The fold
change in RNA abundance was calculated together with the
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Figure 3. Lytic cycle induction system. (A) A schematic diagram of the bi-directional expression vector encoding Zta and is shown. The control vector
has the Zta sequence cloned in the opposite direction. (B) Protein expression was assessed over 4, 8 and 24 h using immunoblotting for Zta and actin
as indicated. (C) The expression of Zta and the late lytic cycle protein VCA were determined in Akata Zta cells induced with doxycycline for 24 h using
multi-parameter FACS analysis. The data are expressed as the% of the GFP positive cells that also stain for Zta and VCA compared to a control antibody.
(D) Expression levels of the viral genes BMLF1 and BDLF3 mRNA were assessed using RT-coupled Q-PCR. The relative change in abundance of the
mRNA is shown with the error bars relating to triplicate cell induction experiments and standard deviation. (E) The relative amount of viral compared to
human DNA (viral genome load) was determined by Q-PCR 24 h after doxycycline addition. This is shown with the mean and standard deviation from
triplicate assays. (F) Cells were induced with doxycycline for 24 h and Zta expressing and control cells were enriched with anti-NGFR coated magnetic
beads. The proportion of cells that express GFP is shown for both the pre-enriched and post-enriched populations of cells.
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Figure 4. Global transcriptome analysis of gene expression changes reprogrammed during viral replication. (A) The expression of cellular genes in two
enriched populations of Akata-control and Akata-Zta cells induced with doxycycline for 24 h were assessed using RNA-seq. The distribution of genes with
a change in expression of at least two and a false discovery rate (FDR) ≤ 0.01 are shown in red on the MA plot (log total counts versus log fold-change).
(B) Percentage of genes enriched (Bonferroni-modified P ≤ 0.01) for Biological Function categories. Data are shown for all genes (black), those that are
up regulated (gray) and those that are down regulated (open).
Table 3. Ten most enriched Gene Ontology biological process terms in the set of Zta-down regulated genes
GO term
Accession
number P Value Bonferroni Benjamini FDR
Immune response GO:0006955 1.67E−08 3.57E−05 3.57E−05 2.89E−05
Induction of apoptosis GO:0006917 2.02E−07 4.31E−04 2.16E−04 3.49E−04
Induction of programmed cell
death
GO:0012502 2.15E−07 4.59E−04 1.53E−04 3.72E−04
Positive regulation of apoptosis GO:0043065 2.66E−07 5.68E−04 1.42E−04 4.60E−04
Positive regulation of programmed
cell death
GO:0043068 3.06E−07 6.55E−04 1.31E−04 5.30E−04
Positive regulation of cell death GO:0010942 3.43E−07 7.35E−04 1.23E−04 5.95E−04
Lymphocyte activation GO:0046649 5.24E−07 1.12E−03 1.60E−04 9.08E−04
Cell activation GO:0001775 1.14E−06 2.45E−03 3.06E−04 1.98E−03
Regulation of apoptosis GO:0042981 3.37E−06 7.18E−03 8.01E−04 5.84E−03
Regulation of programmed cell
death
GO:0043067 4.38E−06 9.33E−03 9.37E−04 7.59E−03
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Figure 5. Intersection of ChIP-seq and RNA-seq data. (A) The diagram shows the intersection between genes associated with a Zta binding peak (brown)
and genes that are regulated during EBV lytic cycle (green). (B) The percentage of all cellular genes and the percentage of the sub-set of cellular genes that
are associated with Zta binding and up regulated during lytic cycle was compared. The significant increase in the percentage of up regulated genes that are
also associated with Zta binding is highlighted (P < 0.01, Binomial distribution (cumulative), n = 92).
standard deviation from three independent cell enrichment
experiments. The TaqMan primer sets were as follows:
GAPDH-Hs99999905 m1; FOSB-Hs00171851 m1;
SCIMP-Hs010294 m1; AN01-Hs00216121 m1; GDF2-
Hs00211913 m1; FSCN1-Hs00602051 mH (Life Tech-
nologies, UK).
RNA-Seq
Sequencing was performed on biological duplicates of
Akata-Zta and Akata control samples on the Illu-
mina HiSeq 2500 platform and generated ∼45 mil-
lion 101-bp paired-end reads per sample. The data
are deposited in GEO (GSE57732). Sequenced reads
were mapped to RefSeq genes archived in the Illu-
mina iGenomes resource (https://support.illumina.com/
sequencing/sequencing software/igenome.ilm using RSEM
(version 1.2.4; (43)). An existing pipeline developed
within the Trinity software package (http://trinityrnaseq.
sourceforge.net/analysis/diff expression analysis.html) (44)
was used to perform differential expression analysis
with edgeR (version 3.01; http://www.bioconductor.org/
packages/release/bioc/html/edgeR.html), which is available
as part of the Bioconductor project developed within the R
programming language (45). Genes with logCPM> 0, fold-
changes above 2-fold and FDR<0.01 were judged to be dif-
ferentially expressed. Genes with a total read count below
20 were excluded from further analysis. Views of the data
are plotted using the Integrative Genomics Viewer (IGV)
(46).
DNA analysis
Total cell DNAwas prepared from cells and the amounts of
EBV genome relative to human genome determined using
Q-PCR as described (47).
RESULTS
Candidate targets of Zta in the human genome
To determine whether Zta interacts with human genes dur-
ing the switch from latency to lytic EBV replication, we
undertook a genomic-scale analysis of Zta binding sites in
AkataEBV-positive BL cells. Lytic replicationwas activated
by engagement of the cell surface B-cell receptor (BCR)
with anti-immunoglobulin. After crosslinking the proteins
to DNA using formaldehyde, chromatin from the activated
cells was immunoprecipitated with a previously validated
Zta antibody (20,47) and the precipitated DNA was ana-
lyzed by massively parallel DNA sequencing (ChIP-seq).
Significant regions of interaction between Zta and the cellu-
lar genome were identified using the Model-based Analysis
of ChIP-Seq (MACS) algorithm (37). This identified 5020
Zta binding peaks (P ≤ 1×10−7). Using a motif-based se-
quence analysis tool (MEME-ChIP) (39,40) to search for
enriched motifs we noted that the most frequent consen-
sus sequences resembled the previously described non-CpG
containing and CpG containing ZRE motifs from the EBV
genome (16,17,20), suggesting that Zta directly binds to
these sites in the human genome.
Although some of the Zta binding sites (14%) were close
to the annotated transcriptional start sites (TSS) of cellular
genes (Figure 1B and Supplementary Table 1), analogous to
the situation observed for the interaction of Zta with viral
genes, the majority of the Zta binding sites (86%) were more
distant (≥4 kb from the nearest TSS). By assigning each of
the Zta peaks to the closest TSS, irrespective of distance,
we identified 2395 cellular genes as potential candidates for
regulation by Zta.
To validate the ChIP-seq, we chose representative ex-
amples of cellular genes associated with Zta binding sites,
based on the patterns of Zta binding and amenability to
analysis by Q-PCR using PCR primer sets that would dis-
criminate enhanced binding within the peak region rela-
tive to the adjacent DNA. We also determined whether Zta
binding occurs in different cell types in which EBV under-
goes lytic replication: the LCL#3 lymphoblastoid cell line
(30) and HONE1-EBV, a cell line derived from a nasopha-
ryngeal carcinoma (48). Examples of the analysis of Zta
binding at the SCIMP and BCL2A1 genes are shown in
Figure 2A and D. In both cases, Zta binding was enriched
within the peak region identified by ChIP-seq in Akata cells
undergoing lytic replication (Figure 2B, C, E and F). This
demonstrates that the specific interaction between Zta and
these genes occurs in three different cell backgrounds.
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Figure 6. Changes in RNA abundance for five cellular genes after induction of EBV lytic replication cycle in Akata cells. (A–E) The raw RNA-seq reads
from two independent isolations of mRNA for control and Zta expressing cells are aligned to the human genome at ANO1; GDF2; FSCN1; SCIMP and
FOSB loci using the IGV genome browser. A scale bar is shown above each region. The location of the Zta binding sites is shown in black. (F) RNA was
prepared from Akata cells following crosslinking BCR with anti-IgG for 48 h. Changes in the expression of each gene: ANO1; GDF2; FSCN1; SCIMP
and FOSB were determined using TaqMan RT-PCR. The fold induction data is shown (with BCR ligation, b), together with the fold change from the
doxycycline induced Akata Zta and Akata controls cells (with dox, a).
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Figure 7. Location of Zta binding sites at up regulated genes. (A) The figure shows the percentage of up regulated genes with Zta binding sites within 2 kb,
between 2 and 4kb and >4 kb from a TSS. (B) The percentage of up regulated genes with 1, 2–4 or >5 Zta binding sites. (C) The numbers of sequencing
reads from Zta-enriched DNA at the GDF2 locus (chr10:48 397 968–48 431 996, hg19) are plotted per million background-subtracted total reads and
aligned with the human genome. The scale bar and genome location are shown, together with the Zta binding. Beneath this are the peaks identified using
MACS (P < 10−7) and RefSeq gene mapping (UCSC genome browser). (D) Similar data for the region surrounding the RASA3 locus (chr13:114 709
728–114 936 080, hg19). (E) Similar data for the region surrounding the FOSB locus (chr19:45 947 279–45 995 778 hg19).
Changes in the cell transcriptome during EBV lytic cycle
To explore the significance of Zta binding throughout the
genome of Akata cells, we wanted to establish whether any
of the genes associated with Zta binding sites are transcrip-
tionally regulated during the EBV lytic replication cycle.
Previous attempts to investigate changes in cellular gene ex-
pression during the EBV lytic cycle have been limited by the
low percentage of Akata cells that undergo EBV lytic repli-
cation following BCR engagement. To optimize the identi-
fication of regulated genes, we introduced an inducible Zta
expression vector with a selectable marker gene (32) into
Akata cells to allow lytic cycle induction in a high propor-
tion of cells (Figure 3A). In parallel, a cell linewas generated
with a vector in which the BZLF1 sequences were inserted
in the opposite orientation. This cell line was used as a com-
parator throughout the investigation to control for any im-
pacts of the inducing agent on cells. Addition of doxycy-
cline resulted in the rapid induction of Zta expression (Fig-
ure 3B and C) with no associated toxicity (Supplementary
Figure S1). This was accompanied by activation of the EBV
lytic cycle, as judged by the expression of the late gene VCA
(Figure 3C), expression of the viral early gene BMLF1 and
late gene BDLF3 (Figure 3D) and replication of the viral
genome (Figure 3E). No evidence for lytic replication was
observed in the control cells. It is important to note that
although a higher percentage of cells express Zta protein
in the inducible system compared to BCR stimulation, the
abundance of Zta protein is equivalent in the two systems
as judged by intracellular staining and FACS analyses (Sup-
plementary Figure S2). Thus, the level of Zta expression in-
duced by doxycycline is physiologically relevant.
Populations of control and Zta expressing cells were en-
riched by selection on anti-NGFR coupled magnetic beads.
This generated pools of cells in which greater than 70%
expressed the induced genes (Figure 3F and Supplemen-
tary Figure S3), in which both the down regulation and
the up regulation of gene expression can be determined.
This was undertaken for two independently enriched pop-
ulations of Zta expressing and control cells by sequencing
the polyadenylated transcripts (RNA-seq). Differential ex-
pression analysis identified 2263 cellular genes whose ex-
pression changed >2-fold following induction of the lytic
cycle (FDR≤0.01) (Figure 4 and Supplementary Table S2).
This included 2242 novel targets and 21 genes that had been
identified in previous studies (27,28). Of the genes identi-
fied in this analysis, 1679 were up regulated and 584 were
down regulated. The genes fell into many functional groups
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Figure 8. Zta can activate gene expression through a long-range element. (A) A synthetic element containing tandem ZREs was cloned 2.2 kb from either
of two minimal promoters (minC and minP) in the pGL3 control luciferase reporter plasmid. (B) Promoter activities of the pGL3 based plasmids SV40p,
minC-Null andminCZREs in the presence (black) and absence (gray) ofHis-Zta expression in the EBV negative BL cell line (DG75). The relative luciferase
activity is shown as promoter activity together with the standard deviation from three replicates. (C) Western blot analysis of Zta and Actin from samples
in (B). (D) Promoter activity of the minP-Null andminP-ZREs reporters in the presence and absence of His-Zta expression in the EBV negative BL cell line
(DG75). The relative luciferase activity is shown as promoter activity together with the standard deviation from three replicates. (E) Western blot analysis
of Zta and actin from samples in (B).
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Figure 9. Zta can activate gene expression through binding sites associated with FOSB. (A) The DNA sequences at three Zta binding sites associated with
FOSBwere cloned upstream from an EBV lytic cycle promoter BHLF1 containing no ZREs (BHLF1mut) to generate BHLF1mut FOSB. A control region
from the human genome is also included. (B) Promoter activity of BHLF1mut, BHLF1mut control and BHLF1mut FOSB in the presence and absence
of His-Zta expression in the EBV negative cell line (DG75). The relative luciferase activity is shown as fold regulation by Zta with the standard deviation
from three replicates. (C) Western blot analysis of Zta and Actin from samples in (B).
but gene ontology analyses showed that among the up reg-
ulated genes, significant enrichment was observed for genes
involved in cell adhesion, morphogenesis, projection and
response to hormones (Table 2 and Figure 4). Within the
down regulated category, there was significant enrichment
for genes involved in the immune response, induction of
apoptosis and lymphocyte activation (Table 3 andFigure 4).
Regulation of Zta-associated genes
Although the presence of a transcription factor on a gene
can be indicative of a regulatory role, it is not definitive:
transcription factor binding can occur without discernible
changes in gene expression. We therefore asked which of
the 2395 cellular genes associated with Zta binding are reg-
ulated following Zta induction of the EBV lytic cycle. Of
the genes whose expression changed ≥ 2-fold in this ex-
periment, 278 were associated with Zta binding sites and
are therefore candidates for direct Zta-mediated regulation
(Figure 5A). Of these, 207 genes were up regulated and 71
were down regulated. The presence of one ormore Zta bind-
ing site correlated with an increased likelihood that a gene
was up regulated (P= 0.014, Binomial distribution, n= 92)
(Figure 5B). In contrast, there was no specific enrichment
for Zta binding sites in the down regulated genes.
The proportion of genes associated with Zta binding that
are demonstrably regulated during EBV lytic replication in
BL cells (11.6%) is typical of many cellular transcription
factors. Published reports suggest that between 1% and 10%
of transcription factor associated genes are transcription-
ally altered by expression of the transcription factor (49–
52).
The Zta-bound genes that are also up regulated during
EBV lytic cycle, listed in Supplementary Table 3, are the
most likely candidates to be regulated directly byZta andwe
focused our follow-up analysis on these.We chose a panel of
five representative genes in which the Zta binding sites were
in different positions relative to the TSS: SCIMP1, FOSB,
ANO1, GDF2 and FSCN11. Figure 6 shows the aligned
RNA sequence data and the locations of Zta binding sites.
For each gene, we obtained appropriate Taq-man probes
and quantified the changes in abundance of the RNA in
Akata cells following the ligation of BCR by cross-linking
with anti-IgG. All of the RNAs showed increased abun-
dance following BCR ligation (Figure 6E), although the ef-
fects were difficult to quantify because signals in the unli-
gated cells were below the levels of detection.
Patterns of Zta binding at regulated genes
Having validated the RNA-seq data at selected targets, we
asked whether there was any general correlation between
the number and location of Zta binding sites and the ob-
served effects on gene expression at up regulated genes (Fig-
ure 7). Although ∼15% of the Zta binding sites were within
2 kb of a TSS, in line with the established model of Zta me-
diated gene activation of viral promoters, it was clear that
the majority (75%) of the Zta binding sites were distal (>4
kb) to the nearest TSS. Approximately half of the up regu-
lated genes associated with a Zta binding site have a single
peak whereas the others have two or more (Figure 7).
At some genes, Zta binding was relatively confined as ex-
emplified by the up regulated GDF2 gene where a cluster of
four Zta binding sites was observed at the 3′ end of the gene,
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Figure 10. Zta can activate gene expression through binding sites associated with RASA3. (A) The DNA sequences at seven Zta binding sites associated
with the 3′ region ofRASA3were cloned in the enhancer position>2 kb from the minP promoter to generate minP-RASA3. (B) Promoter activity of minP
null and RASA3 minP in the presence and absence of His-Zta expression in the EBV negative cell line (DG75). The relative luciferase activity is shown
with the standard deviation from three replicates. (C) Western blot analysis of Zta and Actin from samples in (D).
6–8 kb from the transcription start site (Figure 7C). How-
ever, at other genes, exemplified by RASA3 and FOSB, Zta
binding peaks were found 5′ of the transcription start sites,
within intragenic regions and 3′ of the genes, distributed
over considerable distances (Figure 7D and E).
Zta binding sites act as transferable regulatory elements
The ability of Zta to activate transcription by binding to
promoter elements is well documented (53) but we are not
aware of any previous reports that Zta can act through distal
regulatory elements. To gain support for the idea that Zta
can also influence transcription from a distance, we gener-
ated luciferase reporter constructs in which a tandem ar-
ray of non CpG ZREs was cloned into a classical enhancer
vector, 2.2 kb upstream of one of two minimal promoters
(Figure 8A and Supplementary Figure S2). Tandem arrays
of ZREs embedded within minimal promoters have been
previously used to measure Zta activity (54,55), but action
away from a promoter has not been assessed. In the MinC-
ZREs reporter, we used a minimal promoter derived from
the CIITA gene, which is not regulated by Zta. An alter-
native reporter, designated MinP-ZREs, was based on the
minimal promoter in the commercially sourced pGL4.23
reporter vector (Promega). In each case, we compared the
activity of the promoters with and without the ZREs, with
an SV40 promoter construct as an additional control (Fig-
ure 8B and D). The reporter plasmids were introduced into
EBV negative DG75 BL cells, together with a vector en-
coding Zta or empty vector control. Immunoblotting con-
firmed that Zta was expressed at equivalent levels in the
transfected cell populations (Figure 8C and E). Whereas
Zta had a minimal effect on the activity of the MinC and
SV40 promoters, the inclusion of the ZRE array resulted
in an 8-fold increase in the activity of the MinC construct.
Similarly, although Zta appeared able to activate the MinP
promoter on its own, the presence of the ZRE array resulted
in more substantial activation (75-fold versus 13-fold). The
6-fold differential between these effects is consistent with
the impact of the ZRE array on the MinP promoter. Taken
together, the data suggest that Zta can regulate gene expres-
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sion via ZRE elements that are located at a distance from
promoters, in a classical enhancer assay.
We then asked whether authentic Zta binding sequences
from the cellular targets genes can be transferred onto a het-
erologous promoter. We chose the FOSB andRASA3 genes
as examples. In FOSB each of the four non-CPG Zta bind-
ing sites was ≥2 kb from the FOSB TSS (16 and 9 kb up-
stream, 2.4 and 10 kb downstream) and the gene is up reg-
ulated during the EBV lytic replication cycle (Figure 7E).
We cloned the Zta binding sites from −16 and −9 kb up-
stream from a viral promoter (BHLF1mut) that had been
rendered unresponsive to Zta by virtue of mutations in each
of its ZREs (Figure 9A).We also included a similar size con-
trol region from the cellular genome. The reporter plasmids
were transfected into DG75 cells, together with a plasmid
encoding Zta or the empty vector control. The presence of
the FOSB sequences caused a 2.5-fold increase in the re-
sponse of the promoter to Zta compared to the controls
(Figure 9B). Equivalent expression of Zta protein was seen
for all reporters (Figure 9C).We therefore conclude that the
distal Zta binding sites from the FOSB gene are able to con-
fer Zta responsiveness. For RASA3, where there are multi-
ple Zta binding sites across a >100 kb region, we focused
on elements within seven Zta binding sites from the 3′ end
of theRASA3 gene (≥40 kb from the TSS). These conferred
Zta-mediated induction of expression of theminP promoter
when cloned into the enhancer position of the PGL3 lu-
ciferase reporter vector. The average increase in expression
was 2.2-fold over three experiments (Figure 10), which is in
line with typical ESC enhancers in similar assays (56).
DISCUSSION
We identified 2263 cellular genes whose expression is signif-
icantly altered within the first 24 h of initiation of the EBV
lytic cycle. This was surprising given that a process termed
host cell shut-off, driven by the EBV lytic replication cy-
cle gene BGLF5, is reported to promote a global reduction
in cellular gene expression during the EBV lytic replication
cycle (57–59). The regulation of cellular genes that we ob-
serve must therefore occur either in advance of the impact
of BGLF5 gene expression or perhaps in spite of it.
It is possible that the cellular genes that are regulated dur-
ing the EBV lytic replication cycle are specifically targeted
to aid the success or the efficiency of viral replication. In-
deed, we found a significant enrichment for genes involved
in specific biological functions. For example, 190 of the up
regulated genes are involved in cell morphogenesis (P ≤
1.0−10). We speculate that these genes might facilitate viral
assembly or genome encapsulation in the nucleus, the ex-
port of immature virions from the nucleus, transport and
further assembly within the cytoplasm, or egress from the
cell. Among the down regulated group of genes, there was
a specific enrichment for genes involved in apoptosis. It is
well established that BL cells undergoing EBV lytic replica-
tion are protected from apoptosis (60) and the down regula-
tion of the cellular genes identified here might contribute to
the observed protection. This suggests that EBVmight have
evolved a strategy to reprogram cellular gene expression in
order to tailor the environment of the cell for optimal viral
replication.
During the early stages of the EBV lytic replication cy-
cle, several viral genes, including the transcription factors
Zta and Rta and the post-transcriptional regulator BSLF2
+ BMRF1, act in concert to regulate the expression of the
viral genome (53). In this scenario, it is clear that induction
of Zta expression in Akata cells could drive both direct reg-
ulation of the host cell transcriptome and instigate indirect
regulation of genes through the action of other lytic cycle
proteins. It was therefore important to consider which of
the 2263 host genes whose expression was altered following
Zta activation were associated with a Zta binding peak dur-
ing the EBV lytic replication cycle. Integration of the data-
sets provided 278 cellular genes as candidates for direct Zta-
mediated transcriptional regulation.
One of the unexpected findings was that the majority of
the Zta binding sites identified in this set of cellular genes
are distal to promoters. This is very different from the situ-
ation observed in the viral genome where functional ZREs
have been shown to lie in very close proximity to transcrip-
tion start sites (16,20). Indeed, the interaction of Zta with
RNA polymerase II accessory proteins is considered to aid
the activation of transcription from viral promoters (61–
64). The location of the cellular Zta binding sites suggested
to us that Zta reprograms the regulation of cellular genes
through a different mode of action. In support of this idea,
we present two lines of evidence. First, we find that a tandem
array of ZREs has enhancer-like activity when located dis-
tal to a minimal promoter in a classical enhancer reporter
assay. Second, we find that the Zta binding sites from the
cellular FOSB andRASA3 genes can transfer Zta-mediated
activation onto heterologous promoters. Although the im-
pact is modest, it is in line with the magnitude of regula-
tion recently reported for cellular enhancers in the context
of plasmid based reporter assays (56). As the reporter gene
regulation occurs in the absence of other EBV gene expres-
sion, it supports the hypothesis that Zta is able to directly
activate cellular genes through regulatory elements that lie
distal to their transcription start sites. This raises the possi-
bility that long-range gene mechanisms act through direct-
ing through chromatin looping, in a similar manner to that
recently described for the EBVEBNAgenes (65,66). In light
of the discovery of Zta regulation through distal Zta bind-
ing sites, it will be relevant to reconsider the interactions of
Zta with the viral genome (16,20), with regards to the po-
tential for regulation of distant promoters.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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Abstract: The working model to describe the mechanisms used to replicate the  
cancer-associated virus Epstein-Barr virus (EBV) is partly derived from comparisons with 
other members of the Herpes virus family. Many genes within the EBV genome are 
homologous across the herpes virus family. Published transcriptome data for the EBV 
genome during its lytic replication cycle show extensive transcription, but the identification 
of the proteins is limited. We have taken a global proteomics approach to identify viral 
proteins that are expressed during the EBV lytic replication cycle. We combined an 
OPEN ACCESS
Pathogens 2015, 4 740 
 
 
enrichment method to isolate cells undergoing EBV lytic replication with SILAC-labeling 
coupled to mass-spectrometry and identified viral and host proteins expressed during the 
EBV lytic replication cycle. Amongst the most frequently identified viral proteins are two 
components of the DNA replication machinery, the single strand DNA binding protein 
BALF2, DNA polymerase accessory protein BMRF1 and both subunits of the viral 
ribonucleoside-diphosphate reductase enzyme (BORF2 and BaRF1). An additional 42 EBV 
lytic cycle proteins were also detected. This provides proteomic identification for many EBV 
lytic replication cycle proteins and also identifies post-translational modifications. 
Keywords: virus; cancer; replication; proteome; herpes; Epstein-Barr 
 
1. Introduction 
Epstein-Barr virus (EBV) is associated with diverse cancers including Burkitt’s lymphoma, 
Hodgkin’s lymphoma, NK/T lymphomas, Nasopharyngeal carcinoma and gastric cancer [1–9]. During 
the ~50-years since the identification of the virus [10] and the ~30 years since the genome sequence of 
the first isolate was published [11], there has been a strong focus on research into the viral genes 
commonly expressed in tumors, which has enabled us to obtain a good understanding of the ability of 
EBV to transform cells and so establish viral latency. 
EBV within tumor cells undergoes lytic cycle replication only rarely and ~90% of EBV genes are not 
commonly expressed in tumors. However, these are transcribed following the disruption of latency as 
cells enter the EBV lytic replication cycle. Sensitive transcriptome analysis in Burkitt’s lymphoma cells 
that have been stimulated to initiate the EBV lytic replication cycle [12,13], together with array-based 
strategies [14,15] and earlier mapping approaches (reviewed in [16]), suggests that the entire genome 
complement is expressed once EBV lytic replication cycle is activated. 
The contribution of several EBV lytic cycle genes has been subject to genetic evaluation. This 
identified BZLF1, BRLF1 [17], BSLF2 + BMLF1 [18] and BMRF1 [19] as essential for regulating viral 
gene expression during viral lytic replication and others (BFLF1, BFLF2, BFRF1, BGRF1 and BDRF1) 
contribute to encapsulating the viral genome [20–22]. In contrast, BGLF4 contributes to the efficiency 
of viral replication [23–26] and some viral genes such as BLLF1 and BNRF1 are not required to generate 
virus but rather contribute to the subsequent infection of cells or allow efficient entry and genome  
release [27–29]. Finally, some viral genes contribute to immune evasion of infected cells, e.g.,  
BNLF2a [30]. The contributions that many other EBV lytic replication cycle genes make to the EBV 
lytic replication cycle are inferred through their homology with the alpha herpesvirus family [1]. Several 
of these proteins have been detected by immunofluorescence during viral replication (e.g., [31]). 
Despite three studies using proteomics approaches [32–34], not all EBV lytic cycle genes have been 
previously identified and many have not been independently verified. Here, we used an engineered 
Burkitt’s lymphoma cell system to enrich for cells undergoing EBV lytic replication and coupled this 
with SILAC-proteomics to develop a route to detect EBV proteins in Akata cells undergoing EBV lytic 
replication. This allowed us to identify a total of 44 EBV proteins and post-translational modifications 
of several viral proteins. 
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2. Results 
2.1. Isolation of Proteins in Cells Undergoing EBV Lytic Cycle 
Cells from a Burkitt’s lymphoma which harbor EBV in type I latency had previously been engineered 
to co-express Green Fluorescent Protein (GFP), Nerve Growth Factor receptor (NGFR) and Zta (BZLF1) 
from an inducible bi-directional promoter (Akata-Zta). A cell line in which the Zta coding sequence is 
orientated in the non-coding direction acts as a control [35,36]. Proteins within the Akata control and 
Akata Zta cells were differentially metabolically labeled with amino acids consisting of stable isotopes. 
Following activation of the expression cassette using doxycycline, cells that had successfully been 
induced were isolated by their affinity for anti-NGFR coated magnetic beads. Analysis of GFP 
expression in the enriched cell population revealed a purity of between 57% and 62% (Figure 1). 
 
Figure 1. Enrichment of Burkitt’s Lymphoma (BL) cells induced to enter Epstein-Barr virus 
(EBV) lytic replication cycle. (a) Co-induction of Green Fluorescent Protein (GFP), Nerve 
Growth factor receptor (NGFR) and Zta (or not for control cells) and procedure to induce 
and enrich cells, together with the % enrichment (GFP positivity) is shown; (b) Total protein 
extracts were prepared, fractionated on SDS-PAGE and stained. 
2.2. Identification of Proteins in Cells Undergoing EBV Lytic Cycle 
The proteins from Akata-control and Akata-Zta were mixed in equal amounts and the relative 
abundance of cellular and viral proteins was analyzed by quantitative mass spectrometry (MS). Global 
analysis of the differences in abundance detected through the differential SILAC labeling and the 
difference in abundance of individual proteins determined by Western blot analysis revealed a modest 
Pathogens 2015, 4 742 
 
 
overall reduction in the abundance of cellular proteins (between 1.2 and 2-fold) during EBV lytic cycle 
(Figure 2). Viral proteins were identified only in the Zta-expressing cells. 
 
Figure 2. Stable isotope labeling with amino acids in cell culture (SILAC) coupled to mass 
spectrometry (MS) analysis of proteins in Burkitt’s Lymphoma (BL) cells during EBV lytic 
cycle. Total protein extracts were prepared from the enriched BL cells. MS analysis was 
undertaken. (a) The change in abundance of proteins with SILAC-information from both 
control and Zta expressing cells is shown; (b) The frequency distribution of the difference 
in protein abundance is shown as a Gaussian plot; (c) Total proteins were separated by SDS-
PAGE. Western blots were probed with anti-HSP90 and beta actin antibodies. 
2.3. Identification of EBV Proteins 
To identify EBV proteins in cells undergoing lytic replication, we considered the peptides that match 
with an EBV protein. The Uniprot databases which include proteins from three viral genomes HHV4 
(B95-8 UP000007640; AG876 UP000007639; and GD1 UP000007641). The identity of each of the 169 
peptides that correspond to an EBV protein with a Posterior Error Probability (PEP) score of less than 
1.0 × 10?3 are provided in Table S1. These were all up regulated ?8.6 fold during lytic cycle, with the 
majority being undetectable in latency. This identified peptides corresponding to 33 EBV proteins  
(Table 1). In addition, a custom made database of the Akata EBV proteome was generated and searched 
to ensure that polymorphic regions were not overlooked. However, this revealed no additional protein 
identifications. In order to increase the sensitivity of EBV protein detection in our dataset, we carried 
out a further MaxQuant search against the EBV proteome (UniProt), omitting human sequences [37]. 
This identified an additional 11 EBV proteins, also shown in Table 1 (highlighted). The peptides 
associated with this search are listed in Table S2.  
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Table 1. EBV proteins identified by MS analysis. 
Gene Function 
BALF2 Major DNA-binding protein 
BALF4 Envelope glycoprotein B 
BALF5 DNA polymerase catalytic subunit 
BaRF1 Ribonucleoside-diphosphate reductase small chain 
BBLF2-BBLF3 primase protein 
BBLF4 DNA replication helicase 
BBRF2 Virion egress protein UL7 homolog 
BcLF1 Major capsid protein 
BDLF1 Triplex capsid protein VP23 homolog 
BFLF1 Packaging protein UL32 homolog 
BFLF2 Virion egress protein 
BFRF1 Virion egress protein UL34 homolog 
BFRF3 Capsid protein VP26 
BGLF2 Capsid-binding protein 
BGLF4 Serine/threonine-protein kinase 
BGLF5 Shutoff alkaline exonuclease 
BHRF1 Apoptosis regulator 
BKRF3 Uracil-DNA glycosylase 
BLLF3 Deoxyuridine 5?-triphosphate nucleotidohydrolase 
BLRF2 Tegument protein 
BSLF2-BMLF1 mRNA export factor ICP27 homolog 
BMRF1 DNA polymerase processivity factor 
BNRF1 Major tegument protein 
BORF2 Ribonucleoside-diphosphate reductase large subunit 
BPLF1 Deneddylase 
BRRF1 Transcriptional activator 
BRRF2 Tegument protein 
BSRF1 Tegument protein UL51 homolog 
BTRF1 Uncharacterized protein BTRF1 
BVRF2 Capsid scaffolding protein BdRF1 
BXLF1 Thymidine kinase 
BZLF1 * Trans-activator protein 
BDLF3 pg85 
BLLF1 gp350 
BMRF2 Protein BMRF2 
BORF1 Triplex capsid protein 
BPLF1 deneddylase 
BRLF1 Replication and transcription factor 
BRRF2 tegument protein 
BSLF1 DNA primase 
gH gH 
gL gL 
LF1 LF1 
* BZLF1 expression is driven by the doxycycline induced expression vector in these cells so detection  
cannot be ascribed to the endogenous protein. Yellow highlight represents proteins only identified in the  
EBV-specific search. 
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Table 2. Post-translational modifications of EBV proteins identified by MS analysis.  
Gene Name Modification pep_seq aa of EBV Protein 
Residue of 
Modification 
BALF5 N terminal acetylation [ac]SGGLFYNPFLRPNK 2–15 2 
BLLF3 N terminal acetylation [ac]MEACPHIR 9–16 9 
BLRF2 Phosphorylation GQPS[ph]PGEGTRPR 124–135 127 
BMRF1 2 Phosphorylation HTVS[ph]PSPS[ph]PPPPPR 330–343 333 and 337 
BMRF2 N terminal acetylation [ac]METTQTLR 1–8 1 
BORF1 Phosphorylation RLNIS[ph]R 26–31 30 
BORF2 N terminal acetylation [ac]ATTSHVEHELLSK 2–14 2 
BXLF1 Phosphorylation TQAAVTSNTGNS[ph]PGSR 86–101 97 
BZLF1 N terminal acetylation [ac]MMDPNSTSEDVK 1–12 1 
None of the EBV proteins are associated with EBV latency; all originate from genes with a 
characteristic lytic replication cycle pattern of expression [16]. One of the 44 proteins identified, BZLF1, 
could be derived from either the expression vector or the endogenous virus so it should not be considered 
as proof of identity of the endogenous protein. We confirm expression of one of these proteins, BMRF1, 
by Western blot (Figure 3A) and we show which gene products are uniquely identified here and which 
provides confirmation of proteins previously identified in other reports (Figure 3B). 
 
Figure 3. SILAC MS analysis of proteins EBV proteins detected in Akata cells during lytic 
cycle. (A) Akata control and Akata Zta cells were induced with doxycycline for 24 h and 
total protein extracts prepared. Western blot analysis of BMRF1, Zta and beta actin 
abundance is show; (B) The EBV proteins identified are shown in relation to previously 
published studies. BZLF1 is marked*, its expression is driven by the doxycycline induced 
expression vector in these cells so detection cannot be ascribed to the endogenous protein. 
2.4. Identification of Post-Translational Modifications of EBV Proteins 
We searched for potential post-translational modifications of EBV proteins using MASCOT to search 
a minimal EBV database. All identifications were required to be from medium-labeled peptides, i.e., 
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present after EBV induction. The same phosphorylation and N-terminal acetylation modifications were 
also identified in a MaxQuant search of the EBV database. Those phospho-serine and amino-terminal 
acetylation modifications corresponding to proteins identified in Table 1 are shown in Table 2, with 
peptide identification evidence provided in Table S3. This identified that five lytic EBV proteins sustain 
amino-terminal acetylation; BZLF1 (Zta), BMRF2, BLLF3, BALF5, and BORF2. In addition EBV 
peptides corresponding to serine phosphorylation were identified for BMRF1, BLRF2, BORF1 and BXLF1. 
3. Experimental Section 
3.1. Cell Culture 
Akata-Zta and Akata control cells [36] were cultured in RPMI–SILAC labeled RPMI containing 
13C6-arginine and 4,4,5,5-D4-lysine (R6K4) (medium) and RPMI R0K0 (light) respectively (Dundee 
Cell products). Each was supplemented with 15% (v/v) dialyzed FBS and 100 units/mL penicillin,  
100 ?g/mL streptomycin and 2 mM L-glutamine (Life Technologies) at 37 °C with 5% CO2. Cells were 
maintained between 3 and 10 × 105 cells/mL and were cultured in SILAC-medium for 16 population 
doublings. Doxycycline (Sigma) was added to a final concentration of 500 ng/mL and cells incubated 
for a further 24 h. Successfully induced cells were enriched using anti-NGFR antibodies coupled to 
paramagnetic beads as described [36]. 
3.2. FACS Analysis 
Live cells were analyzed using a multi-parameter fluorescent activated cell analysis (FACs) (Facs 
Canto-Beckton Dickinson). GFP positive cells were identified using BD FACSDiva™ Software 
(Beckton Dickinson). 
3.3. Western Blot Analysis 
An equivalent number of cells were lysed using SDS-PAGE sample buffer at a final concentration of 
1.0 × 104 cells/?L. Extracts from 1.0 × 105 cells were fractionated on SDS-PAGE. The total protein 
complement was detected following staining with Simply Blue stain or transferred to nitrocellulose. 
Proteins were identified using the following primary antibodies, beta actin (A2066, SIGMA), HSP90 
(AC88 ab13492, ABCAM), Zta [38] and BMRF1 (8F92, ab30541, ABCAM). This was followed by 
incubation with species-specific infra-red labeled secondary antibodies (LiCor). The presence and relative 
abundance of proteins was determined using an Odyssey Fc Imager and Odyssey Image Studio (Licor). 
3.4. Mass Spectrometry Collection and Analysis 
Extracts from Zta expressing and not expressing cells were mixed and fractionated on SDS-PAGE 
(Novex). The lane was cut into six slices and each slice was subjected to in-gel digestion with a  
DigestPro MSi automatic digestion system (Intavis Bioanalytical Instruments) as described in [39]. The  
resulting peptides were fractionated using a Dionex Ultimate 3000 nano HPLC system coupled to an  
LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific). In brief, peptides in 1% (v/v) formic acid 
were injected onto an Acclaim PepMap C18 nano-trap column (Dionex). After washing with 0.5% (v/v) 
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acetonitrile 0.1% (v/v) formic acid, peptides were resolved on a 250 mm × 75 ?m Acclaim PepMap C18 
reverse phase analytical column (Dionex) over a 150 min organic gradient, using 7 gradient segments 
(1%–6% solvent B over 1 min, 6%–15% B over 58 min, 15%–32% B over 58 min, 32%–40% B over 3 
min, 40%–90% B over 1 min, held at 90% B for 6 min and then reduced to 1% B over 1 min) with a 
flow rate of 300 nL·min?1. Solvent A was 0.1% formic acid and Solvent B was aqueous 80% acetonitrile 
in 0.1% formic acid. Peptides were ionized by nano-electrospray ionization at 2.3 kV using a stainless 
steel emitter with an internal diameter of 30 ?m (Thermo Scientific) and a capillary temperature of  
250 °C. Tandem mass spectra were acquired using an LTQ-Orbitrap Velos mass spectrometer controlled 
by Xcalibur v2.1 software [40] and operated in data-dependent acquisition mode. The Orbitrap was set 
to analyze the survey scans at 60,000 resolution (at m/z 400) in the mass range m/z 300–2000 and the 
top six multiply charged ions in each duty cycle selected for MS/MS in the LTQ linear ion trap. Charge 
state filtering, where unassigned precursor ions were not selected for fragmentation, and dynamic 
exclusion (repeat count, 1; repeat duration, 30 s; exclusion list size, 500) were used. Fragmentation 
conditions in the LTQ were as follows: normalized collision energy, 40%; activation q, 0.25; activation 
time 10 ms; and minimum ion selection intensity, 500 counts. Data were acquired using the Xcalibar 
v2.1 software. The raw data files were processed and quantified using MaxQuant as described in [39] and 
searched against standard human proteome and EBV protein lists from UNIPROT and a translation of 
the Akata EBV genome. A search was also carried out against the EBV UniProt proteins plus 
contaminants, with the human sequences omitted [37]. Peptide precursor mass tolerance was set at 10 
ppm, and MS/MS tolerance was set at 0.8 Da. Search criteria included carbamidomethylation of cysteine 
(+57.0214) as a fixed modification and oxidation of methionine (+15.9949) and appropriate SILAC 
labels as variable modifications. 
Searches were performed with full tryptic digestion and a maximum of two missed cleavages was 
allowed. The reverse database search option was enabled and all peptide data was filtered to satisfy false 
discovery rate (FDR) of 1%. 
A database search using Mascot was carried out against a database containing 282 EBV protein 
sequences from UniProt. The search used the following parameters: 10 ppm precursor mass tolerance; 
0.6 Da fragment ion mass tolerance; fixed modification: carbamidomethylation (C); variable modifications: 
Protein N-terminus acetylation, methionine oxidation, phosphorylation (STY), 2H(4) K, 13C(6) R. 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium [1] via 
the PRIDE partner repository with the dataset identifier PXD002461 [41]. 
4. Conclusions 
Two previous studies compared the proteomes in BL and primary effusion lymphoma (PEL) cells  
during EBV lytic cycle with the proteomes of cells during latency or to those that are refractory to 
entering EBV lytic cycle [33,34]. The previous studies used the histone deacetylase inhibitor sodium 
butyrate [34] and/or a combination of the histone deacetylase inhibitor sodium butyrate and  
12-O-tetradecanoylphorbol-13-acetate to induce EBV to enter its lytic replication cycle. Here, we used 
a different method to initiate EBV lytic cycle gene expression, the ectopic expression of Zta protein. We 
previously demonstrated that this is sufficient to promote expression of several EBV lytic cycle genes 
leading to replication of the EBV genome [36]. Sensitive transcriptome analysis of EBV identified highly 
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abundant mRNAs [12,14,33]. While some of the proteins encoded by these are readily detected in the 
lytic cells (e.g., BMRF1, BMLF1 and BHRF1), others are not detected in any study (e.g., BALF1). This 
highlights one of the limitations of interpreting a global proteomics study; some proteins do not generate 
peptides that can be unambiguously identified. Whether EBV completes the lytic cycle in response to 
any of these stimuli yet protein expression is too low to be detected by mass spectrometry, or whether 
the lytic cycles are aborted prior to full viral gene expression and release of infectious virus is unknown. 
In addition to the analysis of viral proteins within cells, proteins present in purified EBV virions have 
also been detected using proteomics [32]. 
A comparison of our data with these three datasets revealed that we detected 28 EBV proteins that 
had been identified in two or more previous studies. We therefore provide further support for the 
identification of these proteins. Importantly, our analysis detected 12 viral proteins that were only 
identified in one previous study, providing important independent evidence of their detection. In 
addition, we provide evidence for the first detection of three viral proteins by mass spectrometry. The 
first is BBRF2, which is a homologue of the HSV1 virion egress protein UL7. Clues as to its function 
arise from the recent demonstration that UL7 plays a role in linking tegument proteins of HSV1 to 
membranes [42]. The second protein is BFLF1. Interestingly, BFLF1 is a homologue of the HSV1 UL32 
gene, which plays a role in HSV1 encapsidation [43] which supports the potential involvement of BFLF1 
protein in cleavage and packaging of the viral genome [21]. The third, BSLF1, encodes the DNA primase 
that is required for genome lytic replication [44,45]. In addition, we detected Zta protein (BZLF1), 
although it is not possible to distinguish whether this originates from the endogenous genome or the 
expression vector. 
Further analysis of the data identified evidence for novel post-translational modifications of nine EBV 
proteins. Amino-terminal acetylation events were identified for Zta, BLLF3, BALF5, BMRF2 and 
BORF2. For BALF5 and BORF2 amino terminal processing had occurred and the acetylation is present 
on the second residue, for the remainder it is present on the initiator methionine. Neither the acetylation 
nor the amino terminal processing had been described previously. A large sub-set of cellular proteins 
also sustain the amino terminal acetylation, the function is enigmatic, and roles in protein–protein 
interaction, sub-cellular targeting and degradation have all been postulated [46]. In addition to this, EBV 
peptides corresponding to serine phosphorylation of BMRF1, BLRF2, BORF1 and BXLF1 were 
identified. Of these, BMRF1 is known to be phosphorylated at residue 337 [47], in addition to residues 
344, 349 and 355. We provide evidence for a further site of phosphorylation at serine 333. In addition, 
this is the first report that BLRF2, BORF2 and BXLF1 sustain serine phosphorylation. 
In summary, the definitive identification of 44 EBV proteins in BL cells undergoing EBV replication 
and the identification of novel post-translational modifications of nine of these lytic cycle proteins 
increase the knowledge base of EBV lytic replication and may highlight different targets for future 
strategies to enable the development of therapeutic interventions to manipulate EBV replication. 
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